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Abstract 
Parkinson's disease (PD) has been traditionally viewed as a disease of the substantia nigra 
with motor deficits as the main clinical symptom. However, non-motor symptoms are 
also commonly present, with neuropsychiatric disturbances being among the most 
prominent. Despite extensive research, the pathological basis for neuropsychiatric 
complications in PD is still unclear. The present thesis addresses the possible anatomical 
and pathological substrate(s) of neuropsychiatric complications using clinically well 
characterised post-mortem PD human tissue from the UKPDSTB. 
In the first part of the project the extent of a-synuclein (aSN) deposition and Alzheimer's 
disease (AD)-related pathology was assessed in eight regions of the brain that have been 
shown to play a role in cognitive function. The aim of the study was to localise the 
specific pathological and anatomical correlates of dementia and visual hallucinations in 
PD. The results reveal a strong association between aSN pathology in limbic regions and 
dementia and also possibly shed some new light on the anatomical basis of visual 
hallucinations. In the second part of the project I investigated the extent of striatal 
pathology in PD brains and examined its clinical relevance. There were a number of PD 
cases with extensive striatal P-amyloid pathology and the presence of this pathology 
strongly associated with the presence of dementia. The third section of the thesis deals 
with possible pathological correlates of anxiety, a common psychiatric problem among 
PD sufferers. In non-demented PD subjects with anxiety, aSN pathology was particularly 
prevalent in the amygdala and hippocampus. This observation of an apparent limbic 
origin of anxiety in PD may also have a broader significance in terms of other 
neuropsychiatric disorders. 
Quite apart from the pathological basis of the neuropsychiatric features of PD there is still 
debate over the origin and progression of aSN pathology in the brain. In the fourth and 
final part of the thesis I examined the distribution pattern of aSN in the brain and spinal 
cord of 101 unselected consecutive cases accrued by the UKPDSTB. More than 50% of 
the confirmed PD cases fitted the staging scheme proposed by Braak and colleagues but 
in a significant minority of the cases the distribution of pathology did not support a caudal 
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(medullary) origin. In fact the most consistently affected areas were the substantia nigra 
and the nucleus basalis of Meynert. 
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Chapter 1 
Introduction 
1.1 Parkinson's Disease 
1.1.1 History 
James Parkinson, a British physician, published his medical classic "An Essay on 
the Shaking Palsy", in 1817 at the age of 62 on a subject that he called "paralysis 
agitans". His work is considered a medical classic because of the eloquent and detailed 
description of the main clinical features of the disease that is now known as Parkinson's 
Disease (PD). Parkinson based his description solely on six patients of which three were 
"casually met on the street" or "only seen at a distance". He defined the disease as 
follows: "Involuntary tremulous motions, with lessened muscular power, in parts not in 
action and even when supported; with a propensity to bend the trunk forward, and to pass 
from a walking to a running pace: the senses and intellects being uninjured". There are 
several indications that before 1861 the disease had received little attention. It was in 
1861 and 1862 that Jean-Martin Charcot with Alfred Vulpian recognised this disease as 
distinct from other neurologic entities with which it had been previously confused (i.e. 
multiple sclerosis) and attached the name of James Parkinson to this syndrome. Charcot's 
descriptions of PD were amplified throughout his career. It was Charcot who identified 
rigidity as an important sign in PD and differentiated it from spasticity. Following 
Charcot's seminal contributions to the disease, Bechet in 1891 made the remark that all 
symptoms of PD were secondary to rigidity, tremor being an exception. Although Charcot 
and Parkinson pointed out that patients move slowly and with difficulty, they did not see 
this as a symptom on its own right. The slowness of movement was firstly taken into 
account by Claveleira in 1872 and became a new element of the definition while Jaccoud 
in 1873 referred to this symptom as akinesia. In 1886, the neurologist Sir William 
Richard Gowers, introduced the word bradykinesia and emphasised that this symptom 
should be mentioned in any definition of PD. Over the years the constellation of 
symptoms and signs of this clinical entity have come to describe a discrete clinically 
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recognisable malady that even 190 years after its initial description by James Parkinson 
has an aetiopathogenesis that is largely unknown. Today PD is viewed as a distinctive 
progressive disorder characterised clinically by tremor, rigidity, and bradykinesia as well 
as a variety of non-motor complications including neuropsychiatric and autonomic 
deficits; and pathologically by nerve cell loss in the substantia nigra and the presence of 
Lewy intraneuronal inclusion bodies in nigral and extranigral brain regions (Hughes et al. 
1992). A precise definition of three levels of diagnostic confidence for the diagnosis of 
PD has been proposed (Hughes et al. 1992;Gelb et al. 1999). Patient diagnoses are 
classified as Probable when the patients have clinical features that are absolutely typical 
of PD, at least 3 years of parkinsonian symptoms without the development of atypical 
features, and a clear clinical response to dopaminergic treatment. The criteria for Possible 
PD are less strict: patients are not required to have as many typical features of PD, 
symptom duration can be less than 3 years, and patients need not have received an 
adequate trial of dopaminergic therapy. Patients in either category who have autopsy 
findings consistent with PD are designated as Definite. 
1.1.2 Epidemiological Aspects of PD 
PD is the second most common neurodegenerative disease after Alzheimer's 
Disease (AD). According to the United Nations, at least four million people have the 
disease. It is estimated that the prevalence and incidence rates of PD in Europe is 
approximately 108 to 257/ 100,000 and 11 to 19/ 100,000 per year, respectively. In the 
older age groups (i.e. > 60 years) the rates of prevalence and incidence are much higher: 
1280 to 1500/ 100,000 and 346/ 100,000, respectively (von Campenhausen et al. 2005). 
PD is a progressive neurodegenerative disorder which leads to physical disabilities 
that predispose to deep vein thrombosis, pulmonary embolism, pneumonia, aspiration, 
falls with resulting complications and a premature death (Mosewich et al. 1994). Life 
expectancy in Western countries has increased over the last several decades due to better 
treatment strategies (Rajput et al. 1990), improved socioeconomic conditions and better 
health care. PD patients of today share those longevity gains and hence the life 
expectancy of contemporary patients is longer than that of patients diagnosed 30 or 50 
years ago and is not significantly lower than average life expectancy. 
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1.1.3 PD of Known Cause 
The majority (90%) of patients with PD are described as idiopathic/sporadic (i.e. 
having no specific identified cause). However, although idiopathic PD is the most 
common cause of parkinsonism, a wide range of other aetiologies can lead to 
parkinsonian-like symptomatology (see also section 1.2.1.1). There are some PD cases 
where the symptoms may result from genetic mutations, toxicity, head trauma or other 
factors. 
1.1.3.1 Genetic 
There have been two approaches to genetic studies that have yielded very 
important information with regards to the pathogenesis of PD. The first genetic approach 
is that of investigating families with parkinsonism following Mendelian inheritance. 
These studies have identified genes that underlie monogenic PD in particular a-synuclein 
(aSN; Park 1, and Park 4; triplication of aSN) (Polymeropoulos et al. 1997;Singleton et 
al. 2003), LRRK2 (Park 8) (Zimprich et al. 2004;Paisan-Ruiz et al. 2004) and IGYF2 
(Park 11) (Pankratz et al. 2003) in dominant families as well as the recessive PD genes 
parkin (Park 2) (Kitada et al. 1998), PINK 1 (Park 6) (Valente et al. 2004), DJ-1 (Park 7) 
(Bonifati et al. 2003) and UCH-Ll (Park 5) (Leroy et al. 1998) (Table 1.1). There are also 
three gene loci (Park 3, Park 9 and Park 10) with unknown gene products that have also 
been identified to confer forms of genetic PD (Gasser et al. 1998;Ramirez et al. 
2006;Hicks et al. 2002). These mutations cause PD in a very small subset of families. The 
clinical and neuropathological features of PD cases with different mutations vary, but 
individuals with genetic PD consistently respond well to L-DOPA (Mizuno et al. 2006). 
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Table 1.1 Genetics of PD 
(Following page) Abbreviations: AD: autosomal dominant, AR: autosomal recessive, 
3xa-synuclein: a-synuclein triplication, UCH-Ll: ubiquitin C-terminal hydrolase LI, 
PINK 1: PTEN induced kinase 1, DJ 1: oncogene DJl, LRRK2: leukocine-rich repeat 
kinase 2, 
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Locus Chromosomal Gene Mode of Lewy body Special 
name localisation product inheritance pathology clinical features 
Park 1 4q21 a-synuciein AD Yes Dementia 
Park 2 6q25.2-27 Parkin AR No Early onset, foot dystonia 
Park 3 2p13 Unknown AD Yes Dementia 
Park 4 4q21 3xa-synuclein AD Yes Dementia, postural tremor 
Park 5 4q21 UCH-L1 AD Unknown Not described 
Park 6 1p35-36 PINK1 AR Unknown Early onset, tremor dominant 
Park 7 1p36 DJ 1 AR Unknown Early onset, dystonia, psychic disturbances 
Park 8 12p11.2-q13.1 LRRK2 AD Unknown Unknown 
Park 9 1p32 Unknown AR Unknown Late onset 
Park 10 1p32 Unknown Unknown Unknown Not described 
Park 11 2q36-37 IGYF2 AD Unknown Not described 
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Despite the fruitful insights provided by these previous genetic studies, the 
contribution of the mechanisms of these and other genes to idiopathic PD as a whole is 
still poorly defined. In fact, the second genetic approach aims at defining this contribution 
using association studies or non-paramentric linkage methodology not only in sibling pair 
families but also in large populations of patients with sporadic PD (DeStefano et al. 
2002;Pankratz et al. 2002;Martinez et al. 2004;Paisan-Ruiz et al. 2004;Scott et al. 
2001;Scott et al. 2001;Maraganore et al. 2005). Although these studies have provided 
interesting findings, none of them has lead to the discovery of bona fide disease genes. 
1.1.3.2 Toxins 
There are several studies to suggest that toxins can cause PD or parkinsonism. The 
toxins most strongly suspected at present are pesticides. Evidence of their role as 
neurotoxins is provided by clinical and experimental work. Most, though not all, 
epidemiological studies have found that pesticide exposure is associated with a high risk 
of PD (Seidler et al. 1996;Liou et al. 1997;Gorell et al. 1998;Petrovitch et al 2002). The 
results are consistent with a dose dependent effect in agricultural workers, risk is 
increased with duration of pesticide use (Liou et al. 1997;Petrovitch et al. 2002). 
Information about exposure to specific pesticides also suggests that bipyridyl (paraquat), 
organochlorine and carbamate derivatives could have a permissive or causal role in PD 
(Liou et al. 1997;Seidler et al. 1996). For example, in a study in Taiwan, where the 
herbicide paraquat is commonly sprayed on rice fields, a strong association was reported 
between paraquat exposure and PD risk: the risk was increased by more than six times in 
individuals who had been exposed to paraquat for more than 20 years (Liou et al. 1997). 
Studies of the relation between toxins and the development of PD have also 
focused on metals. In idiopathic PD, experimental work with metals has mostly focused 
on the potential role of iron and other transition elements. Iron is unevenly distributed 
throughout the brain, but it reaches particularly high concentrations in the basal ganglia 
(Zecca et al. 1994). Increased iron in the brains of patients with PD was first reported by 
Earle (Earle 1968) and subsequent studies have confirmed this accumulation in the pars 
compacta of the substantia nigra (Sofic et al. 1988;Dexter et al. 1989). Dexter et al., 
(Dexter et al. 1990) have also measured decreased levels of ferritin in the nigral tissue of 
patients with PD (ferritin is the primary intracellular protein capable of keeping iron 
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bound in a non-reactive status). Thus, iron accumulation together with decreased binding 
capability may enhance the risk for iron-mediated toxic reactions in PD. In particular, the 
Fenton reaction could generate the highly toxic hydroxyl radical in the presence of iron 
and hydrogen peroxide, thus leading to oxidative stress and possibly neurodegeneration. 
In a population-based case-control study, the potential role of metals as risk factors for 
PD was evaluated in the occupational setting in which the effects of metals would be 
expected to be magnified by greater and prolonged exposures (Gorell et al. 1997). 
Increased risk for PD was found in workers exposed to metals for more than 20 years, 
suggesting a long-latency and/or slowly progressive mechanism of accumulation and 
toxicity. Also, enhanced risk was shown as a result of combined metal exposures, i.e. 
lead-copper, lead-iron and iron-copper, raising the possibility that metals may act 
synergistically in contributing to nigrostriatal degeneration. Based on these data, the 
effects of prolonged exposures and interactions should become a focus of future studies 
investigating the relationship between metals and PD. 
In the early 1980s, parkinsonism in young drug addicts was linked to their 
exposure to 1 -methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Langston et al. 
1983). This unfortunate accident provided a new insight into the link between 
envirormiental agents and PD. If MPTP is capable of inducing neurochemical, 
pathological and clinical features that resemble those of idiopathic PD (Di Monte et al. 
2002), comparable effects might be caused by other neurotoxins similar to MPTP but 
naturally occurring in the environment (MPTP analogs). Several classes of heterocyclic 
molecules structurally related to MPTP have been proposed as candidate endogenous and 
exogenous parkinsongenic agents. Among these classes of MPTP analogs, 
tetrahydroisoquinoline (TIQ) and b-carboline (b-C) derivatives have been the most 
studied. TIQs and b-Cs are naturally occurring alkaloids present, for example, in a variety 
of foods (Makino et al. 1988). They can also be generated, however, within the brain by 
reactions involving biogenic amines, such as condensation of the amine group of 
dopamine with the reactive carbonyl groups of aldehydes and a-ketoacids (Collins and 
Origitano 1983). Interestingly, both TIQs and b-Cs have been detected in the human brain 
(Niwa et al. 1987;Matsubara et al. 1993) as well as in the cerebrospinal fluid of patients 
with PD (Kotake et al. 1995;Matsubara et al. 1995). They have also been reported to 
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cause nigrostriatal damage in experimental animals including nonhuman primates 
(Nagatsu and Yoshida 1988;Neafsey et al. 1995). 
1.1.4 Clues to the Cause of PD from Epidemiological Studies 
1.1.4.1 Increasing Age 
Of all factors studied so far, age is the most highly linked to PD. The incidence of 
PD increases steeply from less than 10 new cases per 100,000 at age 50 to at least 200 
new cases per 100,000 at age 80 (Bower et al. 2000;Van Den Eeden et al. 2003). 
Although, some studies show a decrease in the very elderly, this most likely reflects poor 
ascertainment rather than an actual decrease in disease prevalence. 
1.1.4.2 Gender 
PD is approximately 1.2 to 1.5 times more common in men than in women 
(Mayeux et al. 1992;Van Den Eeden et al. 2003;Harada et al. 1983). The increased 
incidence in men over women may result from biological phenomena, for instance, 
influence of sex hormones or genetic factors (i.e. genes on chromosome X vs. Y) or due 
to a male associated exposure such as occupational toxicant exposure. In addition, 
epidemiological studies of oestrogen in women show that women with PD are more likely 
to have undergone hysterectomy and had earlier menopause than control subjects 
(Benedetti et al. 2001). 
1.1.4.3 Race 
Several studies have suggested an increased incidence of PD in Caucasian rather 
than African-American or Asian-American populations, however, this question remains 
unsettled (Van Den Eeden et al. 2003;Schoenberg et al. 1985). Across European 
countries studies have revealed no substantial difference in the prevalence of PD (de Rijk 
et al. 2000;de Rijk et al. 1997;Rocca 2000). Nevertheless, more studies are needed to 
determine whether people of different ethnicity have differing risks of PD. 
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1.1.4.4 Head Trauma 
Several authors have reported a significant association between head trauma and 
the later development of PD (Bower et al. 2003;Goldman et al 2006;Factor and Weiner 
1991;Taylor et al. 1999;Semchuk et al. 1993). A recent study by Bower and colleagues 
found that those who have experienced a head injury are four times more likely to 
develop PD than those who have never suffered a head injury (Bower et al. 2003). In 
addition, this study reported that the risk of developing PD increases eightfold for patients 
who had a head trauma and required hospitalisation and it increases to elevenfold for 
patients who have experienced severe head trauma. Although the results of this study may 
be biased by recall Goldman and co-workers found a similar risk of 3.8, with increasing 
risk associated with more severe injury and hospitalisation (Goldman et al. 2006). 
Interestingly, severe head trauma in mice is associated with age-dependent enhanced 
immunoreactivity to synucleins, which could be the pathogenetic basis of PD after trauma 
in humans (Uryu et al. 2003). Dementia pugilistica, also known as punch-drunk 
syndrome, offers another link between head trauma and the later development of PD 
symptoms. This neurological condition occurs in approximately 20% of professional 
boxers with risk factors including increased exposure (i.e. duration of career, total number 
of bouts, age of retirement), poor performance and increased sparring (Jordan 2000). 
Clinically, boxers present with dementia and parkinsonism (Jordan 2000). Pathologically, 
dementia pugilistica shares many characteristics with AD (i.e. neurofibrillary changes, 
diffuse amyloid plaques) (Jordan 2000;Toth et al. 2005;Schmidt et al. 2001). 
1.1.4.5 Tobacco, Coffee and Alcohol 
Smoking of cigarettes is among the most studied risk factors for PD and one of the 
few for which very consistent results have been obtained. Many epidemiological studies 
have shown a reduced risk of PD among cigarette smokers. The vast majority of these 
were case-control studies, but some large prospective cohort studies confirmed their 
results (Grandinetti et al. 1994;Paganini-Hill 2001;Hernan et al. 2001). 
Several studies assessed coffee consumption in relation to PD risk, with fairly 
consistent results. Again, findings from case-control studies have been confirmed in 
several large follow-up studies (Ascherio et al 2001). A meta-analysis based on eight 
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case-control studies and five cohort studies showed a significantly decreased PD risk for 
coffee drinkers that was not attenuated when analyses were adjusted for smoking (Hernan 
et al. 2001). 
The findings on smoking and coffee consumption and the hypothesised role of 
dopaminergic reward systems have led some researchers to examine the association 
between alcohol consumption and the risk of PD. However, results of a number of case-
control studies and some prospective cohort studies (Heman et al. 2003) have not been 
very straightforward, with inverse associations in some studies (Fall et al. 1999) but no 
significant association in others (Benedetti et al. 2000;Checkoway et al 2002). 
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1.2 Clinical Picture 
1.2.1 Motor Deficits - Cardinal Features of PD 
Tremor at rest, rigidity, bradykinesia and abnormalities of posture, gait and 
balance are the cardinal clinical manifestations of PD. 
Tremor is the most conspicuous of the cardinal features of PD and gave rise to the 
initial name of PD, "shaking palsy". Approximately 70% of patients notice tremor as the 
first symptom (Calne and Stoessl 1986). Tremors of all behavioural type, and therefore of 
differing pathophysiological basis, are recognised in PD (Findley 1996;Findley et al. 
1981) however, PD tremor is classically described to be present at rest rather than a 
postural or action tremor. Characteristically, tremor is 3-5 Hz rhythmic "pill rolling" 
movements of the thumb and forefinger and has varying amplitude (Deuschl et al. 
1998;Hallett 1998). At a later stage of the disease tremor may spread to the proximal 
joints of the limb. Onset of tremor is usually in one of the hands (Findley and Gresty 
1981) and it progresses to involve the other upper limb or ipsilateral lower limb. The jaw, 
tongue, head or trunk may be affected by tremor although, head tremor or trunkal tremor 
are not usually associated with early PD. Early in the disease, tremor is usually 
intermittent for many years and is evident only under stress. Tremor in PD is worsened by 
nervousness, fatigue and stress and diminished with voluntary movement or sleep. 
Studies have revealed that PD patients may also have other types of tremor. In particular, 
in early phases of their disease, many patients report a feeling of tremulousness without 
having an obvious resting tremor (Lees 1992). PD tremor is produced by alternate 
activation of agonist and antagonist muscles. In this respect, PD tremor is distinct from 
essential tremor, which is produced by oscillating co-contractions of agonist and 
antagonist muscles (Boose et al. 1996). 
Rigidity (defined as an increased resistance of a joint to passive movement) 
frequently associated with cogwheeling (palpable tremor), is a plastic, lead-pipe form of 
hypertonia that affects many muscles of the limbs, neck and trunk and is responsible for 
the typical stooped posture of the PD patients especially as the disease progresses (Calne 
et al. 1992). In contrast to spasticity, rigidity is constant throughout the range of 
movement. Rigidity is often asymmetrical in the early stages of the disease. Like tremor, 
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it may vary during the course of the day and with stress. Although rigidity is considered 
as one of the cardinal features of PD, it only minimally contributes to the impairment 
experienced by the patients. The subjective correlate of rigidity is a feeling of stiffness 
and a reduced ability to relax limb muscles. 
Akinesia (literally meaning the absence of movement) is another cardinal 
symptom of PD however, it is an imprecise term to describe the slowness and poverty of 
movements characteristic of PD. From a scientific point of view, bradykinesia and 
hypokinesia is a more appropriate term, since a minority of PD patients experience 
situations in which movements are completely impossible/absent (Klockgether 2004;Fahn 
2003). Bradykinesia/hypokinesia affects all voluntary and involuntary movements and is 
one of the most disabling components of all the clinical signs of PD especially as the 
disease progresses (Hallett and Khoshbin 1980). Bradykinesia/hypokinesia in the upper 
extremities often manifests as micrographia. However, in early stages of PD may 
manifest as minimal slowness. Bradykinesia/hypokinesia and rigidity usually occur 
together and in most cases are comparable in severity (Rao et al. 2006;Fahn 2003). 
Abnormalities of posture, gait and balance usually occur about five years after 
the onset of PD (Marttila and Rinne 1977), although may sometimes occur earlier 
(Zetusky et al. 1985;Gibb and Lees 1988). The posture may show slight flexion of the 
neck or trunk or a lean to one side. Abnormalities of gait may include the following: 1) 
loss of arm swing on one or both sides, 2) slowing, 3) tripping over objects, 4) inability to 
turn quickly, and 5) difficulty in walking on toes or heels. As the disease progresses gait 
becomes a problem. Short term arrests of ongoing movements (known as freezing) also 
occur in advanced PD (Giladi et al. 1992). 
1.2.1.1 Differential Diagnosis 
It is very important for the diagnosis of PD to be differentiated from other 
recognisable parkinsonian disorders or conditions with parkinsonian-like 
symptomatology including multiple system atrophy, progressive supranuclear palsy, 
corticobasal degeneration, dementia with Lewy bodies, vascular parkinsonism, essential 
tremor, drug-induced parkinsonism, toxin-induced parkinsonism and hereditary/metabolic 
parkinsonism (e.g. Wilson's disease, juvenile Huntington's disease, Machado-Joseph 
disease and Hallervorden-Spatz disease) (Oder et al. 1993;Adams et al. 1988;Barbeau et 
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al. 1984;Swaiman 1991;Poewe and Wenning 2002;Weiner 2005;Facca and Koller 
2003;Mark 2001;Hobson 2003). In fact, the triad of cardinal signs described earlier makes 
up what neurologists perceive to constitute PD and when present a diagnosis should be 
seriously considered. If, in addition, there is improvement on L-DOPA treatment with the 
eventual emergence of dyskinesias and motor fluctuations then 80-90% the diagnosis is 
probable. In the absence of a biological marker for PD the diagnosis can only be made 
with certainty at autopsy. However, imaging has proved helpful in confirming the 
diagnosis in some cases. For instance, 2B-carboxymethoxy-3B(4-iodophenyl) tropane also 
known as DOPASCAN™ and Single Photon Emission Computerised Tomography 
(SPECT) as well as Positron Emission Tomography (PET) using various ligands have 
been used to help the diagnosis of PD as well as to exclude secondary causes of 
parkinsonism such as progressive supranuclear palsy, cerebrovascular disease, 
Huntington's disease, normal pressure hydrocephalus and olivopontocerebellar atrophy 
(Seibyle/^a/. 1995;Wolfson eZ a/. 1985;Martin e/'a/. 1984;Garnett a/. 1983;Eidelberg 
al. 1995;Morrish et al. 1995;Guttman et al. 1997;Rinne et al. 1995;Antonini et al. 
1998;Brooks 1990;Brooks 1993;Hobson 2003). 
1.2.2 Non-motor Deficits 
1.2.2.1 Autonomic 
There are several autonomic disorders that occur in PD patients. Although, some 
patients with parkinsonism and autonomic disorders go on to be diagnosed as multiple 
system atrophy and Shy Drager syndrome, most idiopathic PD patients develop some 
degree of autonomic dysfunction over time. These disorders can be divided according to 
the system involved. 
1.2.2.1.1 Gastrointestinal Dysfunction 
Among the most common gastrointestinal symptoms in patients with established 
PD is constipation (Edwards et al. 1993). This may occur secondary to the disease itself 
or may be a side effect of the medications (dopaminergic, anticholinergic) used to treat 
PD (Sakakibara et al. 2003). Constipation in PD may also result from a variety of other 
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factors (not necessarily related to autonomic nervous system dysfunction) including 
decreased physical exercise, diminished intake of food and liquid or dysfunction of 
sphincters. 
Svyallowing difficulty is another common gastrointestinal problem in PD and 
because of the risk of aspiration and the impact on nutrition this can be potentially life-
threatening. The primary symptoms are drooUng and dysphagia, the latter is described as 
a sensation of food sticking at the level of the thyroid cartilage or below (Edwards et al. 
1993). Drooling in PD and difficulty with saliva are manifestations of disordered 
swallowing and not of abnormal salivation. Patients with PD do not secrete excess saliva, 
indeed salivary output in PD is either normal or decreased (Edwards et al. 1992). 
Drooling reflects a difficulty in transporting saliva to the posterior pharynx (Edwards et 
af. 1991). 
1.2.2.1.2 Cardiovascular Dysfunction 
Clinically significant cardiovascular dysfunction in PD is rare, with orthostatic 
hypotension serving as the most notable exception. Orthostatic hypotension is a drop in 
blood pressure when arising from a sitting or lying position, indeed orthostatic 
hypotension is very common in PD (Gross et al. 1972;Goldstein et al. 2002;Goldstein 
2003;Bonuccelli et al. 2003). The drop in blood pressure most often occurs after a change 
in posture but can also occur following exercise and after eating when blood is diverted to 
the splanchnic vasculature (Turkka et al. 1987). 
1.2.2.1.3 Thermoregulatory Dysfunction 
Excessive sweating and less commonly hypohydrosis, may occur in patients with 
PD and may be related to involvement of the hypothalamus (Swirm et al. 2003). Tanner 
and co-workers found 48% of PD patients to have excessive sweating (Tanner et al. 
1982). Often the excessive sweating occurs in patients who develop motor fluctuations 
(Swinn et al. 2003;Tarmer et al. 1982). Of interest, some patients have this in the on state, 
especially with dyskinesias, but most have it in the off state when it is often more severe 
(Witjas et al. 2002). 
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1.2.2.1.4 Urologic Dysfunction 
Urinary frequency and urgency are common complications in PD found in both 
men and women (Olanow et al. 2001). This autonomic symptom is probably due to 
involvement of components of the autonomic nervous system. The pathology in PD 
targets many brain regions normally involved in detrusor control including pathways of 
the basal ganglia, hypothalamus, and locus coeruleus (Sotolongo, Jr. 1988). Detrusor 
hyperactivity occurs in the majority of PD patients (Andersen 1985). Urinary symptoms 
in PD usually take the form of nocturia, urinary frequency during the day, urinary 
urgency and urge incontinence. 
1.2.2.1.5 Pupillary Changes 
Pupillary change is another autonomic change seen in PD patients. Abnormally 
slow pupillary responses to light and pain in PD patients have been described (Micieli et 
al. 1987). More specifically, studies focusing on pupillary responses in PD have found 
that while resting diameters are normal the response to changes in light is less (Micieli et 
al. 1991). The results of instillation of pharmacologic agents to the eye have 
demonstrated that the peripheral autonomic nervous system to be intact in PD subjects. 
The findings suggest that pupillary abnormalities in PD result from central autonomic 
dysfunction centred in the parasympathetic Edinger-Westphal nucleus of the midbrain. 
Nevertheless, clinically significant pupillary changes do not appear to be common. 
1.2.2.1.6 Sexual Dysfunction 
Sexual dysftinction occurs in many patients with PD and can be due to autonomic 
dysfunction as well as the effects of the PD medications (Koller et al. 1990;Wermuth and 
Stenager 1995;Bronner et al. 2004). Men often develop difficulty with attaining and 
maintaining erections or ejaculating, whereas women may have difficulty with orgasms. 
Some patients respond to dopaminergic treatment and in rare instances, both men and 
women may become hypersexual on these medications (Uitti et al. 1989) or after PD 
surgery (Roane et al. 2002). 
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1.2.3 Neuropsychiatric 
Although PD is dominated by motor symptoms during the initial stages, most if 
not all patients develop additional non-motor manifestations. Among the most common 
are neuropsychiatric disturbances. Neuropsychiatric symptoms have a major impact on 
the natural history and prognosis of PD and have been identified as one of the cardinal 
risk factors for nursing home placement and increased mortality (Goetz and Stebbins 
1993). 
1.2.3.1 Anxiety and Depression 
Anxiety disorders are common in PD. One of the first formal studies of anxiety in 
PD was conducted by Rubin et al , (Rubin AJ et al. 1986). The authors reported that 
anxiety was greater than that estimated for the general population. Other subsequent 
studies have also observed that anxiety in patients with PD occurs more frequently than 
expected. Menza and colleagues studied 104 PD patients and 61 medical controls with 
similar disability for symptoms of anxiety and depression (Menza and Mark 1994). All 
patients completed the Zung self rating for depression and the Zung self rating for anxiety 
scale: the mean anxiety scale was 25.2 for patients with PD and 20.9 in control patients. 
Thus, patients with PD scored significantly higher than control subjects on this measure 
of anxiety (p<0.001). In another study by Menza et al., 42 patients with PD were 
compared with 21 matched medical control subjects (patients with chronic debilitating 
osteoarthritis matched for age and length of illness) using Diagnostic and Statistical 
Manual of Mental Disorders (DSM)-III-R criteria and a variety of psychiatric scales 
(Menza et al. 1993). Twelve PD patients (29%) but only one medical control subject 
(5%), had a formal anxiety disorder. Gotham and co-workers assessed patients with PD, 
patients with arthritis and normal controls using the Beck depression inventory, the Beck 
hopelessness scale and the Spielberger anxiety index (Gotham et al. 1986). Patients with 
PD scored significantly higher than the normal controls but did not differ from those with 
arthritis. The prevalence of anxiety in PD patients ranges from 5.3 to 40%. Stein et al., 
systematically evaluated 24 patients with PD for the presence of DSM-III-R axis 
syndromes. He found that nine of the twenty-four had clinical important anxiety (Stein et 
al. 1990). Starkstein et al., found that 40% of patient with PD met DSM-III criteria for 
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anxiety disorders (Starkstein SE et al 1993). While anxiety was associated with 
depression, some patients showed anxiety without depression. Thus most studies have 
shown that anxiety occurs commonly in PD at a higher rate than in normal or other 
disease comparison populations. 
The type of anxiety disorder in PD seems to be clustered in the panic disorder, 
phobic disorder and generalised anxiety disorder areas. However, a variety of other types 
of anxiety disorder have been identified in patients with PD (see Table 1.2) (Menza et al. 
1993;Stein et al. 1990;Schiffer et al. 1988;Lauterbach and Duvoisin 1991). Despite the 
high incidence of anxiety in PD it is still unclear why PD patients are especially prone to 
anxiety. Some suggest that anxiety may relate to the psychological and social difficuhies 
of the disease (i.e. social anxiety) (Ellgring et al. 1990), yet others have found that 
depressed PD patients have significantly higher anxiety levels than depressed multiple 
sclerosis patients (Schiffer et al. 1988). Therefore, anxiety in PD may not simply be the 
result of psychological and social difficulties of the disease but rather may be due to 
specific neurobiological mechanisms. 
Table 1.2 List of different types of anxiety disorder identified in patients with PD 
Anxiety Disorders found in PD 
Generalised Anxiety Disorder 
Panic Disorder 
Social Phobia 
Phobic Disorder 
Agoraphobia 
Obsessive-Compulsive Disorder 
Anxiety Disorder not otherwise specifie 
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Among the most common affective and behavioural symptoms that accompany 
PD is depression (Cummings 1992;Cummings and Masterman 1999;Poewe and Luginger 
1999). Depression in PD has been classified as major depression. Major depression as 
defined by the DSM IV criteria (American Psychiatric Association 1994) is present if a 
patient exhibits five or more of the following: 1) depressed mood, 2) decreased interest 
(apathy) or pleasure in activities (anhedonia), 3) significant weight loss, 4) insomnia or 
excessive sleep, 5) psychomotor retardation, or agitation, 6) loss of energy (anergia), 7) 
feelings of inappropriate guilt and 8) recurrent thoughts of death. Indeed, many of these 
symptoms are seen in PD patients. However, the profile of depressive symptoms observed 
in PD is not identical to that reported in patients with primary depression (also known as 
endogenous depression). Distinctive features of depression in PD include elevated levels 
of dysphoria, irritability, little guilt or feelings of failure and a low suicide rate despite a 
high frequency of suicidal ideation. Diagnosis of depression in PD is complicated by 
overlapping symptoms of the two disorders. Symptoms of depression including 
psychomotor slowing and retardation; reduced mimics and apathy may be 
indistinguishable from neurological motor deficits in PD. Diagnosis of depression in PD 
is almost exclusively based on subjectively experienced depressive symptoms including: 
(1) feeling of emptiness and hopelessness, (2) reduced reactivity to emotional stimuli, (3) 
loss of the ability to enjoy and feel pleasure (anhedonia). 
Given the difficulties in diagnosing depression in PD is not surprising the marked 
differences in the prevalence of depression in PD as reported in Europe and North 
America: from 4% to 70% (Leentjens 2004;Burn 2002;Zesiewicz et al. 1999;Cummings 
1992). The results of prevalence studies are further confounded by the diagnostic 
instrument used, how depression is defined and the nature of the study population 
(hospital vs. community-based). In a review of all studies of depression in PD published 
from 1992 to 1998, a total of 45 studies comprising 5911 PD patients, 31% of patients 
were at any given time depressed (Brooks and Doder 2001). This compares to a 
prevalence of depression in the general population of 16% (Kessler et al 2003). 
Attempts have been made to correlate depression with disease severity as well as 
disease duration, young age of onset and age (Leentjens 2004;Burn 2002;Zesiewicz el al. 
1999;Menza and Mark 1994;Slaughter et al 2001). Some reports show a correlation 
between depression and disease severity, some with young age of onset, and some show 
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no correlation between depression and disease severity. The weak correlation between 
depression and disease severity speaks to depression being not a psychological reaction to 
PD, but being part of PD related to neurodegeneration in the nervous system. In addition, 
the relative absence of guilt, shame, or sorrow in depressed PD patients speaks to 
depression not being a psychological reaction to PD. 
Both depression and anxiety may predate the onset of motor features of PD by a 
number of years. In one series, depressive symptoms preceded the motor disturbance in 
12-37% of patients (Taylor et al. 1986). Shiba and colleagues studied the association 
between preceding anxiety, depression and PD using a case control design (Shiba et al. 
2000). Depressive disorders were significantly associated with PD, although the 
significance of the association was lost when depressive disorders first recognised within 
the 5 years preceding onset of PD were excluded. Anxiety disorders were also 
significantly associated with PD and the association remained significant up to 20 years 
or more before the onset of motor symptoms of PD. These finding would be consistent 
with anxiety and depression being early non-motor manifestations of the disease process 
underlying PD. 
It is well known that in psychiatric populations, anxiety and depression commonly 
coexist. In a review of coexisting anxiety and depression, Lydiard noted that up to 60% of 
patients with depressive symptoms also had anxiety (Lydiard 1991). Interestingly, there 
appears to be a relationship between anxiety and depression in PD as well (Gotham et al. 
1986). Patients with the disease have significantly higher levels of depression and anxiety 
than normal controls (Gotham et al. 1986). Henderson et al found that depression in 
combination with panic and/or anxiety occurred in 38% of parkinsonian patients 
compared with 8% of healthy spouse controls: depression and anxiety were highly 
correlated in patients with PD (Henderson et al. 1992). Twenty per cent of these patients 
reported the onset of depression and/or anxiety before the onset of physical symptoms. 
Menza et al found that 92% of patients with PD who had an anxiety disorder diagnosis 
also had depressive disorders or symptoms and 67% of patients with a depressive disorder 
had an anxiety disorder diagnosis (Menza et al. 1993). A number of other studies have 
also found that the degree of comorbidity between anxiety and depression in patients with 
PD is in excess of that found in those without (Cummings 1992). These findings may 
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suggest that the structures and pathways mediating depression and anxiety may be 
contiguous and shared explaining, in part, the high comorbidity of both symptoms in PD. 
Depression and anxiety are important contributors to caregiver stress (Aarsland et 
al. 1999b). Caregivers of PD patients with psychiatric symptoms including depression 
and anxiety a greater number of them report tiredness, sadness and less satisfaction with 
life compared with healthy elderly subjects (Aarsland et al. 1999b). 
1.2.3.2 Psychosis (Hallucinations and Delusions) 
Psychosis is a prominent neuropsychiatric symptom among PD patients. 
According to DSM-IV the definition of psychosis requires hallucinations and/or delusions 
with loss of insight. Delusions are false, fixed, idiosyncratic beliefs that are maintained 
despite evidence to the contrary. Hallucinations are defined as abnormal perceptions 
without physical stimulus that can involve any sensory modality and may be simple or 
complex. Visual hallucinations (VH) are the most common psychotic symptoms in PD 
with some studies reporting more than 90% of all psychotic PD patients having 
experienced VH (Graham et al. 1997). One categorisation of VH in PD is simple vs. 
complex. Simple VH are characterised by the absence of form and are often photopsias 
such as flashes or light or colour. On the other hand, complex VH are characterised by 
visions that are clearly defined, have specific form and can include animals, objects and 
humans. VH in some cases are confused with illusions which are misperceptions of real 
stimuli that are often visual in nature. 
VH in PD tend to be present intermittently, lasting seconds to minutes at a time 
unlike schizophrenic hallucinations (Barnes and David 2001). The frequency can vary, 
but most studies register the presence of hallucinations when they occur at least one time 
per week. Often, they occur several times per day. VH tend to occur during times of low 
ambient stimulation, most typically in the evening or when the patient is alone in a quiet 
environment. VH in PD tend to persist, so that while each VH episode is brief, the 
hallucinatory state, once established, is a chronic one (de Maindreville et al. 2005;Goetz 
et al. 2001). Delusions are commonly paranoid, consisting of beliefs about spousal 
infidelity or abandonment (Marsh 2004). Grandiose, somatic, persecutory (Factor and 
Molho 2004) and religious delusions also occur, but are less frequently reported in 
clinical series (Diederich et al. 2003). 
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Auditory hallucinations (AH), although, less common than VH are generally 
experienced by PD patients. AH range from indistinct whispers or music to threatening 
voices (Inzelberg et al. 1998b;Marsh 2004;Factor and Molho 2004). AH variably co-
occur with visual hallucinations (8%-13%) and are less likely to be seen in isolation 
(Inzelberg et al. 1998b;Marsh 2004). This pattern is in contrast to the AH typical of 
schizophrenia. Similarly, in PD tactile, olfactory and gustatory hallucinations are 
relatively uncommon and generally occur with visual hallucinations (Marsh 2004). 
VH in PD are classically considered as adverse events of anti-parkinsonian 
medication (Friedman 1991 fac tor et al. 1995). This is based on common clinical 
experience that psychotic symptoms are closely linked to dopaminergic treatment, while 
dopamine receptor blockers can alleviate these symptoms (Friedman 1991). However, 
comparisons of hallucinators and non-hallucinators have seldom shown major differences 
in drug history. Goetz et al., studied five non-demented patients with PD with daily 
hallucinations who were given high dose of levodopa infusions in a placebo controlled 
trial (Goetz et al. 1998). No hallucinations were provoked. In two other studies no 
correlation was found between levodopa administration and hallucinations or delusions in 
patients with PD (Klein et al. 1997;Aarsland et al. 1999a). Other risk factors for the 
development of hallucinations in PD have been described including older age and longer 
duration of disease, cognitive impairment, depression and sleep disturbances (Barnes and 
David 2001 ;Graham a/. 1997;Aarsland e? a/. 1999a;Fenelon e? a/. 2000). 
Psychosis (hallucinations and delusions) is associated with increased caregiver 
burden (Aarsland et al. 1999b), nursing home placement and increased mortality (Factor 
et al. 2003). A case-control study examined PD patients who entered nursing homes and 
compared each of them with 2 community-dwelling PD subjects who were matched for 
age, gender and PD duration. The investigators compared motor disability, dementia and 
hallucinations as putative risk factors for nursing home placement. The only statistically 
differentiating features were the presence and severity of hallucinations, witli 82% of tlie 
nursing home subjects having this behaviour compared to 5% of the subjects living in the 
community (Goetz and Stebbins 1995). 
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1.2.3.3 Dementia 
Cognitive impairment is commonly associated with PD, although deficits may be 
relatively subtle and not clinically apparent or not overtly affect daily functioning. In fact, 
cognitive dysfunction in PD can be classified as domain-specific cognitive impairments 
not extensive or severe enough to fulfil the DSM-IV criteria for the diagnosis of dementia 
or severe enough to qualify as dementia. 
The prevalence of dementia in PD varies considerably among studies, possibly 
due to differences in patient population, study design and criteria for diagnosing PD with 
dementia. In cross-sectional studies, prevalence of dementia in PD ranges from 10% to 
over 40% (Aarsland et al. 1996;Mayeux et al. 1988;Mayeux et al. 1992). Features 
associated with prevalence of dementia includes age (Mayeux et al. 1988;Aarsland et al. 
1996), age at onset of PD (Aarsland et al. 1996;Mayeux et al. 1988;Mayeux et al. 1992), 
disease severity (Mayeux et al. 1988), disease duration (Aarsland et al. 1996), depression 
(Aarsland et al. 1996) and presence of atypical parkinsonian symptoms such as early 
occurrence of autonomic failure, symmetrical disease presentation and moderate response 
to dopaminergic treatment (Aarsland et al. 1996). The association with older age is of 
particular importance. The ApoE 4 allele, which has been consistently shown to be 
associated with a higher risk of AD does not constitute a risk factor for dementia in PD 
(Inzelberg et al. 1998a). Prospective studies have reported a cumulative incidence of 19 
to 53% (Hughes et al. 2000). Recently, in a prospective study with 8 years follow-up, 
78.2% of patients eventually developed dementia (Aarsland et al. 2003). In another 
prospective study the incidence of developing dementia in PD patients was up to six times 
higher compared to age-matched control subjects (Aarsland et al. 2001). In these 
prospective studies factors associated with the risk of dementia were found to be age 
(Levy et al. 2002), age at onset of PD (Mahieux et al. 1998), disease severity (Aarsland et 
al. 2001;Hughes et al. 2000), age at entry in the study (Hughes et al. 2000), confusional 
state (Stern et al. 1993), early hallucinations and the mixed tremor/akinetic form of PD 
(Aarsland et al. 2003). 
The clinical profile of dementia in PD encompasses qualitatively the same deficits 
as in non-demented PD subjects but the impairments are more extensive and severe. A 
wide variety of cognitive deficits have been described, the most prominent of which is a 
deficit in executive function. Executive function is a broad term used to describe a range 
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of cognitive functions involved in the realisations of goal-directed, adaptive behaviour in 
response to new, challenging, environmental situations, including attention, inhibition, 
task management, planning, monitoring and coding (Smith and Jonides 1999). 
Impairment of executive functions such as impairment in concept formation, rule finding, 
problem solving, set elaboration and planning, set shifting and set maintenance have all 
been described in PD patients (Pillon et al. 1986;Litvan et al. 1991). The finding that 
patients have difficulties of internally cued behaviour and they substantially benefit from 
external cues to the fact that executive dysfunction in PD differs from that due to frontal 
cortical involvement (Owen et al. 1993). 
Besides executive dysfunction, there is considerable evidence of deficits in 
visuospatial function even when tests contain few motor components (Boiler et al. 1984). 
Tasks that require visuospatial analysis and orientation are the most affected, which 
suggests that visual perception is the most impaired function (Girotti et al. 1988). 
Nevertheless, with the exception of orientation, most authors believe that visuospatial 
dysfunction to be the result of high cognitive demand that is usually required by such 
tasks. Indeed, it would appear that visuospatial dysfunction in PD can be readily 
explained by the demand of visuospatial tasks on executive functions such as planning 
and shifting of attention (Brown and Marsden 1988). 
Memory deficits including working memory, long-term memory, visuospatial 
memory and procedural memory have been frequently reported in demented PD patients 
but the impairment differs from the amnesia seen in patients with AD (Pillon et al. 1991). 
Deficits in learning of new information have been consistently described, although these 
deficits are less severe than that seen in AD (Pillon et al. 1991;Helkala et al. 1989). 
Several studies have shown that demented PD patients have impaired free recall similar to 
that seen in AD patients but PD patients benefit substantially from semantic cueing or 
probing which implies that new information are stored but not easily/readily accessed 
(Helkala et al. 1988;Pillon et al. 1993). Therefore, the problem in PD patients with 
dementia seems to be of retrieval and not of encoding. Indeed, recognition memoiy is 
often well preserved in PD patients with dementia. In addition, unlike AD aphasia, 
apraxia or agnosia are not very common in demented PD patients (Dubois and Pillon 
1997;Huber et al. 1989). Quite analogous to visuospatial dysfunction, most authors 
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suggest that memory dysfunction in PD would for the most part be secondarily impaired 
due to the reliance of its manifestation on executive functionality. 
Attention, as measured by parameters such as cognitive reaction and vigilance has 
been found to be impaired in PD patients with dementia (Litvan et al 1991) and there is 
also evidence of fluctuations in attention (Ballard et al. 2002). These findings are very 
similar to those found in patients with dementia with Lewy bodies (DLB) (McKeith et al. 
1996). Indeed, PD patients with dementia and DLB share many clinical features (Ballard 
et al. 2002) and are often difficult to distinguish other than by the temporal onset of 
dementia and psychosis in relation to parkinsonism (McKeith et al. 1996;McKeith et al. 
2005). Therefore, according to clinical diagnostic criteria if extrapyramidal symptoms 
precede dementia by more than 12 months the patient is classified as having PD with 
dementia. If on the other hand, dementia and extrapyramidal symptoms develop together 
within a 12 month period or dementia precedes extrapyramidal symptoms (by 
approximately 1 year) then the patient is classified as having DLB (McKeith et al. 
1996;McKeithgra/. 2005). 
Dementia in PD is a major risk factor for nursing home placement and the risk of 
death in patients with PD and dementia is substantially higher than those without 
dementia: the survival rate of patients with dementia was found to be significantly shorter 
compared to non-demented patients (Mindham et al. 1982;Boller et al. 1980). 
1.2.4 Treatment 
Treatment of PD is complex due to the progressive nature of the disease and the 
array of motor and non-motor features combined with early and late side effects 
associated with therapeutic interventions. A growing number of medical and surgical 
treatment options are available. Table 1.3 and 1.4 provide a general overview of the 
current treatments for PD motor, neuropsychiatric and autonomic symptoms. These tables 
were adopted from Rascol et al., (Rascol et al. 2002a) and modified based on information 
from the following references (Rascol et al. 2003;Rascol et al. 2002b;Rascol et al. 
2001;Senard et al. 2001;Weintraub and Stern 2007;Bonuccelli et al. 2003). 
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Table 1.3 Therapeutic Interventions for Symptoms of PD 
(Following page) MAO-B: mono-amineoxidase-B 
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Drugs Promote Dopamine Synthesis Activate Specific Receptors Prolong Dopamine Availability 
Dopaminergic Levodopa+ dopa-decarboxylase Dopamine agonists 
inhibitor 
MAO-B inliibitors 
Antiglutamatergic 
Anticholinergic 
Surgery Lesion 
Apomorphine 
Bromocriptine Toicapone 
Cabergoline 
Dihydroergocriptine 
Lisuride 
Pergolide 
Piribedil 
Pramipexole 
Ropinirole 
Amantadine 
Benztropine 
Biperiden 
Orphenadrine 
Procyclidine 
Trihexyphenidyl 
Deep Brain Stimulation 
Selegiline 
Transplantation 
Rehabilitation 
Thalamotomy 
Pallidotomy 
Subthalamic nucleotomy 
Rehabilitation procedures 
Thalamus 
Pallidum 
Subthalamic nucleus 
Fetal mesencephalic cells 
Physical therapy 
Occupational therapy 
Speech Therapy 
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Table 1.4 Therapeutic Interventions for Non-Motor Symptoms of PD 
(Following page) 
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Mental Dysfunction Medication 
Dementia 
Psychosis/Drug-induced 
psychosis 
Depression 
Rivastigmine, donepezil, tacrine, galantamine 
Quetiapine, olanzapine, risperidone, zotepin, odensatron, 
rivastigmine, donepezil, tacrine, galantamine, clozapine 
Tricyclic antidepressants, MAO-inhibitors, 
serotonin-reuptake-inhibitors, electroconvulsive therapy 
Autonomic Dysfunction 
Orthostatic hypotension 
Urinary dysfunction 
Gastrointestinal Dysfunction 
Constipation 
Sexual dysfunction 
Midodrine, fludrocortisone, dihydroergotamine, etilefrine, 
indomethacine, yohimbine 
Oxybutinine, tolterodin, flavoxate, Propiverine, Prazosin 
Cisapride 
Yohimbine, papaverine, sildenafil, vardenafil 
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1.3 Neuropathology of PD 
1.3.1 Pre Alpha-Synuclein Era 
1.3.1.1 Historical Observations 
PD is considered to be a consequence of degeneration of the dopaminergic 
nigrostriatal system with associated changes in the neuronal cytoskeleton that result in the 
formation of Lewy bodies (LBs) (Forno 1996). 
LBs were first described by the German pathologist Friedrich H. Lewy in 1912 in 
patients with PD (then known as paralysis agitans) (Lewy FH 1912). Lewy discovered 
these eosinophilic, round cytoplasmic inclusions in the dorsal motor nucleus of the vagus 
nerve (DMV), nucleus basaUs of Meynert (NBM), paraventricular nucleus and lateral 
thalamic nucleus (Gibb and Poewe 1986). The involvement of LBs in the substantia nigra 
however, was first described by Tretiakoff in 1919, who coined the term "corps de Lewy" 
(Gibb and Poewe 1986) and also speculated that degeneration of the substantia nigra 
relates to the motor symptoms seen in the disease. Later, Hassler confirmed these findings 
and showed the focal distribution of pathology: the most pronounced nerve cell loss was 
found in the caudal and ventrolateral parts of the substantia nigra (Hassler R 1938). These 
findings on the neuronal depletion of nigral neurons were corroborated by later studies 
that also showed that the substantia nigra zona compacta (SNc) suffers a 60-85% loss of 
melanised, tyrosine hydroxylase containing neurons with a regional selectivity which is 
greatest in the lateral ventral tier (approx. 91%) followed by the medial ventral tier 
(approx. 71%) and the dorsal tier (approx 56%) (Fearnley and Lees 1991). With respect to 
LBs many later authors confirmed the presence of LBs in the substantia nigra as well as 
in other pigmented neurons of the brainstem most notably the locus coeruleus (LC) 
(Lipkin L.E 1959;Eadie M.J 1963;Greenfield J.G and Bosanquet 1953). As LBs were 
detected where most of the cell loss occurs in the PD brain, LBs were considered to be 
responsible for the neuronal degeneration. Thus, LBs became the sine qua non of PD and 
thus secured their position as pathological hallmarks of the disease along with the severe 
nerve depletion in the SNc. In fact, degeneration of the SNc and the occurrence of LBs in 
the remaining neurons constitute the anatomico-pathological hallmarks of the disease. 
However, LBs have also been observed and described in regions outside the substantia 
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nigra including the amygdala, hypothalamus, hippocampus, thalamus, pedunculopontine 
nucleus (PPN), olfactory bulb and the cerebral cortex (Braak and Braak 2000). Of all 
neuronal populations prone to develop LBs, the nerve cell loss is frequently observed in 
the DMV, SN and NBM however, it still remains to be elucidated why some neuronal 
populations are selectively vulnerable in PD, while others remain resistant. 
1.3.1.2 Neuropathology of the Ageing Brain -Its Relation to PD 
Studies on normal ageing have demonstrated that degeneration in the SNc is not 
seen in the normal ageing brain although cell loss occurs at approximately 4.7% per 
decade (Fearnley and Lees 1991). In fact, the regional pattern of cell loss is opposite to 
that seen in PD. It is generally agreed that neuronal loss in normal ageing is not sufficient 
to cause PD. Nevertheless, age is the main risk factor for PD (Esiri 2007). Interestingly 
50% of those over 80 show some clinical features of parkinsonism (e.g. slow movement). 
There have been a few studies to estimate the prevalence of LBs in normal elderly 
individuals (Lipkin L.E 1959;Woodard J.S 1962;Forno 1969). These have found a 
prevalence of incidential LBs of 5-10% in cases without parkinsonian manifestations. 
However, these studies they were heterogeneous as were derived from veterans and 
chronic disease hospitals or mental institutions and thus were biased towards psychiatric 
illnesses, age or male gender. The first study that could be reliably cited to have 
examined the prevalence of LBs in normal ageing is by Perry et al., (Perry et al. 1990). 
This study found that only 2% of subjects without any neurological or psychiatric 
condition had LBs. Therefore, LBs were concluded not to be an age-related feature but 
strongly associated to neurodegeneration. Interestingly, the prevalence of incidential LBs 
in the normal elderly population has been examined in a few subsequent studies (directly 
or indirectly) which have reported that rises between the 6^ and 9*'' decades (Jellinger 
2004;Saito et al. 2004). The LBs in all these studies occurred in the same brain regions as 
in PD. This condition of incidental LBs in cases without any neurologic or psychiatric 
illness is termed Incidental Lewy Body Disease (ILBD). Incidental Lewy bodies are 
thought to represent a pre-symptomatic phase of PD i.e. if the person had lived longer, 
parkinsonian clinical features were likely to have developed. 
57 
1.3.1.3 Detection of Lewy Bodies 
LBs were initially identified with the use of conventional staining techniques such 
as haematoxylin and eosin (H&E) (Figure 1.1). The shape and size of LBs depends on the 
neuronal perikaryon it occupies but usually LBs have a spherical configuration around 5-
25nm in diameter. In H&E staining LBs in the brainstem are considered to have a 
classical morphology consisting of a dark eosinophilic centre (body) surrounded by a 
paler halo. LBs in the cortex on the other hand, have a less conspicuous morphology and 
therefore are not readily evident on H&E stained sections (Lennox et al. 1989). 
Ultrastructurarly, LBs in the brainstem are formed of straight filaments of around 8-lOnm 
in diameter that are arranged in a radial orientation around an electron dense core (Duffy 
PE and Tennyson VM 1965;Pollanen et al. 1993). The concentric lamination of LBs can 
consequently be explained by greater packing density of filaments in the core. LBs can 
extend into nerve cell processes or lie in the neuropil. 
In the late 1980's specific detection methods involving immunohistochemistry 
(IHC) were introduced. The introduction of IHC identified a variety of different antigenic 
components within LBs that could be divided as the main structural elements (proteins, 
enzymes and passively entrapped proteins) (Pollanen et al. 1993;Galvin et al. 1999). The 
most consistently recognised proteins were the cytoskeletal proteins such as 
neurofilaments (NFs) and ubiquitin (Ub), a protein that is involved in the non-lysosomal 
degradation of cellular products (Goldman et al. 1983;Kuzuhara et al. 1988;Lowe et al. 
1988). Comparison between antibodies raised against NFs and Ub showed that Ub IHC 
was a more reliable and sensitive method for the detection of LBs as antibodies against 
NFs only immunolabeled around half of the H&E stained LBs (Dale et al. 1992) (Figure 
1.1). The use of Ub-IHC was even recommended by the first consortium guidelines 
(McKeith et al. 1996). In particular this antibody was especially helpful for the detection 
of cortical LBs that possessed a less stereotypical morphology in comparison to their 
brainstem counterparts (Kosaka 1978). Nevertheless, Ub immunoreactivity was not 
unique to LBs but was also present in other pathological inclusions such as neurofibrillary 
tEingles (NFTs) that were difficult to distinguish from LBs (Lowe et al. 1988). For this 
reason, double immunostaining with both Ub and tau antibodies (tau: the main constituent 
of NFTs) was recommended especially in DLB where both NFTs and LBs co-exist 
(Dickson et al. 1989). 
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Figure 1.1 H&E and Ubiquitin stained sections from a PD case 
(Following page) A) Lewy body in the substantia nigra neuron using hematoxylin-eosin 
staining is characterized by a red core and a surrounding white halo. Arrow - pigment 
melanin, a feature of substantia nigra neurons; double arrow - Lewy body on 
hematoxylin-eosin staining is characterized by red core and white halo. B) Lewy body 
characteristically stained by anti-ubiquitin antibody used in a routine neuropathological 
diagnostic procedure. The characteristic round shape with immunopositive core and pale 
ring around. Arrow - Lewy body. Magnification 20x (Image taken from Bogdanovic 
(Bogdanovic 2001). 
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1.3.2 Alpha-Synuclein (aSN) 
1.3.2.1 Structure and Function 
a-synuclein (aSN) is a member of the human synuclein protein family along with 
P-synuclein (PSN) and 7-synuclein (ySN). These proteins are small (19-20KDa) with a 
similar amino acid sequence but are encoded by different genes (Goedert 2001). The first 
synuclein to be discovered was aSN. aSN was first isolated in 1988 by Maroteaux and 
colleagues by expression screening from the electric organ of the fish Torpedo californica 
using an anti-serum against purified cholinergic synaptic vesicles (Maroteaux et al. 
1988). The name synuclein was given to this protein as it was shown to localise in 
presynaptic nerve terminals and portions of the nuclear envelop (Goedert 2001). 
However, subsequent studies although confirming the presence of aSN in nerve terminals 
have failed to confirm its nuclear localisation, but the original nomenclature survived. 
aSN is abundantly found in the brain mainly as an isoform of 140 amino acids but a 
shorter alternatively spliced isoform of aSN 112 has also been identified although this 
isoform is predominately expressed in the heart, skeletal muscle and pancreas (Ueda et al. 
1994). In fact aSN is the most studied member of the human synuclein protein family as 
it is the only one to be implicated directly in human neurological diseases (see following 
section). In 1990, Nakajo purified a presynaptic phosphoprotein (PNP14) from bovine 
brain that was very similar to aSN, which is now known as (3SN. pSN like aSN is 
expressed predominately in the brain where is concentrated in the presynaptic nerve 
terminals. It consists of 134 amino acids and seems to be regulated by phosphorylation 
(Nakajo et al. 1990;Nakajo et al. 1993) (Figure 1.2). The third member of the human 
synuclein family, ySN was cloned from an EST library and identified as the breast cancer 
specific gene (BCSGl) whose expression was shown previously in invasive types of 
breast cancer (Ji et al. 1997). ySN consists of 127 amino acids and is predominantly 
expressed in peripheral sympathetic neurons (Akopian and Wood 1995) (Figure 1.2). 
Structurally, aSN is composed of three main domains (Figure 1.2). The N terminal 
amphipathic domain is composed of imperfect 11 amino acid repeats with a consensus 
sequence (KTKEGV). This domain appears to be responsible for its lipid binding ability. 
The three known mutations (A30P, A53T and E46K) are also found in this domain. 
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Although, aSN has been shown in vitro to bind to monolayer phospholipid membranes 
acquiring an a-helical secondary structure (Davidson et al. 1998), not all cellular aSN 
seems to be linked to membranes, as it can also be purified from the cytosol (George et 
al. 1995;McLean et al. 2000). The middle hydrophobic domain, the NAC (non-amyloid 
component) domain is extremely amyloidogenic and is responsible for the ability of the 
protein to undergo a conformational change from a random coil to the (3-sheet 
conformation required for its aggregation (Iwai et al. 1995). Interestingly, PSN has a 
deletion in the NAC domain which makes it non-amyloidogenic. The acidic C-terminal 
domain remains free and unfolded and does not associate with membranes (Eliezer et al. 
2001). 
Figure 1.2 The human synuclein family 
(Following page) The different synucleins are shown and represented as a bar. The N-
terminal amphipathic region, the hydrophobic region and the acidic tail are separated by 
vertical dashed lines and are differently hashed. The a-synuclein 112 splice variant as 
well as the P- and y-synucleins are shown. The NAC region of PSN lacks 11 amino acids 
(residues 73-83). The phosphorylation and nitration sites of aSN are also indicated with 
black boxes. Image taken and modified from Lucking and Brice 2000 (Lucking and Brice 
2000). 
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The physiological function of aSN is largely unknown. Immunoelectron 
microscopic studies have demonstrated it to be closely localised and associated with 
synaptic vesicular membranes suggesting that aSN may play a role in function of synaptic 
vesicles (Jensen et al. 1998). Immunohistochemical analyses using laser scanning 
confocal microscope showed that aSN immunoreactivity was predominantly located in 
presynaptic regions. Due to this presynaptic localisation, aSN has been postulated to have 
a role in the regulation of synaptic plasticity (George et al. 1995), in neuronal 
differentiation (Bayer et al 1999a), or in neurotransmitter release (Abeliovich et al. 
2000). As in other proteins prone to aggregate, aSN is natively unfolded (Weinreb et al. 
1996). On binding to phospholipid membranes it takes on an a-helical structure that may 
stabilise the vesicle membrane and inhibit their lysis (Davidson et al. 1998). It has also 
been demosnstrated in vitro and in vivo that aSN is an inhibitor of the enzyme 
phospholipase D2 which hydrolyses phosphatidylcholine to phosphatidic acid and may be 
involved in vesicle trafficking in the secretory pathway (Jenco et al. 1998). In 
developmental studies, expression of aSN was first detectable at embryonic days 12 to 
15, followed by a dramatic decrease at later time points (Hsu et al. 1998). Its expression 
was detected earlier than another major synaptic vesicle protein, synaptophysin. These 
findings may suggest that aSN plays a role in synaptogenesis. 
1.3.2.2 Pathological Significance of aSN 
The role of aSN in the neurodegenerative diseases was demonstrated when Ueda 
and co-workers in 1993 isolated a 35 amino acid peptide (known as NAC, non amyloid 
component) from amyloid plaques of AD brain tissue (Ueda et al. 1993). cDNA of a 
larger NAC precursor (NACP) was cloned and afterwards this protein was identified as 
the human aSN, this is why aSN is still sometimes referred as the NACP. Nevertheless, 
subsequent studies failed to verify the presence of NAC in amyloid plaques (Bayer et al. 
1999b;Culvenor et al. 1999). The finding that directly implicated aSN in 
neurodegenerative diseases was the discovery that aSN gene mutations can result in PD 
(Polymeropoulos et al. 1997;Kruger et al. 1998;Zarranz et al. 2004) (see also section 
1.3.2.1). As in other neurodegenerative diseases, it became evident that the gene that was 
mutated in the inherited cases of the disease, also encoded for the protein that formed the 
main component of hallmark lesions of the disorder (Spillantini et al. 1997), Spillantini et 
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al., first reported that LBs and dystrophic neurites were robustly immunoreactive for aSN 
(Spillantini et al. 1997). Soon it was noticed that aSN was the main component of these 
structures, as the immunoelectron microscopic studies detected isolated filaments of 5-
lOnm in diameter from purified LBs to be intensely decorated with aSN (Spillantini et al. 
1998;Spillantini et al 1997;Wakabayashi et al. 1997). Further to this, Iwatsubo et al., 
prepared monoclonal antibodies using highly purified LBs from DLB patients and hence 
biochemically corroborated that aSN was accumulated in LBs (Iwatsubo et al. 1996). In 
fact aSN immunohistochemistry is now the gold standard for the detection and 
visualisation of LBs and its application has also demonstrated the presence of abnormal 
deposition of aSN in neuritic processes known as Lewy neurites (LNs). Western blot 
analysis and immunohistochemistry have shown that both LBs and LNs contain insoluble 
aggregates of frill-length and truncated protein (Baba et al. 1998;Culvenor et al. 1999). 
All these genetic, biochemical and pathological studies have contributed to establishing 
the central role that aSN holds in the pathogenesis of PD and DLB. 
L3.2.3 aSN Aggregation and Putative Pathogenetic Mechanisms 
aSN is one of several proteins associated with neurodegenerative diseases that 
have a high propensity to aggregate. In fact one of the most intriguing issues of medical 
pathology, in the post-genomic era, represented by 'Conformational diseases' whose 
pathogenesis is rooted in abnormalities of protein's three-dimensional structure (Soto 
2003). In these diseases, one of which is PD, an important role is played by protein 
aggregation. Protein aggregation is a negative event in nature that represents a failure in 
the accomplishment of the correct spatial arrangement (folded state) necessary to a 
frinctional protein. 
aSN is a natively unfolded protein that 15% is bound to cell membranes with a 
stable a-helical structure and the rest (85%) is free in the cytosol that is essentially 
disordered (McLean et al 2000). The end result of aSN aggregation is the formation of 
insoluble polymers of protein known as fibrils. In this form p-pleated sheet-like bonding 
stabilises the aggregated form. It is thought that fibrillar aSN is the building block of LBs. 
The most direct evidence for this is immunogold labelling showing that aSN is present at 
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sites along the fibrils isolated from LBs (Crowther et al. 2000). LBs contain many 
proteins such as NFs and other cytoskeletal proteins suggesting that co-precipitants may 
be important for aggregation. However, fibrils can be formed in vitro from aSN alone, 
suggesting that this protein is sufficient to form inclusions (Uversky 2003). The fact that 
aSN is the most sensitive marker for LBs strengthens this argument that aSN is necessary 
for LB formation. 
Further insights into aSN fibrillogenesis come from studies on the known 
mutations of the aSN gene. All known mutations (A53T, A30P and E46K) promote the 
formation of oligomeric species and not fibrils. Oligomeric species also known as 
protofibrils are intermediate species resembling an elongated filament that is formed in 
the fibrillisation from monomer to fibril (Lotharius and Brundin 2002). Protofibrils can 
form annular structures that have pore-like properties and may damage the membranes for 
instance by leakage of small molecules such as calcium and dopamine into the cell 
cytoplasm with toxic consequences. In this way aSN protofibrils could potentially 
disrupt ionic and metabolic homeostasis leading to toxicity by numerous downstream 
mechanisms (e.g. oxidative stress) (Lashuel et al. 2002). Recently, protofibrils of non-
disease-associated proteins were shown to be cytotoxic, indicating that perhaps aSN 
protofibrils rather than the fibrils commonly found in the LBs and LNs are the deleterious 
species (Bucciantini et al. 2002). One hypothesis of the mechanism for LB formation is 
shown in Figure 1.3. 
Figure 1.3 aSN fibrillogenesis 
(Following page) One hypothesis for the formation of LBs is that aSN monomers join to 
generate oligomers (protofibrils) (a and b). These protofibrils have the potential to form 
elliptical or circular pores that can punctuate cell membranes, resulting in the release of 
cellular content and cell death. This supports the "protofibrilar hypothesis" outlined 
above. aSN protofibrils coalesce into fibrils (c and d) which have the ^-pleated 
conformation of amyloid. The fibrils can aggregate into LB inclusions (e and f). f 
demonstrates the architecture of LBs that is characterised by an electron-dense core and a 
lighter surrounding halo. (Image taken from Couzin 2001 (Couzin 2001)). 
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A key unresolved issue is how the pathological aggregation of aSN as an 
inclusion is mechanistically linked to neuronal dysfunction or cell death that accounts for 
the manifestation of the clinical symptoms. One possible pathological mechanism would 
be that the aggregation of aSN disrupts normal cellular function. Nonetheless, loss of 
function appears unlikely as elimination of the aSN gene in knockout mice does not 
produce a characteristic phenotype of PD i.e. LBs, neuronal loss and motor deficits 
(Abeliovich et al. 2000). Therefore, a more plausible mechanism would be that the 
aggregation of aSN as an inclusion may itself possess the toxic gain of function that 
compromises the cell physiology, leading to demise of neurons. Current research efforts 
are directed towards a better understanding of the fatal insults that provoke aSN to 
aggregate as an inclusion. The mechanisms that have been proposed include 
overexpression of aSN, post-translational modification including oxidation and impaired 
degradation. 
Various methods of overexpressing native or mutant aSN have been utilised in 
order to gain a further insight into the pathogenic potential of this protein. Transgenic 
mice and fruit flies that overexpress wild-type or mutant human aSN have been shown to 
exhibit abnormal cellular accumulation of aSN, neuronal loss and behavioural deficits 
(Meredith et al. 2004). In line with these studies fibrillar aggregates of aSN in an in vitro 
model demonstrated that accumulation of aSN induced apoptotic cell death (El-Agnaf et 
al. 1998;Zhou et al. 2000). Interestingly, the triplication of the normal aSN gene causes 
familial PD, further suggesting that mutant aSN behaves differently from wild-type 
protein in a quantitative rather than a qualitative manner (Singleton et al. 2003). 
However, the evidence from both in vivo and in vitro studies supporting the notion the 
overexpression of aSN could lead to cell death, is not in line with human studies that have 
failed to detect elevation of aSN mRNA in PD or DLB (Wirdefeldt et al. 2001). 
The post-translational mechanisms that predispose aSN to undergo pathogenetic 
transformation are not very well understood. In transfected cell lines aSN becomes 
phosphorylated at serine residues 87 and 129 (Okochi et al. 2000). Phosphorylation at 
serine 129 in vitro promotes fibril formation (Fujiwara et al. 2002). Nevertheless, 
hyperphosphorylation of aSN may be a secondary event and not a prerequisite for the 
inclusion formation. In addition, under oxidative stress the tyrosine residue 125 of aSN 
can undergo nitration (Giasson et al. 2000). Similarly to phosporylation at Ser- 129, 
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nitration does not appear to be a requirement for aSN deposition (Gomez-Tortosa et al. 
2002). 
Given the anatomical pattern of neuropathology in PD, it was proposed that 
oxidative stress and dopamine contribute to the abnormal build up of aSN (Lotharius and 
Brundin 2002). In fact, in vitro studies have demonstrated that iron and free radical 
generators stimulate the production of aSN aggregates (Paxinou et al. 2001;0strerova-
Golts et al 2000). Further to this, studies have shown that inclusion formation is blocked 
by pre-treatment with antioxidants and or metal chelators (Hashimoto et al. 1999;Hsu et 
al. 2000). Perhaps the most direct evidence to implicate oxidative stress and dopamine in 
the formation of aSN aggregates comes from post mortem studies which have reported an 
increased oxidation state of the substantia nigra, increased iron levels, mitochondrial 
defects and decreases in antioxidant protective systems (Jenner and Olanow 1998). In 
addition, nigral dopaminergic neurons are particularly vulnerable to oxidative stress 
because of the dopamine auto-oxidation. In vitro studies have shown that overexpression 
of aSN induces apoptosis in the human dopaminergic cells (Xu et al. 2002). Therefore, 
the selective loss of dopaminergic neurons may be due to complex interactions between 
dopamine and aSN initiating a chain of events that lead to oxidative stress and increased 
production of free radicals. However, pathological changes in PD by no means are 
confined to the substantia dopaminergic neurons with many other neuronal populations 
including cholinergic, serotonergic and noradrenergic also been affected both in terms of 
aSN aggregates as well as neuronal loss (Jellinger 1997;Jellinger 1999;Jellinger 2000). 
Perhaps the most studied hypothesis for the formation of aSN positive inclusions 
is that of impaired degradation. The ubiquitin-proteasome pathway (UPP) is responsible 
for degrading misfolded or damaged proteins. By inference its dysfunction would result 
in accumulation/aggregation of unwanted proteins such as aSN. Interestingly, two 
mutations parkin (Kitada et al. 1998) and ubiquitin C-terminal hydrolase LI (UCH-Ll) 
(Leroy et al. 1998) that encode key enzymes of the UPP become mutated in familial PD 
(see also section 1.1.3.1). Therefore, inhibiting the function of these enzymes by 
mutations could lead to disruption of UPP, impaired protein clearance and accumulation 
of aSN (McNaught and Olanow 2003). In support of this hypothesis, enzymatic 
proteasomal function has been observed to be reduced in the substantia nigra of PD 
patients (McNaught and Jenner 2001). 
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1.3.2.4 Neuronal Involvement - Lewy bodies, Lewy neurites 
The most common type of aSN positive inclusion is the LB. However, the 
introduction of aSN IHC has revealed a wide range of aSN positive structures including 
"punctuate or diffuse" cytoplasmic staining, "grain-like dots" or "threads" in the neuropil, 
LBs with irregular shape, partially compact LBs and fully compact LBs (Kuusisto et al. 
2003;Saito et al. 2003). In fact this spectrum of aSN staining has been interpreted to 
reflect the morphogenesis of LBs (Kuusisto et al. 2003). According to this hypothesis, the 
earliest stage comprises a punctuate and diffuse aSN accumulation that lacks 
immunoreactivity for Ub or a Ub binding protein known as p62 (Kuusisto et al. 2003). In 
later stages pale bodies appear. Pale bodies are immunopositive for aSN, Ub and p62 and 
have been reported to be more numerous in PD cases with short disease duration than 
those with longer disease duration (Wakabayashi et al. 1998) and thus thought to 
represent the precursors of LBs. In latter stages fully compact LBs appear (Kuusisto et al. 
2003). The second most common aSN positive structure to be detected in the PD brain is 
LNs. LNs were not easily detectable before aSN IHC if at all and thus pathological 
significance is still largely unknown. LN type pathological change has only recently 
attracted attention. LNs are mostly observed in the amygdala, CA2 sector of the 
hippocampus and striatum (Duda er a/. 2002;Dickson e/'a/. 1991;Dickson e/a/. 1994). 
The aggregation of aSN has been proposed to be initiated either in the somal or in 
the axonal compartment. According to the first hypothesis, although LBs are seen in the 
perikaryon studies suggest that protein aggregation appears initially in the axonal 
terminal, subsequently in the cell body and finally in the dendrite (Marui et al. 2002). 
Hence, according to this hypothesis initial pathology is in the axons leading to a "dying 
back" process that may cause functional and physiological disconnection of neural 
circuits perhaps even well before cell bodies are affected. This view is supported by 
studies showing initially LN type pathology (irrespective of anatomical localisation) in 
the brain (Braak et al. 2003). According to the second hypothesis LBs and LNs occur 
simultaneously (Katsuse et al. 2003). 
Irrespective of the initial spatial distribution of aSN aggregates within neurons 
others have attempted to localise the induction site and propagation of aSN pathology 
within the brain. Professor Braak and colleagues have recently devised a staging system 
whereby aSN pathology progresses in a systematic fashion tlirough the PD brain in six 
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distinct stages (Braak et al. 2003). According to this hypothesis aSN pathology begins in 
the lower brainstem and from there follows an ascending course to more rostrally situated 
regions eventually extending to the cerebral cortex. More specifically, based on precise 
patho-architectonic analysis, the earliest pathology is observed in the DMV (stage 1) 
whence it is thought to proceed in an upward direction via the pons (stage 2) to the 
midbrain (stage 3) and thence to the basal forebrain and mesocortex (stage 4) and finally 
to the neocortex (stages 5-6). Indeed this study reports early changes in the DMV and not 
in the SN. Although initially this hypothesis was very intriguing subsequent studies have 
questioned its reliability/validity (Parkkinen et al. 2005a;Jellinger 2003a). 
1.3.2.5 Glial Involvement- Glial Cytoplasmic Inclusions (GCIs) 
aSN aggregates are by no means found exclusively in neurons. Multiple System 
Atrophy (MSA) is a disease that is clinically characterised by any combination of 
extrapyramidal, pyramidal, cerebellar and autonomic features and neuropathologically by 
aSN deposition in ohgodendrocytes as glial cytoplasmic inclusions (GCIs) (Papp et al 
1989;Gilman et al. 1999). GCIs can be found through out the white matter but in 
abundance are found in the substantia nigra, LC, inferior olives, cerebellum and regions 
in the spinal cord (Gilman et al. 1999). GCIs are sickle or flame-shaped inclusions that 
are positive for Ub but negative for NFs and glial fibrillary acidic protein (GFAP) 
(Castellani 1998). As aSN is produced in neurons the origin of aSN in oligodendrocytes 
has been debated. However, MSA is not the only disease where aSN positive glial 
inclusions are found. aSN positive inclusions in the astrocytes and oligodendrocytes in 
PD and DLB brains have been reported (Piao et al. 2000;Wakabayashi et al. 2000) as 
well as in astroglia and Schwann cells in the spinal cord in Amyotrophic Lateral Sclerosis 
(ALS) (Mezey etal. 1998). 
In fact the term synucleinopathy has been recently introduced to describe several 
distinct neurodegenerative diseases that share, among other properties, the presence of 
abnormal aSN aggregates in neurons and/or glial cells. Some of these diseases include 
PD, MSA, DLB, sporadic and familial AD, Down syndrome and neurodegeneration with 
brain iron accumulation type 1 (NBIA I) ALS and pure autonomic failure (Gorell et al. 
1994;Papp and Lantos 1994;Arawaka et al. 1998;Gai et al. 1998;Bayer et al. 
1999b;Dickson e? a/. 1999;Mezey ef a/. 1998;Arai ef a/. 2000;Hamilton 2000;Lippa e? a/. 
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1999). Nevertheless, aSN aggregates are considered to be a primary causal pathology in 
PD, DLB and MSA. 
1,3.3 Concomitant Pathologies in the PD brain 
1.3.3.1 Alzheimer's Disease Type Pathology 
aSN pathology is commonly found in sporadic and familial AD as well as Down 
syndrome (patients with a triplicate of amyloid precursor protein (APP)) with estimates 
ranging from 50 -60% (Hamilton 2000;Lippa et al. 1998;Victoroff et al. 1995). Vice 
versa, AD-related pathology (amyloid plaques and NFTs) is often found in PD brains to a 
varying degree (Jellinger 1997;Jellinger and Paulus 1992;JeUinger 1999;Jellinger et al. 
2002;Jellinger 2000;Jellinger 2006;Jellinger 1991). 
NFTs are one of the neuropathological hallmarks of AD (Braak et al. 2006a;Braak 
et al. 1998). Histologically, NFTs are clearly visualised by silver impregnation or 
amyloid stains and are tau-immunopositive. In AD brains, NFTs appear as flame-shaped 
or globoid masses of fibrous intraneuronal material, the morphology depending on the 
neuronal type and the developmental stage of the tangle. NFTs are accompanied by 
abnormal neuronal processes, i.e., neuropil tlireads (NTs) and dystrophic neurites that are 
also tau-immunoreactive. Ultrastructurally, NFTs mainly consist of dense bundles of 
paired helical filaments (PHFs) 8-20 nm across (Lee et al. 2001). PHFs may be 
associated with straight filaments and more complex types of fibrillar structures (Itoh et 
al. 1997;Gomez-Ramos and Moran 1998). The principal constituent of PHFs is the tau 
protein in its hyperphosphorylated form (Goedert et al. 1995). Immunohistochemistry 
also reveals the variable incorporation of Ub (Rancher et al. 1989) and a range of other 
proteins into NFTs (Lee et al. 2001). In AD brains, NFTs occur in the cerebral cortex and 
in several subcortical regions (Braak and Braak 1991). Within cortical areas, the 
distribution of NFTs suggests a hierarchical progression that first involves the 
transentorhinal cortex, from where the pathology spreads via limbic areas to the isocortex 
(Braak and Braak 1991). A growing number of studies have demonstrated tau-
immunoreactive neuronal or glial inclusions in a variety of conditions beyond AD 
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including progressive supranuclear palsy, Pick's disease, corticobasal degeneration and 
frontotemporal dementia with parkinsonism linked to chromosome 17 (Sorrentino and 
Bonavita 2007;Goedert 2004;Dickson 1998) collectively referred to as taupathies. 
Amyloid plaques are another major histopathological hallmark found in the AD 
brain. The amyloid-p-peptide (AP) deposits extracellularly forming amyloid plaques in 
AD brain. There are two major types of amyloid plaques in AD brain: neuritic plaques 
and diffuse plaques. Neuritic plaques contain dense bundles of amyloid fibrils and are 
surrounded by dystrophic neurites, astrocytes, and microglia (Finder and Glockshuber 
2007). Diffuse plaques contain nonstructured amyloid and are not surrounded by 
dystrophic neurites. There are studies suggesting that neuritic plaques may develop from 
diffuse plaques but this awaits verification. Amyloid plaques are formed of insoluble Ap 
peptides that are cleaved from APP (Small and McLean 1999). AP peptides occur 
principally in two lengths, 40 or 42 amino acids, the latter being more susceptible to 
aggregate. In AD, the proportion of Ap42 is increased, and the mutations causing familial 
forms of AD enhance the production of Ap42. Interestingly, the levels of AP42 seem to 
be central to the pathogenesis of AD and correlate with the cognitive impairment in AD 
(Younkin 1995). 
Although, plaques have been traditionally classified as either neuritic or diffuse 
their detection using IHC does not readily distinguish these plaque subtypes. Recently 
using Ap IHC a wide range of morphologies of amyloid plaques has been described in 
AD but these different subtypes insofar have only been reported in the medial temporal 
lobe where NFTs are also found in abundance (Thai et al. 2000). On the basis of that 
amyloid plaques detected with Ap IHC can be assigned to one of the following classes 
(see also Figure 1.4); diffuse plaque, subpial band-like Ap, lake-like amyloid, fleecy 
amyloid, cored plaque (classic/neuritic plaque), core-only plaque, white matter plaque. 
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Figure 1.4 Plaque type using Ap IHC 
(Following page) Diffuse plaques (a, i). a: diffuse non-neuritic plaque that is sharply 
delineated and evenly distributed, i: diffuse neuritic plaque that conatins Gallyas positive 
dystrophic neurites. Subpial band-like plaques (b). b; sharply-delineated, evenly 
distributed band-like Ap, lake-like amyloid (c). c: sharply delineated, evenly distributed 
AP-deposits, fleecy amyloid (d). d: cloud like deposits, cored plaque (e, j). e: cored non-
neuritic plaque; sharply delineated Ap-deposits with an amyloid core in the centre 
surrounded by a corona of diffuse Ap-deposits. Between core and corona is a small gap 
without Ap. This non-neuritic plaque is free of dystrophic neurites containing 
neurofibrillary lesions as detectable with the Gallyas silver method, j: Cored neuritic 
plaque: cored plaque which contains Gallyas positive dystrophic neurites. Core-only 
plaque (f): f; pure, sharply delineated amyloid cores without associated diffuse Ap-
deposits, white matter plaque (g, h). g: diffuse type that is sharply delineated, evenly 
distributed Ap-deposits within the white matter and h: globular type sharply delineated 
AP-deposits in the white matter which contain globular aggregates of Ap. Calibration 
bars; a, b, e, f, g, h= 40 mm; c - 200 mm; d, i, 28 mm.(Image taken from (Thai et al. 
2000) 
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The fact that aSN inclusions commonly co-exist with AD-related changes, 
especially in patients with more prevalent/extensive amyloid plaques and NFTs (i.e. 
DLB), suggests that they may be mechanistically linked. In vitro models have 
demonstrated that aSN binds A(3 and enhances its aggregation (Yoshimoto et al. 
1995;Jensen et al. 1997). Further to this, in transgenic mice (a model that links AD and 
PD), Ap peptide enhanced the accumulation of fibrillar aSN to inclusions that resemble 
LBs found in humans (Masliah et al. 2001). In human studies the presence of Ap deposits 
in the neocortex of DLB brains was associated with increased aSN lesions and higher 
levels of insoluble Ap (Pletnikova et al. 2005). With regards, to aSN and tau, studies have 
shown that LBs and NFTs are commonly found in the same neurons of the limbic system, 
especially in the amygdala in the brains of AD cases (Marui et al. 2000). Giasson and co-
workers showed that in vitro aSN promotes the fibrilhsation of tau and the co-incubation 
of tau and aSN synergistically induced the fibrillisation of each other (Giasson et al. 
2003). In addition, aSN has been demonstrated to bind to tau and stimulate its 
phosphorylation (Jensen et al. 1999). 
1.3.3.2 Vascular Pathology 
Cerebrovascular pathology occurs frequently in the ageing brain and often co-
exists with AD, PD and DLB. Cerebral amyloid angiopathy (CAA), the deposition of Ap 
in meningeal and cortical arterioles, venules and capillaries, is a major histopathological 
feature in the AD brain but often is also found in PD (Zekry et al. 2002;Rektor et al. 
2006). Several recent studies on the prevalence of cerebrovascular lesions (CVLs), 
including CAA, have demonstrated that the higher frequency is found in AD patients 
whereas in PD and DLB cases it is low (Jellinger 2003b). Therefore, although 
neurovascular dysfunction could have a major role in the pathogenesis of AD its 
contribution to PD is less likely clear. 
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1.3.4 Neurochemical Deficits Associated with Motor and Neuropsychiatric Deficits 
in PD 
The classical motor signs in PD are ascribed to dopaminergic cell loss in the SNc 
(Feamley and Lees 1991). Progressive degeneration of the substantia nigra in PD leads to 
depletion of striatal dopamine with functional disturbances in the complex regulatory 
loops of the basal ganglia resulting in the clinical motor signs and symptoms (Figure 1.5). 
Neuronal damage in PD is not random (refer to section 1.3.1.1) and progresses slowly but 
unremittingly until a certain threshold is reached for the clinical manifestation of the 
disease. Degeneration of the nigro-striatal dopaminergic system has also been considered 
responsible for subtle cognitive changes such as impaired simultaneous test performance 
or inefficient reaction of retrieval process and other fronto-striatal deficits in PD resulting 
from disturbances in caudate outflow into the motor loop interconnecting the ventral 
striatum and frontal lobe (Pillon et al. 1994;Rolls 1994). 
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Figure 1.5 Circuitry of the basal ganglia 
(Following page) Simplified schematic representation of the circuitry tlirough the basal 
ganglia. Input arriving in the striatum is relayed to other basal ganglia nuclei through two 
pathways, known as the direct and indirect pathway. The direct pathway is the striatal 
projection to the internal segment of the globus pallidus. These medium spiny neurons 
express D1 receptors that are coupled via Gg proteins, to stimulation of adenyl cyclase. 
This population of neurons receive excitatory input from the SNc dopamine and 
glutamatergic cortical projections. Stimulation of the direct pathway leads to increased, 
inhibitory, GAB A transmission in the internal segment of the globus pallidus. As a result 
of inhibiting these neurons, which exert an inhibitory (GABAergic) effect on the 
thalamus, activation of the direct pathway leads to disinhibition of the thalamus. The 
indirect pathway runs from the putamen to the internal globus pallidus initially via 
neurons projecting to the external segment of the globus pallidus. This population of 
striatal medium spiny neurons express dopamine D2 receptors, which are coupled via Gj 
proteins, to inhibition of adenylyl cyclase. Therefore, dopamine input from the SNc 
inhibits the activity of the indirect pathway. From the external globus pallidus a 
GABAergic projection runs to the subthalamic nucleus, which sends excitatory, 
glutamatergic input to the neurons of the internal globus pallidus. Activation of the 
GAB A striatal projection to the external globus pallidus tends to suppress its inhibition of 
the subthalamic nucleus, increasing the excitatory drive to the internal globus pallidus and 
hence increasing inhibition of the thalamus. The pathophysiology in PD arises from an 
overactivity of the indirect pathway whereas the opposite is true for hyperkinetic 
disorders. 
Abbreviations; STN; subthalamic nucleus, GPe; external segment of the globus pallidus, 
GPi: internal segment of the globus pallidus. 
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PD appears to be a multisystem disorder involving a variety of subcortical 
neuronal systems causing multiple neuromediator dysfunctions that might result in the 
complex clinical picture seen. In PD, there is a considerable loss of neurons in the ventral 
tegmental area (VTA) which provides major dopaminergic input to limbic and prefrontal 
areas. Dementia in PD patients has been associated with greater cell depletion in VTA (in 
the range of 40-60%) than non-demented patients (Zweig et al. 1993;Jellinger 1991). 
The LC in PD, the main source of noradrenergic input to the forebrain and 
neocortex, demonstrates neuronal loss that ranges from 40-50% and is more severe in 
demented PD subjects or those with depression than non-demented or non-depressed 
patients (Jellinger 2000). As a result of LC neuronal depletion there is severe deprivation 
of noradrenergic innervation of the forebrain and neocortex the effect of which apart from 
dementia and depression has also been related to autonomic dysfunction (Hoogendijk et 
al. 1995). The LC in PD does not only show cell loss but also cell shrinkage that is 
independent of cortical pathological changes suggesting a primary degeneration of this 
nucleus (Hoogendijk et al. 1995). 
The dorsal raphe nucleus (DRN) that gives rise to ascending serotonergic 
pathways that are bidirectionally cormected with many centres in the central nervous 
system degenerate leading to a central serotonergic deficiency that is reflected by 
reduction of serotonin, its metabolites and receptors in the striatum and medial frontal 
cortex (Agid et al. 1990). Cell depletion in the DRN averages 20-40% ((Jellinger 1991). 
DRN cell loss is more severe in depressed than non-depressed patients. Serotonergic 
deficiency has also been related to cognitive dysfunction (Agid et al. 1990). 
Degeneration of the cholinergic system is characterised by cell loss and shrinkage 
in the magnocellular posterior parts of the Ch4 region of the NBM which projects to the 
neocortex, the PPN and the Edinger-Westphal nucleus (Jellinger 1991). In PD, NBM cell 
loss averages 30-40% and is much higher in demented than non-demented PD patients 
(Jellinger 1991). However, some authors have also reported severe cell loss in the NBM 
without overt dementia suggesting that degeneration of the NBM may precede the onset 
of mental dysfunction and that there is a critical threshold of neuronal loss with 
equivalent cortical cholinergic denervation before dementia becomes apparent (Caspar 
and Gray 1984). The PPN pars compacta (PPNr) is a cholinergic nucleus that is thought 
to affect the balance between cholinergic and dopaminergic functions of the basal ganglia 
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(Graybiel et al. 1990;Steriade M 1990). Cell loss in the PPNr occurs in PD which ranges 
from 36 to 57% however, the clinical significance of this neuronal depletion remains 
unclear (Zweig et al. 1989). The Edinger-Westphal nucleus suffers a 54% neuronal loss 
in PD (Hunter 1985). This nucleus gives rise to cholinergic fibres to the ciliary ganglion 
regulating pupilloconstriction (Bender 1980) which may explain the abnormally slow 
pupillary responses to light in PD (see also section 1.2.2.1.5). 
1.3.5 Clinico-pathological Correlations in PD Patients with Neuropsychiatric Deficits 
One approach to neuropathological research is that of clinico-pathological 
correlations. This process of correlation permits the optimum characterisation of the brain 
in a diseased state as it examines the relationship between two negative events that 
characterise a disease; that of pathological change and the occurrence of clinical 
symptoms. 
One of the most studied neuropsychiatric deficits in PD is dementia. Although, 
several clinico-pathological studies have been published, the underlying pathological 
conditions responsible for dementia in PD have been a matter of controversy, both in 
terms of site and type. The presence of LBs in limbic and neocortical regions has been 
suggested as a cause for dementia but this does not account for the co-existent AD type 
changes that are often found alongside aSN pathology. In cases with mixed pathology it 
is indeed difficult to determine whether aSN lesions or AD-type pathology are 
responsible for dementia, particularly in a clinically heterogeneous PD cohort where 
dementia may be present along with other neuropsychiatric deficits and medications that 
may aggravate the clinical picture. In addition, it remains debatable whether VH represent 
a primary clinical feature in disease progression reflecting specific neuroanatomical loci 
of pathology or a secondary feature of dementia, cognitive impairment and or drug 
treatment. Indeed, there are very few clinico-pathological studies on VH in comparison to 
those on dementia. Furthermore, the contribution of vascular changes (e.g. CAA) to the 
development of dementia and VH in PD has not been closely studied. The uncertainty of 
the pathological and anatomical basis of dementia and VH in PD more likely stems from 
methodological differences (case selection etc), differences in pathological protocols (e.g. 
staining methods, quantification methods etc) and different diagnostic criteria (e.g. early 
studies may have included cases with dementia as the presenting symptom followed by 
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parkinsonism (i.e. DLB)) used in each study. Furthermore, overlapping behaviours in PD 
complicate the analysis and make it difficult to examine changes related to a single 
clinical feature in isolation. Indeed, most of the previous reports that have focused on a 
single behavioural change fail to take into account concomitant neuropsychiatric 
symptoms in their subjects. On the other hand, the patho-anatomical bases of anxiety in 
PD are largely unknown as thus far there has been no clinico-pathological study to 
examine the pathological nature of this neuropsychiatric symptom. 
Although, PD patients often develop dementia and VH later in the disease course, 
these neuropsychiatric manifestations predominate the clinical picture of DLB cases (Ince 
et al. 1998;McKeith et al. 2005). Clinicopathological studies in DLB cohorts point to LB 
densities in limbic lobe as pathological correlates of dementia in these patients (Uchikado 
et al. 2002). However, LB burden in limbic structures has also been associated as the 
pathological substrate of dementia in PD case series (Kovari et al. 2003;Mattila et al. 
2000;Hurtig et al. 2000). In addition, studies on VH in DLB, PD and PDD point to LB 
pathology in amygdala as an important correlate of this clinical feature (Harding et al. 
2002a;Harding et al. 2002b). On the whole, these studies demonstrate that the 
pathological correlates of dementia and VH in DLB and PD seem to converge. In fact, the 
relationship of DLB to PDD is unresolved and the topic of current research efforts. 
Several studies have now shown that with most diagnostic measures, there are few 
significant differences between DLB and PDD (Aarsland et al. 2004;McKeith and 
Mosimaim 2004). Studying the patho-anatomical correlates of VH and dementia in PD 
one will by inference add to a greater understanding of the association between these two 
diseases. 
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1.4 Aims of the Thesis 
From the introduction presented above it is clear that non-motor complications are 
frequent in PD patients and that in some cases they may overshadow the motor aspects of 
the disease. Among the most prominent non-motor deficits are neuropsychiatric 
complications with dementia, VH and anxiety having a major impact on the clinical 
course and prognosis of PD. Given the on-going controversy concerning the pathological 
and anatomical nature of these deficits in PD the primary aim of this thesis was to 
examine possible associations between these deficits and pathology in specific anatomical 
areas as a means of providing a better insight into their aetiopathogenesis. Having 
examined aSN pathology in a relatively large number of regions in the PD brain the need 
arose to define whether this PD-related pathological change followed the proposed 
predicted caudo-rostral spread as suggested by Professor Braak and colleagues. Thus, 
quite apart from the pathological basis of neuropsychiatric features of PD, a secondary 
aim of this thesis was also to examine the topographical distribution of aSN lesions in the 
PD brain. 
The specific aims of this thesis were as follows: 
1) To determine the relative contribution of aSN, AD-type pathology and vascular 
pathology in neocortical and subcortical regions known to play a role in cognitive 
function to dementia and VH in PD subjects presenting with these symptoms in 
isolation or in combination (Chapter 3). 
2) To examine the nature and extent of striatal pathology in PD brains and study its 
clinical relevance to dementia and VH (Chapter 4). 
3) To study the pathological and anatomical bases of anxiety in PD (Chapter 5) 
4) To examine the topographical distribution of aSN pathology in a large series of 
PD brains (Chapter 6). 
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Chapter 2 
Materials and Methods 
2.1 Materials 
2.1.1 Human Brain Samples 
All post-mortem human brain specimens used in this research were obtained from 
the UK Parkinson's Disease Society Tissue Bank at Imperial College, London 
(UKPDSTB). The cases included in this thesis are those that were available from the 
UKPDSTB up to 15"^  of July 2006. A summary of the cases used and the brain areas 
examined in each study/experimental chapter are shown in Table 2.1 and 2.2. According 
to the dissection protocol used in the UKPDSTB, the brains were weighed, grossly 
examined and hemisected. The half used in this study was immersed in 10% buffered 
formalin for at least 2 weeks. Formalin-fixed, paraffin-embedded tissue was provided 
either in blocks from which sections were subsequently cut (as described in 2.2.3) or in 
Sp-m sections on SuperFrost Plus sUdes. 
2.1.2 Antibodies 
The antibodies used in this research, their supplier, dilution and pre-treatment are 
summarised in Table 2.3. The selection of the aSN Ab used in the present research was 
based on its consistency and strong immunoreactivity with a variety of aSN-containing 
structures shown in a comparative study of different aSN Abs performed by Croisier et 
al., (Croisier et al. 2006). The selection of the tau and tyrosine hydroxylase (TH) Abs was 
based on their high specificity and sensitivity on human tissue shown in a comparative 
study of different tau and TH Abs performed by the UKPDSTB during the process of 
optimisation of Abs for diagnostic purposes. In addition, the tau antibody (clone ATS) 
used in this work is routinely used across many different centres for diagnostic purposes 
(Alafuzoff et al. 2006) and it has also recently used as the Ab of choice for staging AD 
neurofibrillary pathology according to the Braak and Braak scheme (Braak et al. 2006a). 
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The 1E8 Ab was a gift from GlaxoSmithKhne (GSK), via Dr. Stephen Gentleman and 
was chosen on the basis of its intense staining pattern that covered the full range of Ap-
related pathology; diffuse and cored plaques (for definition of plaque types see section 
2.2.5) and deposits in the walls of cerebral blood vessels (Gentleman et al. 1997). Further 
details about the antibodies are provided in section 2.2.4.3. 
Table 2.1 Summary of cases examined in each chapter 
(Following page) 
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Age at 
Case Death 
'umber Gender (years) Chapter studied 
1 f 87 (6) 
2 m 84 0 , 4 . 6 ) 
3 m 77 (6) 
4 m 68 (excluded: DLB/AD) 
5 f 80 (3.4,6) 
6 m 72 (6) 
7 m 78 (3,4,5,6) 
8 m 72 (6) 
9 f 86 (6) 
10 f 81 (excluded: selection criteria not met) 
11 m 71 (3.4,6) 
12 m 42 (excluded: MSA) 
13 m 78 (3,4,6) 
14 m 79 (3,4,6) 
15 m 70 (3,4,6) 
16 f 85 (3,4,6) 
17 m 75 (6) 
18 m 82 (3.4,6) 
19 f 72 (5.6) 
20 m 75 (3.4,6) 
21 m 76 (3.4,6) 
22 f 75 (3,4,5,6) 
23 m 82 (3.4,5,6) 
24 m 81 (3,4.6) 
25 f 63 (excluded: MSA) 
26 m 74 (excluded: DLB) 
27 m 74 (6) 
28 m 82 (6) 
29 m 76 (3,4,5,6) 
30 m 73 (3.4,6) 
31 m 81 (excluded: PSP) 
32 m 89 (3,4,5,6) 
33 f 74 (6) 
34 f 84 (3,4,6) 
35 m 77 (excluded; PSP) 
36 m 77 (3,4,5,6) 
37 m 87 ( & 9 
38 f 79 (excluded: essential tremor) 
39 f 82 (5,6) 
40 m 92 (excluded: aging) 
41 m 77 ( ^ 9 
42 f 79 (3,4,6) 
43 m 86 (excluded: MSA) 
44 m 87 (3,4,6) 
45 m 80 (3,4.6) 
46 f 68 (excluded; aging) 
47 m 78 (excluded: PSP) 
48 m 71 (excluded: Possible Fragile-X ataxia) 
49 m 75 (6) 
50 f 82 (6) 
51 m 80 (6) 
52 f 71 (6) 
53 m 76 (excluded: essential tremor) 
54 m 75 (5,6) 
55 f 76 (6) 
56 m 54 (3,4,6) 
57 m 83 (6) 
58 f 58 (3.4,5,6) 
59 m 81 (6) 
60 m 84 (3.4,6) 
61 m 78 (6) 
62 m 73 (6) 
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Continued 
63 f 80 
64 m 88 (excluded; PSP) 
65 f 84 (excluded: aging) 
66 m 82 (6) 
67 m 83 (6) 
68 m 82 (6) 
69 m 82 (3.4,6) 
70 m 75 (6) 
71 tn 81 (excluded; aging) 
72 m 62 (3,4,6) 
73 m 73 (excluded: Frontotemporal lobar degeneration & MND) 
74 m 85 (3.4.5.6) 
75 m 66 (excluded: PSP) 
76 m 61 (excluded: DLB) 
77 m 58 (excluded: selection criteria not met) 
78 m 79 (6) 
79 f 78 (6) 
80 m 71 (excluded: MSA) 
81 m 73 (6) 
82 m 82 (excluded: DLB) 
83 f 77 (excluded: MSA) 
84 m 86 (6) 
85 m 78 (excluded: selection criteria not met) 
86 f 87 (6) 
87 f 80 (excluded: PSP) 
88 f 81 (6) 
89 m 70 (excluded: DLB) 
90 f 83 (6) 
91 m 50 (6) 
92 m 83 (6) 
93 f 81 (6) 
94 m 75 (5,6) 
95 m 74 (3.4.5.6) 
96 m 88 (excluded: PSP) 
97 f 88 (6) 
98 m 75 (excluded: DLB) 
99 m 83 (6) 
100 m 81 (6) 
101 m 69 (excluded: selection criteria not met) 
87 
Table 2.2 Summary of brain areas examined in each chapter 
(Following page) 
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Brain Area Chapter 3 Chapter 4 Chapter 5 Chapter 6 
Superior Frontal gyrus X X X 
Cingulate gyrus X X 
Temporal Cortex X X X 
Entorhinal Cortex X X X X 
Hippocampus CA2 sector X X X X 
Subiculum X X 
Amygdaloid Complex X X X 
Nucleus Basalis of Meynert X X X 
Caudate Nucleus X 
Putamen X 
Nucleus Accumbens X 
Substantia Nigra X 
Locus Coeruleus X X 
Raphe Nuclei X 
Dorsal Motor Nucleus of Vagus X 
Spinal Cord X 
Total 8 7 9 9 
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Table 2.3 Description of antibodies used throughout this research 
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Name Clone/Type 
Epitope 
(Immunogen) Pre-Treatment Dilution Source 
aSN 42 
(mouse monoclonal) 
rat aSN ,5.,23 For dilution 1/1000 - 80% FA, 60min 
For dilution 1/300 - 100% FA, 5min 
1/1000 for chapters 3, 4 and 5 
and 1/300 for chapter 6 
Becton-Dickinson 
Tau ATS 
(mouse monoclonal) 
tau phosphorylated 
at Ser-202/Thr-205 
None 1/800 AutogenBioclear 
AP 1E8 
(mouse monoclonal) 
residues 18-22 of the Ap peptide 80% FA, 8min 1/1000 
Tyrosine Hydroxylase 1B5 
(mouse monoclonal) 
carboxyl terminal end of the 
mouse tyrosine hydroxylase molecule 
Ht EDTA 1/30 Vector 
Abbreviations; aSN; alptia-synuclein, Ap; beta-amyloid, FA; formic acid, EDTA: ethyienediaminetetraacetic acid, Ht: high temperature 
**: gift from Dr. Stephen Gentleman 
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2.1.3 Chemicals 
All chemical used in this research were pursued ftom VWR (www.VWR.comV 
2.2 Methods 
2.2.1 Neuropathological Assessment of Cases 
Neuropathological assessment and diagnosis was performed by two clinical 
neuropathologists (Prof Manuel B. Graeber and Dr. Federico Roncaroli) and one research 
neuropathologist (Dr. Stephen M. Gentleman), all from the Department of 
Neuropathology, Imperial College London. The diagnosis was based on slides provided 
by the UKPDSTB for aSN, tau and P-amyloid immunohistochemistiy of the superior 
frontal gyrus, hippocampus, and midbrain. Screening of cases for confounding pathology 
was based on hematoxylin and eosin examination of a standard series of 18 tissue blocks 
following a standardized dissection procedure (Vonsattel et al. 1995). Neuropathological 
diagnosis was performed using international neuropathological consensus criteria for a 
definite diagnosis of PD (http://www.ICDNS.org'). The extent of AD (both ^-amyloid and 
tau) isocortical and/or entorhinal pathology was assessed using the grading system posted 
at http ://www.ICDNS.org as well as the Braak and Braak staging to stage tangle 
pathology using ATS immunohistochemistry (Braak et al. 2006a). A representative 
neuropathological report of a PD case is provided in appendix I. 
2.2.2 Clinical Assessment of Cases 
Clinical profiles of cases were compiled retrospectively from clinical records 
which included in all cases specialist secondary care physicians: consultant neurologist, 
geriatrician and psychiatrist notes by a movement disorder neurologist (Dr. Ronald K.B. 
Pearce). This clinical documentation was complemented by nurse specialist and therapist 
letters. Only subjects who had been evaluated by a clinician within 2 years prior to death 
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and had complete clinical histories were included in this work in order to reduce the 
possibility of incomplete ascertainment. The clinical diagnosis of PD followed 
established criteria whereby PD was considered to be present if the patient had at least 2 
of the 4 cardinal symptoms (rigidity, hypokinesia, resting tremor and postural instability) 
and exhibited a positive response to levodopa (Daniel and Lees 1993) with a typical 
progressive course. The diagnosis of DLB was made if dementia preceded extrapyramidal 
symptoms by 2 years or they developed together within a 12-month period (McKeith et 
al 1996). Patients were classified with probable DLB when cognitive impairment was 
accompanied with at least 2 of the 3 core features (extrapyramidal symptoms, fluctuating 
cognition and visual hallucinations) and with possible DLB when only 1 of these core 
features was present (McKeith et al. 1996). Patients with PD who developed late 
dementia (> 2 years after motor symptoms) were classified as PD with dementia (PDD) 
(Hurtig et al. 2000). The diagnosis of dementia was established on the basis of a recorded 
clinical diagnosis by the treating physician and satisfied the DSM-IV (American 
Psychiatric Association 1994) and ICD-10 clinical criteria for dementia. The diagnoses of 
visual hallucinations, anxiety, depression, delusions and paranoia were made by the 
treating physician and were clearly documented in the medical files. A representative 
clinical summary of a PD case is provided in appendix I. 
2.2.2.1 Clinical Assessment of Signs and Symptoms 
Demographic data, family history, gender, age at disease onset, age at death, 
duration of disease, laterality and treatment were abstracted and reviewed systematically 
with assistance of Dr. Ronald K.B. Pearce. In addition to these standard clinical 
parameters, particular attention was paid to the assessment of the clinical features 
reported. These included presenting symptoms (within 2 years after diagnosis: tremor, 
drooling, gait-balance abnormalities, akinetic-rigid, stiffness, cognitive dysfunction and 
autonomic deficits), motor deficits (>2 years after diagnosis: tremor, drooling, gait-
balance abnormalities, akinetic-rigid, stiffness, laterality of hemi-parkinsonian signs and 
falls), neuropsychiatric complications (dementia, visual hallucinations, anxiety, 
depression, delusions and paranoia) and autonomic deficits (such as diarrhoea, 
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constipation, orthostatic hypotension, bladder dysfunction, sexual dysfunction, skin rash, 
speech problems, swallowing problems, drooling and sleep problems). Of the 101 cases 
included in this work, the chnical phenomenology of 81 cases was thoroughly examined. 
The incidence of the abovementioned deficits in those 81 cases is shown in figures 2.1, 
2.2, 2.3 and 2.4. As this work was based on retrospective data, the clinical severity of 
presenting symptoms (within 2 years of diagnosis), motor deficits (>2 years of diagnosis) 
and neuropsychiatric complications was measured on a semi-quantitative global 
impression scale (0: absent, 1: mild, 2: moderate and 3: severe) with assistance of Dr. 
Ronald K.B. Pearce. A mild score indicates no significant disability or interference with 
every day living while a moderate score implies more troubling symptoms with some 
impact on quality of life while a severe score would entail significant disability/ 
impairment with profound disruption of activities of daily living and loss of 
independence. Judgments qualifying severity were very often present in the original 
clinical correspondence which, in all cases, provided a detailed narrative history of each 
individual's illness as reflected in GP, nurse specialist, neurologist/physician, geriatrician, 
psychiatrist and therapist letters. For dementia specifically the criteria used for the 
different grades are as follow: 0== No cognitive impairment recorded, 1= Mild dementia 
with minor impairment of activities of daily living (ADL) but with largely retained 
independence, 2= Moderate dementia with some loss of independence and ability to 
perform ADL with some supervision required and 3= Severe dementia with constant 
supervision/placement in institution/ inability to perform ADL. All data were entered on a 
database for subsequent analysis. Retrospective chart analysis from movement disorders 
specialists is a well accepted method of case ascertainment and has been frequently used 
in clinico-pathological studies involving both dementia and parkinsonism 
(Papapetropoulos et al. 2005b;Papapetropoulos et al. 2005a;Litvan et al. 1998). 
Figure 2.1 Mode of presentation (presenting symptoms within 2 years of diagnosis; 
n=81) 
(Following page) 
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Mode of Presentation 
3% 5% 
48% 66% 
28% 1 1 % 
• Tremor 
• Drooling 
• Gait-balance 
• Akinetic-Rigit 
• Cognitive dysfunction 
• Autonomic 
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Figure 2.2 Cumulative incidence of motor deficits 2 years after clinical diagnosis 
(n=81). 
(Following page) 
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Motor Course 
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Figure 2.3 Cumulative incidence of autonomic deficits in the entire clinical course 
(n=81). 
(Following page) 
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Autonomic Dysfunction 
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Figure 2.4 Cumulative incidence of neuropsychiatric complications in the entire 
clinical course (n=81). 
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2.2.2.2 Selection of Cases 
The specific criteria used for the selection of cases included in each study are 
discussed within the following chapters. 
2.2.3 Sectioning of Formalin-Fixed, Paraffin-Embedded Tissue 
Paraffin blocks were stored at 4°C prior to sectioning. Sections were cut at a 
thickness of 8 [im on a microtome using disposable blades (Accu-Edge). Sections were 
floated in a water bath at 50°C until smooth and then dried onto Superfrost Plus slides at 
room temperature for approximately 30 min. Sections were incubated at 37°C overnight 
and subsequently stored at room temperature until used. 
2.2.4 Immunohistochemistry 
2.2.4.1 ABC Method 
Immunohistochemistry (IHC) is the primary technique used in the research 
described in this thesis. IHC allows for the identification of specific tissue proteins by 
means of a specific antigen/antibody reaction tagged with a visible label. 
Polyclonal antibodies (pAb) are produced by injecting a suitable mammal, such as 
a mouse, rabbit or goat with an antigen that is specific to an amino acid sequence of 
interest found in another species, inducing the production of antigen-specific 
immunoglobulins which are then purified. Different B cells each produce different 
antibodies to the same antigen, so Abs derived from this methodology may bind to a 
spectrum of epitopes within the antigen of interest. Monoclonal antibodies (mAb) are 
generally produced in hybridoma cells, a fusion of mouse-derived B cells and an 
immortalised myeloma tumour cell line. A single hybridoma cell can be cloned to 
produce large amounts of a specific antibody, and clones can be selected based on the 
affinity to antigen of the Ab they produce (Kohler and Milstein 1975). Often, mAb can 
subsequently be mapped to a specific amino acid sequence on the antigen. 
Coons and colleagues were the first to label Abs with a fluorescent label to 
identify antigens in tissue sections (COONS and KAPLAN 1950). Enzyme-conjugated 
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Abs allow for the visualisation of the antigen-Ab complex by a reaction between the 
enzyme and a substrate compound (Nakane and Pierce, Jr. 1967;Moriarty et al. 1973). 
This method is permanent and visible with a standard light microscope. The specificity 
and intensity of the immunohistochemical reaction can be increased through layering, 
using the primary Ab as an antigen for a subsequent, secondary Ab. 
The avidin-biotinylated enzyme complex (ABC) was developed by Hsu et al. and 
relies on the very high affinity between avidin, a molecule found in egg white, for the 
vitamin biotin, which can also be conjugated to peroxidase or alkaline-phosphatase 
enzymes as well as Abs (Hsu et al 1981a;Hsu et al. 1981b). Avidin, with four binding 
sites to biotin, forms a very high-affinity bridge between a biotinylated Ab and 
biotinylated enzyme, which can be visualised in the presence of the enzyme substrate. 
2.2.4.2 Immunohistochemistry of Formalin-Fixed, Paraffin-Embedded Tissue 
A detailed protocol can be found in appendix II. In the fume hood, sections are 
first dewaxed in xylene. They then pass through a series of four 5 min. alcohol washes 
(100%, 100%, 90% and 70%) in industrial methylated spirits (IMS) and are finally placed 
in distilled water. To block endogenous peroxidase activity, sections were placed in 0.3% 
hydrogen peroxide in methanol for 30mins. If a pre-treatment for antigen unmasking is 
required (see Section 2.1.2), it is carried out at this point. Sections are then rinsed in Ix 
PBS. The sections were then individually removed from the Ix PBS, wiped around and at 
the back, before the pap pen was applied around the tissue and subsequently placed in 
moist incubation chamber. Approximately 200^1 per section of primary Ab (made up in 
1®^  diluent to appropriate dilution, see appendix II) was applied on the tissue. Sections 
were incubated overnight at 4° C, then rinsed in 3 x 5 min washes of Ix PBS. Following 
the washes, the sections were incubated with a horse-anti-mouse secondary Ab at room 
temperature for 1 hour (made up in 2"^  diluent to appropriate dilution, see Appendix II). 
After rinsing in 3 x 5 min washes in Ix PBS, the avidin-biotin tertiary complex (Vector 
ABC kit) was applied for 1 hour at room temperature (made up also in 2"^ dilutent to 
appropriate dilution). After this period, a further 3 x 5 min washes in PBS were 
performed. Visualization of the reaction was achieved with the use of 3,3'-
diaminobenzidine (DAB) chromogen (Vector kit, for recipe see Appendix II). Sections 
were incubated with DAB for 3 mins and rinsed in running water. Subsequently, slides 
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were lightly counterstained in haematoxylin and then rinsed in running water until the 
water became clear. Following this procedure, sections were dehydrated by moving them 
in the following solutions for 5mins each 1) 70% alcohol, 2) 90% alcohol, 3) 100% 
alcohol, 4) 100% alcohol, and then placed in xylene for complete dehydration. Using the 
xylene-based mountant DPX sections were then cover-slipped. 
To ascertain the specificity of primary Ab staining a negative control slide was 
included in most instances (due to tissue availability), which was treated identically to the 
other slides with the exception that no primary Ab was applied to it. These slides were 
expected not to demonstrate any immunopositivity provided that no non-specific binding 
to tissue occurred in the rest of the reaction. 
2.2.4.3 Antigen Unmasking 
Formalin fixation and wax embedding leads to cross-linking of protein that may 
result in the "masking" of antigenic determinants and thus reducing the number of 
antigenic sites available for demonstration. Antigen unmasking is a process which makes 
tissue more permissive to Ab labelling (Maclntyre 2001). The structural biochemistry of 
antigen masking and unmasking is unclear. It has been reported that a need for antigen 
unmasking after formalin fixation is associated with the presence of a tyrosine residue in 
or near the Ab binding site and an arginine residue elsewhere on the antigen, suggesting 
that the Mannich reaction, in which formaldehyde and arginine can form a reactive 
intermediate that binds to tyrosine, may be involved (Sompuram et al. 2004). 
Two antigen unmasking techniques were used in this series of experiments. For 
the aSN Ab (described in Table 2.3), sections are incubated in 100% formic acid (FA) for 
5 min or 80% FA for 60 min. For one Ab, anti-Ap clone 1E8, a similar antigen 
unmasking pre-treatment consisting of an 8 min. incubation in 80% FA was used. 
Although, the selection and optimisation of the aSN Ab used in this research was 
performed elsewhere (Croisier et al. 2006) following recommendation of BrainNet 
Europe a new protocol was tested whereby sections are incubated for 60 min in 80% FA 
and with a dilution of the primary Ab 1/1000. Immunohistochemistry with this protocol 
revealed that aSN lesions were more clearly visible due to a less intensely stained 
background (Figure 2.5). In order to test the specificity of this protocol and to ensure that 
no normal aSN is picked up due to prolonged FA pre-treatment, immunohistochemistry 
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for aSN was performed in Alzheimer's disease (frontal cortex), Multiple Sclerosis (spinal 
cord) and Control (caudate-putamen) tissue (Figure 2.5). Immunostaining was absent in 
all three cases thus confirming specificity for pathological aSN inclusions. As a 
consequence, this protocol was adopted for chapters 3, 4 and 5 whereas for chapter 6 
sections were incubated in 100% FA for 5 min and with a dilution of the primary Ab 
1/300. Antigen retrieval methods have been shown to be particularly important in 
detection of pathologic forms of aSN. This is related to the fact that aSN is normally 
abundant in synaptic termini. Pre-treatments abolish much or all of the normal aSN and 
permit selective visualisation of pathologic aSN. For the anti-A(3 clone 1E8 Ab, 
optimisation was performed elsewhere and because it was non-commercial and only a 
limited supply was available, the estabhshed protocol was used (Table 2.3). 
The other primary method of antigen unmasking, high temperature antigen 
unmasking (Ht), involves microwaving sections in a solution of O.OOIM EDTA in 
distilled water, pH 8. Sections are placed in approximately 400 mL of EDTA and 
microwaved at 350W for 20 min (see appendix II). 
Figure 2.5 Specificity of a-synuclein immunohistochemistry with 1 hour FA pre-
treatment. 
(Following page). Immunoreactivity of aSN in A: MS tissue, B: Control and C: AD. The 
absence of staining confirms that 1 hour FA pre-treatment does not pick up normal aSN 
and thus verifies the specificity of the protocol. D: Representative aSN stained section 
(with 1 hour FA pre-treatment) from the hypothalamus of a PD case. Abbreviations; MS: 
Multiple Sclerosis, aSN: a-synuclein. Primary magnification for A-C: x40 and for D: 
x20. 
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2.2.5 Definition of aSN, and AD-type Pathology 
The operational definitions of the neuropathological changes investigated in the 
present research are described below. 
aSN pathology: The major histopathological hallmark of PD is the presence of LBs and 
LNs in the substantia nigra as well as various extranigral structures. The detection of LBs 
and LNs pre-aSN era is described elsewhere (see section 1.3.1.3). Following the 
recognition that Abs to aSN specifically label LBs and LNs as well as a wide range of 
aSN positive structures, IHC for aSN has become the preferred method in 
neuropathological research (see section 1.3.1.3). Given the superior nature of aSN Ab-
based staining methods, in the present work aSN inclusions were visualised with the use 
of aSN IHC. aSN-containing inclusions displayed a variety of morphologies that are 
described in Table 2.4. Figure 2.6 illustrates the major morphologies of aSN inclusions 
observed in the present thesis but is by no means comprehensive. In the perikaryon of 
neurons, deposits were seen as compact spherical inclusions (i.e. LBs) (Figure 2.6 A, B 
and C), moderately immunoreactive deposits with irregular shape (Figure 2.6 D) or small 
particulate deposits (Figure 2.6 E). Less frequently, aSN aggregated also in glial cells 
(Figure 2.6 F). Combinations of the abovementioned morphologies were also observed, 
especially in the form of co-existing LBs with fine particulate deposits in the remaining 
cytoplasm (Figure 2.6 B). Multiple LBs in one neuron were principally found in the SN 
(Figure 2.6 C). aSN inclusions resembling the morphology and size of fully compact LBs 
were also seen extracellularly with no obvious association to a neuronal cell (Figure 2.6 
A). These probably correspond to neuronal intracytoplasmic inclusions that were left 
behind when neurons died. Pathological involvement in neuronal processes (i.e. LNs) was 
predominantly seen in the CA2 sector of the hippocampus, NBM, amygdala and lower 
brainstem structures. LNs also displayed a range of morphologies varying from sausage-
like, segmental serpentine to continuous serpentine and pearl-like arrangements (Figure 
2.6 G-J) 
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Table 2.4 Diverse morphology of aSN-positive structures as detected with aSN IHC 
in the perikaryon of neurons and neuronal processes 
(Following page) 
Abbreviations: IHC; immunohistochemistry, LNs: Lewy neurites, LB: Lewy body 
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Morphology of aSN deposits 
in the perikaryon of neurons using aSN ICH 
1) Small particulate deposits (dust-like particles) 
2) Lightly immunoreactive with irregular shape 
3) Lightly immunoreactive with sperical shape 
4) Moderately immunoreactivity with irregular shape 
5) Partly compact and partly loose 
6)Compact structure and spherical with intense 
immunoreactivit}' with some fine dust-like particles 
in the remaining cytoplasm 
7) Fully compact LB occupying the whole cytoplasm 
8) Free-lying fully compact LB 
Morphology of aSN deposits 
in neuronal processes (LNs) using aSN ICH 
1) Sausage-like LNs 
2) Segmental serpentine- like LNs 
3) Continuous serpentine-like LNs 
4) Pearl-like LNs 
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Figure 2.6 Heterogeneity aSN-positive inclusions 
(Following page) A) Fully compact LB in the NBM with no obvious association to a 
neuron. B) Fully compact LB in the SN with small particulate deposits in the remaining 
of the cytoplasm. C) Several LBs in a pigmented neuron in the SN. D) Moderately 
immunoreactive deposit with irregular shape in the entorhinal cortex. E) Small particulate 
deposits in the SN. F) aSN in glial cell processes (possibly astrocyte) in the NBM. G) 
Large LN in the SN, H) LN terminating with a varicose in the DMV. I) LN exhibiting a 
pearl-like arrangement (arrow), segmental serpentine with dilatations (arrowhead), 
continuous serpentine-like with dilatations (dashed arrow) in the NBM. J) Long LN 
faintly stained in the AC. Magnification A-H; lOOx oil objective, I and J; 40x. 
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AD-type pathology (i.e. plaques and NFTs): As described in section 1.3.3.1 AD-type 
pathology is characterised by two major histopathological features- plaques and NFTs. 
Traditional histologic stains for the visualisation of AD pathology were developed 
empirically without understanding of their biological basis. Early descriptions of the AD 
histopathologic features were based on silver stains, amyloid stains and modifications 
thereof such as thioflavin-S fluorescence, Bielschowsky silver stain, Campbell-Switzer 
silver stain, Bodian stain and the Gallyas silver stain (Dickson 2005). Although, some of 
these stains (e.g. thioflavin-S fluorescence) are useful for the study of AD, they are not 
selective for a particular AD neuropathological feature. For instance, thioflavin-S 
fluorescence and Bielschowsky silver stain detect both plaques and NFTs while 
Campbell-Switzer silver stain detects plaques, NFTs as well as LBs (Braak and Braak 
1999;McKee et al. 1991). In addition, there is considerable heterogeneity in the 
appearance of AD-type pathology of those early detection stains depending upon the 
particular laboratory in which it is performed and local modifications to the protocol. 
Immunohistochemical detection of AD-type pathology has proved superior to those early 
stains as it is specific and sensitive to a particular pathological feature (i.e. plaques or 
NFTs) and provides a biological meaningful stain that is derived from molecular and 
biochemical characteristics of the pathological changes under study. On the basis of the 
above argument in this work IHC was employed to detect AD-type changes- plaques and 
NFTs. AP IHC using the 1E8 Ab was used for the visualisation of amyloid plaques as 
well as CAA (described in chapter 3). Although, plaques have been traditionally 
classified as either neuritic or diffuse their detection using IHC does not readily 
distinguish these plaque subtypes (see also section 1.3.3.1). Using A|3 IHC a wide range 
of morphologies of amyloid plaques have been described in AD but these different 
subtypes insofar have only been reported in the medial temporal lobe (Thai et al. 2000) 
(see also section 1.3.3.1 Figure 1.4). In this work two major types of amyloid plaques 
predominated: cored and diffuse plaques. Plaques were classified as cored when they 
contained a central core composed of AP fibrils and surrounded by a corona of diffuse AP 
deposits. Between the core and the corona is a small gap without Ap. On the other hand, 
diffuse plaques contained non-structured amyloid (Figure 2.7). Ap IHC was also used for 
the visualisation of CAA changes (a description of CAA changes is provided in chapter 3 
section 3.2.5). Tau IHC was employed for the visualisation of NFTs using the ATS Ab. 
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NFTs appeared as flame-shaped or globoid masses of fibrous intraneuronal material often 
accompanied by abnormal neuronal processes, i.e., neuropil threads (NTs) and dystrophic 
neurites that were also tau-immunoreactive (Figure 2.8). 
Figure 2.7 Visualisation of amyloid plaques. 
(Following page). Different types of amyloid plaques using AP IHC. A: Cored plaque in 
the temporal cortex of a PD case. B: Diffuse plaque in the temporal cortex of the same PD 
case. Primary magnification x40. 
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Figure 2.8 Visualisation of tau-positive inclusions. 
(Following page). Examples of tau inclusions using IHC. A: Overview of tau-positive 
inclusions in the CAl sector of the hippocampus. NFTs as well as NTs and dystrophic 
neurites are clearly visible. B-C: NFTs appeared either as globoid or flame-shaped and 
often accompanied by NTs (entorhinal cortex). D: Dystrophic neurites in the entorhinal 
cortex forming a halo around a dense white core (^-amyloid). Primary magnification for 
A; xlO and for B-D: x40. 
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2.2.6 Analysis of Immunohistochemical Tissue Staining 
The use of quantitative methods has become an increasingly important aspect in 
the study of neurodegenerative disorders. Various methodologies have been developed 
each of which has its own advantages and disadvantages. Image analysis systems have 
enabled images of histological sections to be captured and enhanced on a computer screen 
so that brain lesions can be quantified. However, this approach is vulnerable to numerous 
variables. Limiting a count to a particular area of the section, delineated anatomically or 
by the presence of another protein, precludes any differences in other areas from being 
detected. Automated cell counts do not distinguish cell types and measurements of the 
density of immunoreactivity across an area are prone to inaccuracies, as software tends to 
pick up haematoxylin-counterstained nuclei and, depending on the antibody used, cross-
reactive blood vessels or lipofuscins. There is also little evidence of a linear relationship 
between the intensity of immunostaining and the amount of protein present. 
Another relatively recent quantitative methodology is the so called unbiased or 
assumption-free stereology to distinguish it from the older assumption-based quantitative 
methods. Stereological methods have proved to be a valuable tool for gaining accurate 
quantitative information from histological sections. However, there is now an increasing 
consensus that 'unbiased' is a misnomer for stereological analysis because of ample 
evidence for potential biases - what could be unbiased theoretically, can well be biased 
when applied to real-world tissue sections (Benes and Lange 2001;Guillei7 and Herrup 
1997;Guillery 2002). Indeed, there are some significant practical difficulties that in some 
studies preclude the use of stereology. One problem of using stereology in quantifying 
pathological lesions stems principally from the incomplete penetrance of the 
immunohistochemical stains as most of the Abs used in neuropathological research 
cannot penetrate the embedding mediums necessary for the preparation of thick tissue 
sections for stereological analysis (e.g. plastic techniques using glycol methacrylate) 
(Dorph-Petersen et al. 2001). Such incomplete stains not only will give false 
measurements of section thickness, but also incomplete counts. This problem could 
perhaps be overturned if fixed frozen tissue is used in conjunction with tissue 
permeabilisation (e.g. using triton). Although, this would increase the Ab penetration 
considerably, possible limitation would be the access to suitable sectioning device (e.g. 
freezing microtome or vibratome) and tissue shrinkage especially differential tissue 
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deformation on the z-axis. Another practical drawback is the necessity of using the entire 
brain region for stereological analysis (i.e. tissue availability). This in practice is not 
always possible especially in studies using human tissue. 
Despite the advantages and disadvantages of different methods for quantifying 
brain lesions in neurodegenerative diseases the quantitative methodology to be adopted in 
any study should depend on the problem to be solved (i.e. should be relevant to the 
objective of the study). In this thesis the semi-quantitative methodology was used. Semi-
quantitative severity ratings could be problematic in that it is not necessarily possible to 
replicate the methodology of a study without also replicating to some degree the training 
of the observer. It is also highly dependent on experience and familiarity with the stain 
under study. However, semi-quantitative methods allow for the assessment of large 
numbers of cases and are more robust to flaws in data acquisition (Armstrong 2003). 
Once the problem of inter-rater reliability is overcome, semi-quantitative methods have 
been shown to provide sufficiently accurate data (Armstrong 2003). 
More specifically, in this work the immunoreactivity of aSN and AD type lesions 
was assessed using a CERAD-based (Mirra et al. 1991) visual impression of the 
numerical density of lesions under study ranging from 0-3 (absent-severe). Slides were 
assessed using an Olympus BX50 light microscope. The specific criteria and 
methodology applied are described thoroughly in the chapters in which it is assessed. 
Slides were randomised, their case and block number obscured with tape and marked with 
a number or letter prior to assignment of semi-quantitative ratings in order to minimise 
any bias held by the assessors. The reliability of semi-quantitative ratings was ensured as 
ratings were assigned by two independent observers. Cohen's kappa statistic was then 
used to test inter-rater reliability between the observers. 
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Chapter 3 
Cortical and Limbic Pathology in Parkinson's Disease: 
Relation to Dementia and Visual Hallucinations 
3.1 Introduction 
Traditionally, PD has been characterised as a hypokinetic movement disorder with 
the main clinical features of resting tremor, bradykinesia, rigidity and abnormalities of 
gait, balance and posture (Lee et al. 1994;Lee et al. 1994). Experimental and clinico-
pathological studies have shown that the primary anatomic substrate of these motor 
complications is the degeneration of the pigmented dopamine-producing neurons in the 
substantia nigra pars compacta (SNc) (see also section 1.3.4) (Forno 1996;Fearnley and 
Lees 1991). However, the complexity and variety of clinical symptoms experienced in PD 
(described in section 1.2) reflect an anatomically wide-ranging disease, a concept 
supported by animal studies, which have demonstrated that lesions restricted to the 
substantia nigra or dopamine pathways do not accurately model PD. Indeed, PD appears 
to be a multisystem disorder involving a variety of cortical and subcortical systems 
causing multiple neuromediator dysfunctions (Jellinger 1999). The present chapter will 
try to elucidate further the specific contribution of cortical and subcortical lesions to 
mental impairment in PD, with a focus on dementia and visual hallucinations (VH). 
3.1.1 Clinico-pathological Studies of Dementia in PD 
Contrary to initial assumptions that cognitive dysfunction is not an essential 
feature of PD, it has become increasingly apparent that patients with PD can have 
impairment of certain cognitive functions (described in section 1.2.3) and go on to 
develop dementia. Despite intense research efforts the underlying pathology and 
anatomical origin of dementia associated with PD remain a matter of controversy. Studies 
of clinico-pathological association in demented PD patients can be broadly categorised 
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into three groups by the suggested cause of dementia: subcortical pathology, limbic or 
cortical Lewy-body type pathology and those suggesting coincident AD-type pathology. 
Degeneration of nigral neurons is the classical pathological feature in PD. The 
initial hypothesis therefore was that neuronal loss in the SNc also causes cognitive 
dysfunction although patients without cognitive impairment can have severe motor 
deficits. The first evidence to support this hypothesis was provided by Rirme and 
colleagues (Rinne et al. 1989), where they reported that cell loss in the medial substantia 
nigra was associated with dementia even when accounting for confounding Ap burden. 
Jellinger and Paulus also reported a relationship between cell loss in the medial substantia 
nigra in demented PD patients although, this was associated with more severe AD-type 
pathology in the hippocampus and isocortex (Jellinger and Paulus 1992). Involvement of 
other subcortical nuclei such as the LC and the NBM have also been shown to contribute 
to dementia (Caspar and Gray 1984). 
LBs in the cortex and limbic structures are commonly found in PD brains to a 
varying degree. A number of clinico-pathological studies have reported an increased 
cortical LB burden in PD patients with dementia (Mattila et al. 2000;Mattila et al. 
1998;Kovari et al. 2003;Hurtig et al. 2000). Mattila and colleagues have demonstrated a 
strong association between LBs in the frontal cortex and dementia, independently of 
concomitant AD pathology (Mattila et al. 2000). Similar results have been reported by 
Hurtig et al., where cortical LBs were found to be a more sensitive and specific correlate 
of dementia than AD-type pathology in 22 demented as compared with 20 non-demented 
PD subjects (Hurtig et al. 2000). In another study dementia correlated with LB densities 
in the entorhinal cortex and anterior cingulate gyrus (Kovari et al. 2003). Others have 
suggested LB and LN-type pathology in limbic structures (e.g. amygdala, hippocampus) 
to relate to cognitive decline and dementia in PD (Bertrand et al. 2003 ;Bertrand et al. 
2004;Churchyard and Lees 1997). Overall, these studies point to LB-type degeneration in 
cortical and limbic regions as a main correlate of dementia in PD, independently of 
concomitant AD-type pathology. 
A third group of studies suggest coincident AD-type pathology might cause 
dementia in PD. Boiler et al., found AD-type pathology in all severely demented PD 
patients and only in a small proportion of non-demented (Boiler et al. 1980). In another 
study amyloid deposits were found in 100% of cases with dementia but only 50% of those 
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who were non-demented (Mann and Jones 1990). In a large study of 610 patients with 
parkinsonism, 30% of those with PD were demented and dementia was associated with 
AD-related changes (Jellinger 1997). Finally, in 200 PD cases, 94% of those with 
dementia had cortical AD-type changes however, the relation to LB pathology was not 
investigated in this study (Jellinger et al. 2002). 
Although studies have focused on PD-related and AD-type abnormal protein 
deposition as the possible substrate of dementia in PD, less attention has been given to 
vascular changes. CVLs, including CAA, the deposition of P-amyloid protein in 
meningeal and cortical (parenchymal) arteries, arterioles, veins and capillaries (Jellinger 
et al. 2002;Zekry et al. 2002;Preston et al. 2003) are frequently observed in the ageing 
brain and often co-exist with AD and PD. They may also play a significant synergistic 
role in the development of cognitive deficits and parkinsonism (Zekry et al. 2002;Rektor 
et al. 2006). In fact, CAA is a frequent, almost invariant component of the AD process. 
However, the contributory effect of CVLs and especially CAA in dementia in PD has 
gathered little attention. A recent autopsy study comparing 617 cases of PD with 535 age-
matched controls revealed a 44.7% increase of CVLs which was slightly lower than in 
AD cases (Jellinger 2003b). In addition, the frequency of CVLs in demented PD cases 
was higher. In another study the occurrence of vascular P-amyloid in PD cases with 
dementia was greater than in age-matched controls, however due to inadequate clinical 
information a direct correlation with dementia was not possible (Mastaglia et al. 2003). 
Although, the association between CAA and AD has been extensively studied, the 
contributory factor of CAA in dementia in PD remains unclear. 
3.1.2 Clinico-pathological Studies of Visual Hallucinations in PD and DLB 
Although the most studied mental deficit in PD is dementia, VH are also a 
common symptom that often co-exist with dementia in PD patients with a recent literature 
survey demonstrating a prevalence in the range of 6-60% (Cummings 1991 ;Diederich et 
al. 2005) (for further information about VH in PD refer to section 1.2.3.2). Despite a high 
incidence there are very few neuropathologic studies of PD patients with VH and 
therefore the anatomico-pathological basis remains undefined although several studies 
point to a temporal lobe origin of this symptom. Harding et al., have demonstrated an 
increased burden of LBs in the inferior temporal cortex, parahippocampal gyrus and 
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amygdala in FDD and DLB cases with VH (Harding et al. 2002a). In a study where PD 
subjects were analysed without concomitant dementia an increased LB burden in the 
basolateral nucleus of the amygdala was associated with VH (Harding et al 2002b). 
Recently, Papapetropoulos and colleagues have also reported an increased LB burden in 
the amygdala as well as frontal, temporal and parietal cortices in PD patients with VH 
(Papapetropoulos et al. 2006). On the other hand, imaging studies point to hypoperfusion 
in the inferior temporal gyrus, inferior parietal lobule, precuneus gyrus and occipital 
cortex in PD cases with VH as compared to those without (Matsui et al. 2006), while 
others point to the superior frontal gyrus and right fusiform gyrus as responsible for this 
complication (Stebbins et al. 2004;0ishi et al. 2005). 
Many studies suggest that common factors associated with VH are higher age, 
duration of disease, cognitive impairment, medication, depression and sleep disturbances 
(Barnes and David 2001;Fenelon et al. 2000;Graham et al. 1997;Sanchez-Ramos et al 
1996). Although, higher doses of levodopa and other antiparkinsonian agents, such as 
dopamine agonists and anticholinergics have been associated with VH, a direct cause-
effect relationship between a specific drug and hallucinations remains unclear (see also 
section intro 1.2.3.2). 
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3.1.3 Aims 
In this study, the aim was to elucidate further the specific contribution of cortical and 
subcortical pathological lesions to dementia and VH in a relatively large PD cohort with 
minimal concomitant neuropsychiatric features. The pathology was assessed in eight 
brain regions that are affected in PD and which are known to play a role in cognitive 
function. The antiparkinsonian medication of the PD cases included in this work was also 
reviewed in order to gain a better understanding of any potential relationship with the 
clinical features under study. 
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3.2 Materials and Methods 
3.2.1 Neuropathological Assessment 
Neuropathological assessment and diagnosis were performed as described in 
section 2.2.1. 
3.2.2 Selection of Cases 
A total of 81 cases were included in this study. The cases were screened and the 
clinical severity of dementia, VH, anxiety, depression, delusions and paranoia were 
graded on a semi-quantitative global impression scale (0-3+, absent to severe) as 
described in section 2.2.2.1. For the purpose of the present study, cases were stratified 
into four groups according to clinical characteristics. 17 cases were identified with no 
dementia and no VH, 15 cases with moderate to severe scores for dementia and with VH 
(range 2-3), 7 cases with moderate to severe scores for VH alone without concomitant 
dementia (range 2-3) and 5 cases with moderate to severe scores for dementia alone 
without concomitant VH (range 2-3). Cases with severe co-existing neuropsychiatric 
features such as paranoia, delusions, depression and anxiety were excluded (n=26). 
The clinical assessment of cases followed established criteria (see section 2.2.2). 
Upon disclosure of the clinical and neuropathological diagnoses, 9/17 cases with no 
dementia and no VH (with the exception of one case with mild VH) were diagnosed with 
PD (PD(H-) group), 1 case with Multiple System Atrophy (MSA), 1 case with 
Progressive Supranuclear Palsy (PSP), 3 cases with ageing-related changes and 3 cases 
with essential tremor. Out of the 15 cases with moderate to severe scores for dementia 
and VH 12 cases were diagnosed with PD (PDD(H+) group), 1 case with PD and AD and 
2 cases with DLB. For cases with moderate to severe scores for VH alone without 
concomitant dementia 5 cases were diagnosed with PD (PD(H+) group) and 2 cases with 
MSA. For cases with moderate to severe scores for dementia without concomitant VH 4 
cases were diagnosed with PD (PDD(H-) group) and 1 case with possible Fragile-X 
ataxia. All cases with a clinico-pathological diagnosis other than PD were excluded from 
the study. Thus, the cohort included a total of 30 PD cases of which 9 cases in the PD(H-) 
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group, 12 cases in the PDD(H+) group, 5 cases in the PD(H+) group and 4 cases in the 
PDD(H-) group (Table 3.1). For these cases gender, age at PD onset, age at death, 
duration of disease, as well as the clinical severity of the individual neuropsychiatric 
symptoms assessed are presented in Table 3.1. All apart from possibly one case were L-
Dopa responsive (Table 3.1). Details of drug treatment including potential aggravating 
medication and cognitive enhancing agents are presented in Table 3.1. The mini mental 
state examination scores available for some of PDD cases are provided in Appendix III. 
Table 3.1 Clinical data for the PD groups. 
(Following page) Abbreviations: PDD(H-): PD cases with high clinical scores for 
dementia and no VH, PD(H+): PD cases with high clinical scores for VH and no 
dementia, PDD(H+): PD cases with high clinical scores for both dementia and VH, 
PD(H-): cognitively intact PD cases, D: Dementia, VH: Visual Hallucinations, A: 
Anxiety, De; Depression, Pr; Paranoia, Dl: Delusions PD; Parkinson's disease, m; male, 
f: female, semi-quantitative clinical severity scores 0: absent, 1: mild, 2: moderate, 3: 
severe, +: yes, no, ±: possibly 
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PDfH-1 Group 
PDD(H+) Group (0212) 
PDDfH-) Group 
(n=4) 
PD(H+1 Group 
ln=51 
Age at Age at Duration Neuropathological Clinical Severity 
Case Onset Death of Disease Diagnosis ICONS AD GRADE Braak Scores of Neuropsychiatric Features L-Dopa Anti-Parkinsonian Other 
Number Gender (years) (years) (years) (www.ICDNS.org) (www.lCDNS.org) AD-Stages D VH A De Pr Dl Responsiveness Medication Medication* 
58 f 52 58 6 PD isocortical 0 - entorhinal 1 l-II 0 0 1-2 0 0 0 ± Madopar 
74 76 85 9 PD isocortical II entorhinal 0 l-II 0 0 1 0 0 0 + Sinemet. Madopar, Pergolide -
95 47 74 27 PD Isocortical 1 entorhinal 0 l-II 0 0 0 1 0 0 + Sinemet, Pergolide -
2 3 m 75 82 7 PD isocortical 1 entorhinal 11 l-ll 0 0 0 1 0 0 + Sinemet -
7 m 68 78 10 PD l-ll 0 0 0 0 0 0 + Amantadine -
22 f 65 75 10 PD isocortical 0 entorhinal 0 0 0 0 0 0 0 0 + Madopar -
29 70 77 7 PD isocortical 0 - entorhinal 1 l-II 0 1 0 0 0 0 + Madopar -
32 86 89 3 PD isocortical 0 - entorhinal 1 l-ll 0 0 0 0 0 0 + Madopar -
36 67 77 10 PD isocortical 0 - entorhinal 1 l-ll 0 0 0 0 0 0 + Madopar -
Mean 67 77 9.8 
5 f 57 80 23 PD isocortical II entorhinal 11 l-ll 2 3 0 0 0 0 Sinemet. Amantadine 
18 77 82 5 PD isocortical 1 entorhinal 11 0 2-3 3 1 1 0 0 + Madopar Donepezil 
15 56 70 14 PD isocortical IV - entorhinal 111 III 2-3 2 1 0 0 1 + Sinemet, Madopar Olanzapine 
24 72 81 9 PD isocortical 0 - entorhinal 1 l-II 2-3 2 1-2 0 0 0 Sinemet, Madopar -
30 57 7 3 16 PD isocortical 1 entorhinal II l-ll 2 2 0 0 0 0 + Benzhexoi, Sinemet, Madopar Olanzapine 
69 71 82 11 PD isocortical 1 - entorhinal 11 l-ll 2 2-3 0 1 0 1-2 + Ropinirole, Sinemet Rivastigmine 
2 75 84 9 PD isocortical 0 - entorhinal 1 0 2 2 3 2 0 0 + Pergolide, Sinemet Donepezil. Risperidone 
16 f 67 85 18 PD isocortical II - entorhinal 1 l-ll 2-3 2-3 1 1 0 0 + Bromocriptine. Madopar. Sinemet -
44 74 87 13 PD isocortical 1 entorhinal 11 l-ll 2 3 0 0 0 0 + Pergolide. Madopar -
13 54 78 24 PD isocortical 0 - entorhinal 1 1-11 2-3 3 2 0 0 0 + Sinemet, Amantadine. Cabergoline Olanzapine. Melleril 
34 73 84 11 PD isocortical IV - entorhinal 111 111 3 2 3 0 0 0 + Sinemet Diazepam. Olanzapine 
60 78 84 6 PD isocortical II -entorhinal 11 l-ll 2 2 0 0 0 0 + Pergolide, Sinemet, Ropinirole Donepezil, Olanzapine 
Mean 67 80 1 3 ^ 
11 62 71 9 PD isocortical III entorhinal II l-ll 2 0 0 0 0 0 Sinemet 
45 61 80 19 PD isocortical 0 - entorhinal III III 2-3 0 2 2 0 1 + Sinemet -
56 35 54 19 PD isocortical 0 - entorhinal 1 0 2 1-2 0 0 0 0 + Bromocriptine, Sinemet. Pergolide, Madopar -
14 67 79 12 PD isocortical IV - entorhinal 111 l-ll 3 1 0 0 0 0 + Madopar -
Mean 56 71 14.7 
63 f 67 80 13 PD isocortical 0 - entorhinal 1 l-ll 0 3 0 0 0 0 Sinemet . 
42 f 58 79 20 PD isocortical 0 - entorhinal I l-ll 0 2 1 ^ 1 0 0 + Sinemet, Amantadine, Cabergoline Risperidone 
72 42 62 20 PD isocortical 0 entorhinal 0 0 0 2-3 0 0 0 0 + Pergolide, Ropinirole, Pramipexole -
20 41 75 34 PD isocortical 1 - entorhinal 11 l-ll 0 2 0 1 0 0 + Pergolide, Sinemet, Artane Quatiapine 
21 48 76 28 PD isocortical 0 - entorhinal I l-ll 1 2-3 1 0 0 0 Amantadine, Pergolide. Sinemet. Madopar -
Mean 51 7 4 23 
126 
3.2.3 Immunohistochemistry 
Immxmohistochemical reactions were performed as described in section 2.2.4. All 
30 cases were stained for aSN for the identification of aSN lesions (Becton-Dickinson at 
a dilution of 1:1000), tau for visualization of neurofibrillary changes (Autogen Bioclear 
PHF-Tau (clone ATS) at a dilution of 1:800) and 1E8 for visualization of AP plaques 
(AP) (at a dilution of 1:1000). 
3.2.4 Semi-quantitative Assessment of aSN and AD Lesions 
For each case, three representative sections from the superior frontal gyrus, 
cingulate gyrus, temporal cortex (middle temporal gyrus), entorhinal cortex, hippocampus 
CA2 sector, subiculum, amygdaloid complex and nucleus basalis of Meynert (NBM) 
were assessed for the occurrence of aSN, Ap and tau pathological changes. The pathology 
was examined semi-quantitatively based on a scale ranging from 0-3 (absent to frequent; 
a pictorial representation of the different ratings of pathology is shown in Figure 3.1). 
Sections were screened in their entirety at lOx primary magnification for overall 
deposit burden. The occipital lobe was also examined in the same manner for the PD(H-) 
and PD(H+) groups only. Sections were graded by two investigators (Mr. Michail E. 
Kalaitzakis and Ms Lynne Christian). Cohen's kappa statistics revealed an inter-rater 
reliability of 0.8 for aSN, 0.9 for tau and 0.86 for AP (i.e. kappa statistic has a range of 0-
1, with larger values indicating better reliability; generally a kappa of >0.70 is considered 
satisfactory). Intra-rater repeatability was also assessed by measuring the cingulate gyrus 
of five to six randomly selected subjects on five occasions at least a week apart. On each 
occasion, all operator-dependent processes (i.e. region of interest semi-quantitative 
assessment) were performed without reference to previous values. High intra-rater 
reliability was observed. The raw data for aSN, tau and AP pathology can be found in 
appendix III. 
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Figure 3.1 Semi-quantitative assessment of aSN, tau and Ap deposition in a 
representative cortical region (i.e. entorhinal cortex). 
(Following page) Semi-quantitative ratings of pathology. Assessment of aSN, tau and AjB 
pathology in the regions under study was carried out using a CERAD-based (Mirra et al. 
1991) visual impression of the numerical density of lesions ranging from 1-3 
corresponding to sparse, moderate and frequent. A value of 0.5 was assigned to those 
fields where only a single lesion was present. In a few cases, where the density did not 
clearly fit into one of the main categories, intermediate values were assigned. No cases 
had a high enough density in cortical and subcortical areas to warrant a rating of 3 for tau 
and Ap pathology. Magnification xlO. 
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3.2.5 Assessment of Vascular P-Amyloid Deposits 
Assessment of P-amyloid deposition in large and small leptomeningeal vessels 
and medium sized and small parenchymal vessels was determined in superior frontal 
gyrus, cingulate gyrus and temporal cortex and occipital cortex (Figure 3.2). The presence 
of P-amyloid deposition in leptomeningeal and parenchymal vessel was noted as 
thickening of the basal membrane, stenosis of the vessel lumen or fragmentation of the 
internal elastic lamina. Given the difficulties of assessing the severity of these pathologies 
semi-quantitatively, the presence or absence was recorded. 
Figure 3.2 CAA changes in cortical regions 
(Following page). A: Leptomeningeal A|3 deposition in the temporal cortex of a PD case. 
B: Parenchymal deposition of Ap in medium sized vessels in the cingulate gyrus. C: 
Parenchymal penetrating vessel filled with Ap in the cingulate gyrus. D: Parenchymal 
vessel with AP deposition in the superior frontal gyrus of a PD case. Magnification; lOx 
for A and C, 20x for B and D 
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3.2.6 Statistical Analysis 
The association of aSN, tau and Ap with dementia and VH plus the interaction 
between these two factors was tested using a two-way ANOVA in each anatomical 
region. Although these measures are on an ordinal scale, the use of a parametric ANOVA 
is appropriate (as opposed to a non-parametric ordinal regression) because the number of 
items in the scale is large. The test was used to detect possible significant differences 
in CAA changes in the populations of the different PD groups sampled. The extent of 
aSN, tau and Ap burden in the occipital lobe between the PD(H-) and PD(H+) cases was 
examined with the use of the non-parametric Mann-Whitney [/-test. The interaction 
between the clinical variables of age at death and duration of disease with the 
neuropathological variables (aSN, tau and AP) was assessed using Spearman's two-tailed 
correlation analysis (non-parametric). Ordinal regression was applied to detect 
relationships between age at disease onset, age at death and duration of disease with 
dementia and VH. Cohen's kappa statistic was used to test inter-rater reliability for the 
aSN, tau and AP semi-quantitative assessment between the two investigators. Statistical 
analysis was performed using the SPSS programme version 15.0 for Windows XP. P 
values <0.05 were considered significant. 
The diagnostic performance of aSN and AP deposition in predicting dementia 
(regardless of the presence of VH) was calculated with measures of sensitivity, positive 
predictive value (PPV), specificity and negative predictive value (NPV). The 
methodology was adopted from Harding et al., (Harding and Halliday 2001). Briefly, 
sensitivity refers to the probability of having moderate to severe aSN and/or Ap 
deposition with high clinical scores for dementia. Specificity refers to the probability of 
not reaching moderate to severe aSN and/or AP burden in cases not having high clinical 
scores for dementia. PPV refers to the probability of having high scores for dementia on 
reaching moderate to severe aSN and/or Ap deposition. NPV refers to the probability of 
not having high scores for dementia in the absence of moderate to severe aSN and/or Ap 
burden. 
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3.3 Results 
3.3.1 Clinical Data 
A total of 30 PD cases were included in this study (Table 3.1). Age at disease 
onset and age at death did not differ between groups, however PD(H+) cases had a 
statistically significant longer disease duration (p=0.03). All PD cases had received 
medication with the potential to exacerbate hallucinations (Table 3.1). 
3.3.2 Histopathological Findings in Cortical and Subcortical Regions in the PD 
Brain 
In cortical regions aSN lesions were predominantly found in the lower layers V 
and VI. LBs represented the primary type of aSN lesions in the cortex while LNs were 
rarely observed. A(3 and tau deposits were distributed evenly throughout the cortex with 
no clustering or patchy appearance of pathological lesions. Among subcortical areas a 
preferential susceptibility to LN-type pathology was seen in the CA2 sector of the 
hippocampus exhibiting a thick web of LNs (Figure 3.3) while neighbouring sectors 
remained relatively spared. In the amygdaloid complex and NBM both LB and LN-type 
pathology was observed with LBs as the principal pathological change. 
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Figure 3.3 LNs in the CA2 sector of the hippocampus 
(Following page). Selective vxilnerability of, the CA2 sector of the hippocampus to LN-
type pathology. Insert: higher magnification showing the web of LNs. Primary 
magnification 4x and for insert lOx. 
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3.3.3 Association of aSN, tau and Ap Pathology with Dementia and VH 
Statistical analysis revealed a significant association between dementia in PD and 
aSN burden in the cingulate gyrus (p=0.01), superior frontal gyrus (p=0.02), temporal 
cortex (p=0.02), entorhinal cortex (p=0.002), amygdaloid complex (p=0.007) and CA2 
sector of the hippocampus (p=0.01) (Table 3.2). Although aSN burden did not associate 
with VH when present in isolation (PD(H+) group), a strong association was found 
between aSN burden in the amygdaloid complex (p=0.01) and VH in PD cases with 
concomitant dementia (PDD(H+)) (Figure 3.4, Table 3.2). Of note is that aSN load in the 
NBM did not associate with dementia. Interestingly, however aSN pathology in the NBM 
was severe in all groups studied independent of clinical phenotype. 
A strong association was also found between dementia and Ap load in the 
cingulate gyrus (p=0.01), entorhinal cortex (p=0.002), amygdaloid complex (p=0.004) 
and NBM (p=0.02) whereas no association was detected between Ap burden in PD cases 
with VH in isolation or with associated dementia (Table 3.2). Although tau pathology 
occurred mildly in all groups, tau burden in the CA2 sector of the hippocampus 
significantly associated with the presence of dementia (p=0.01) (Table 3.2). The 
associations observed herein cannot be attributed to an age related effect, as neither aSN 
nor tau or AP burden correlated with age at death or duration of disease. 
Neither aSN nor tau was detected in the occipital lobe of PD(H-) or PD(H+) cases 
while the occipital Ap burden was mild in both groups (Figure 3.5). 
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Figure 3.4 aSN burden in the amygdaloid complex 
(Following page). Immunostaining for aSN in the amygdala of a PD case without VH 
(A) and a case with VH associated with dementia (B). Magnification x20 
Abbreviations: PD; Parkinson's disease, VH; visual hallucinations, aSN; a-synuclein 
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Table 3.2 Statistical associations behveen pathology in neocortical and subcortical 
regions with dementia and VH in PD patients 
(Following page) Abbreviations: PD: Parkinson's disease, VH: visual hallucinations 
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Brain Area Dementia Visual Hallucinations 
a S N 
Superior Frontal gyrus 0.02 0.8 
Cingulate gyrus 0.01 0.6 
Temporal Cortex 0.02 0.4 
Entorhinal Cortex 0.002 0.9 
Hippocampus CA2 sector 0.01 0.2 
Subiculum 0.08 0.6 
Amygdaloid Complex 0.007* 0.9 
Nucleus Basalis of Meynert 0.4 0.5 
A3 
Superior Frontal gyrus 0.08 0.5 
Cingulate gyrus 0.01 0.3 
Temporal Cortex 0.07 0.4 
Entorhinal Cortex 0.002 0.9 
Hippocampus CA2 sector 0.1 0.4 
Subiculum 0.07 0.7 
Amygdaloid Complex 0.004 0.7 
Nucleus Basalis of Meynert 0.06 0.9 
Tau 
Superior Frontal gyrus 0.2 0.8 
Cingulate gyrus 0.5 0.8 
Temporal Cortex 0.7 0.6 
Entorhinal Cortex 0.4 0.5 
Hippocampus CA2 sector 0.01 0.9 
Subiculum 0,3 0.5 
Amygdaloid Complex 0.1 0.6 
Nucleus Basalis of Meynert 0.07 0.3 
In PD cases with dementia and concomitant visual hallucination p=0.01 
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Figure 3.5 Ap burden in the occipital lobe 
(Following page) The severity of Ap deposition was similar between non-demented PD 
cases with or without VH. 
Abbreviations: PD(H-); non-demented Parkinson's disease patients without visual 
hallucinations PD(H+): non-demented Parkinson's disease patients with visual 
hallucinations 
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As dementia associated with both aSN and AD-type pathology in various regions, 
in order to identify an anatomico-pathological marker that would differentiate PD cases 
with or without dementia (irrespective of the presence of VH), the sensitivity, PPV, 
specificity and NPV for all regions examined was calculated (i.e. PDD(H+) and PDD(H-) 
vs. PD(H-) and PD(H+) groups). The sensitivity and PPV for moderate to severe aSN 
burden in cases with dementia (PDD(H+) and PDD(H-) group) was highest in the range 
of 75-85% in the cingulate gyrus (Table 3.3). The sensitivity and PPV for Ap deposition 
was also the highest in the cingulate gyrus and was 25% and 80% respectively. These 
values indicate that aSN in the cingulate gyrus is a better pathological marker for 
detecting cases with dementia with or without VH (Figure 3.6). Furthermore, the 
specificity and NPV for cases without dementia (i.e. PD(H-) and PD(H+) groups) was 
high in the range of 75-85%. 
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Table 3.3 Two by two contingency table for calculation of sensitivity, PPV, 
specificity and NPV for aSN burden in the cingulate gyrus in demented PD subjects 
regardless of the presence of VH 
Sensitivity for demented PD cases (12/16X100)= 75%, PPV for demented PD cases 
(12/14X100)= 85%. Specificity for cases without dementia (12/14X100)= 85%, NPV for 
cases without dementia (12/16X100)= 75% 
Cingulate Clinically 
Gyrus demented Total 
aSN burden number of cases 
yes no 
2-3 12 2 14 
0-1 4 12 16 
Total Cases 16 14 30 
Abbreviations: aSN: a-synuclein, PDD(H+): cases with high clinical scores for both 
dementia and visual hallucinations, PDD(H-): cases with high clinical scores for dementia 
but no visual hallucinations, PPV: positive predictive value, NPV: negative predictive 
value 
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Figure 3.6 aSN burden in the cingulate gyrus 
(Following page) Immunostaining for aSN in the cingulate gyrus of a PD case without 
dementia or VH (A) in contrast to a case exhibiting both dementia and VH (B). 
Abbreviations: PD: Parkinson's disease, VH: visual hallucinations, aSN; a-synuclein 
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3.3.4 Vascular Changes 
CAA was observed in both leptomeningeal and cortical (parenchymal) vessels 
(Figure 3.2, Table 3.4). Leptomeningeal CAA changes in the cingulate gyrus, superior 
frontal gyrus and temporal cortex of demented PD subjects (i.e. PDD(H+) and PDD(H-)) 
were observed in 8/16, 7/16 and 10/16 cases respectively as opposed to 0/14, 3/14 and 
1/14 among non-demented PD cases (PD(H-) and PD(H+)). Parenchymal CAA in the 
cingulate gyrus, superior frontal gyrus and temporal cortex of demented PD subjects was 
observed in 6/16, 7/16 and 4/16 cases respectively as opposed to 0/14, 0/14 and 1/14 non-
demented PD subjects. Among PD cases with VH (irrespective of the presence of 
dementia) leptomeningeal CAA in the cingulate gyrus, superior frontal gyrus and 
temporal cortex was observed in 6/17, 7/17 and 8/17 cases respectively as opposed to 
2/13, 3/13 and 3/13 PD cases without VH. Parenchymal CAA in the cingulate gyrus, 
superior frontal gyrus and temporal cortex of hallucinating PD cases was observed in 
5/17, 6/17 and 4/17 cases respectively as opposed to 1/13, 1/13 and 1/13 of non-
hallucinating PD cases. statistical analysis between demented and non-demented PD 
cases (i.e. PDD(H+) and PDD(H-) vs. PD(H-) and PD(H+)) revealed a strong association 
between dementia and CAA changes in leptomeningeal vessels in the cingulate gyrus 
(p=0.001) and temporal cortex (p=0.0001) and parenchymal Ap deposition in the 
cingulate gyrus (p=0.001) and superior frontal gyrus (p=0.001) whereas no statistical 
significant association was observed between CAA and VH. Further to this, comparison 
of the occipital cortex of non-demented PD cases with and without VH did not 
demonstrate any differences with regard to vascular Ap deposition. The CAA changes in 
the cingulate gyrus, superior frontal gyrus, temporal cortex and occipital cortex are 
presented in Table 3.4. 
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Table 3.4 Presence or absence of CAA changes in this cohort among the different PD 
groups. 
(Following page). Abbreviations: PDD(H-); PD cases with high clinical scores for 
dementia and no VH, PD(H+); PD cases with high clinical scores for VH and no 
dementia, PDD(H+): PD cases with high clinical scores for both dementia and VH, 
PD(H-): cognitively intact PD cases, Lepto: leptomeningeal vessels, Parench: 
parenchymal vessels 
148 
PD c a s e Cingulate Gyrus PD c a s e Superior Frontal Gyrus PD c a s e Temporal Cortex PD c a s e Occipital Cortex 
Lepto Parench Lepto Parench Lepto Parench Lepto Parench 
PD(H-) 58 0 0 58 0 0 58 0 0 58 0 0 
74 0 0 74 1 0 74 0 0 74 1 0 
95 0 0 95 1 0 95 1 1 95 0 1 
23 0 0 23 1 0 23 0 0 23 0 0 
7 0 0 7 0 0 7 0 0 7 0 0 
22 0 0 22 0 0 22 0 0 22 0 0 
29 0 0 29 0 0 29 0 0 29 0 0 
32 0 0 32 0 0 32 0 0 32 0 0 
36 0 0 36 0 0 36 0 0 36 0 0 
PDD(H+) 5 1 1 5 1 1 5 1 0 5 - -
18 0 0 18 0 0 18 1 0 18 - -
15 0 0 15 0 0 15 0 0 15 - -
24 0 0 24 0 0 24 1 0 24 - -
30 1 0 30 1 1 30 1 0 30 - -
69 0 0 69 1 0 69 0 0 69 - -
2 1 0 2 1 0 69 0 0 69 - -
16 0 0 16 0 0 16 0 0 16 - -
44 0 1 44 1 1 4 4 1 1 44 - -
13 1 1 13 NA 1 13 1 1 13 - -
34 1 1 34 1 1 34 1 1 34 - -
60 1 1 60 1 1 60 1 1 60 
- -
PDD(H-) 11 0 0 11 0 0 11 0 0 11 - -
45 1 1 45 0 1 45 1 0 45 - -
56 0 0 56 0 0 56 0 0 56 - -
14 1 0 14 0 0 14 1 0 14 - -
PD(H+) 63 0 0 63 0 0 63 0 0 63 0 0 
42 0 0 42 0 0 42 0 0 42 0 0 
72 0 0 72 0 0 72 0 0 72 0 0 
20 0 0 20 0 0 20 0 0 20 0 0 
21 0 0 21 0 0 21 0 0 21 1 1 
not studied, NA: not available 
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3.4 Discussion 
Dementia is a common complication in PD but its anatomical correlates remain a 
matter of controversy. For the cases examined in this study dementia was associated with 
significant degenerative changes in the limbic system. While the number of cases with 
dementia was relatively small (n=16), pathological changes in the amygdaloid complex, 
entorhinal cortex, cingulate gyrus and CA2 sector of the hippocampus are more 
frequently found with dementia in PD. Recent published findings demonstrate a 
relationship between LB densities in the parahippocampal gyrus and amygdala (Apaydin 
et al. 2002;Harding and Halliday 2001;Kovari et al. 2003;Mattila et al. 1999) and LNs in 
the CA2 sector of the hippocampus, with dementia in PD (Harding and Halliday 
2001;Churchyard and Lees 1997). The data in this work are in agreement with these 
studies, pointing to the presence of limbic dysfunction as a central basis of dementia in 
PD. It is also of interest that the extent of aSN pathology in the NBM was high in both 
demented and cognitively intact cases highlighting a universal cholinergic deficit in PD, 
with or without clinical cognitive decline. 
Some studies have demonstrated that increased numbers of cortical LBs correlate 
with cognitive decline independently of or in addition to AD type pathology (Mattila et 
al. 2000;Mattila et al. 1998;Hurtig et al. 2000). The results presented in this study suggest 
aSN pathology as a central correlate of dementia in PD. This is in agreement with a 
recent prospective community-based study indicating that LB pathology and not AD 
histopathological changes drive the progression of cognitive impairment in PD (Aarsland 
et al. 2005). However, AD-type pathology was also associated with dementia in this 
cohort. This finding, demonstrates that AD-type pathology may have a permissive effect 
in precipitating dementia in PD. In fact it has been recently shown with the use of both 
immunohistochemical and biochemical techniques that LBs in the cerebral cortex in PD 
patients are significantly increased in brains with a high ^-amyloid load pointing to an 
interaction between these two pathologies at the molecular level (Pletnikova et al. 2005). 
The pathological and clinical significance of LNs in PD is still uncertain. 
Although studies have focused on cortical and limbic LB-type pathology as the basis of 
dementia, in this work a strong association was also observed between aSN burden (i.e. 
LNs) in the CA2 sector of the hippocampus and dementia. LNs were not initially seen in 
PD (Dickson et al 1991). However, several subsequent studies have observed such 
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pathology (Pollanen et al. 1993;Imamura et al. 2003;Imamura et al. 2005) and have seen 
a correlation with the presence of dementia in PD (Kim et al 1995;Churchyard and Lees 
1997). More specifically, Churchyard and Lees extended their analysis to find a 
correlation between LN burden and severity of dementia, although this correlation has 
remained controversial (de Vos et al. 1996;Mattila et al. 1999;Churchyard and Lees 
1997) perhaps as ubiquitin immunohistochemistry was used which is a less sensitive 
method for the visualisation of LBs and LNs (see also section 1.3.1.3). The current work 
with the use of aSN immunohistochemistry corroborates the existence of numerous LNs 
in the CA2 sector of the hippocampus as well as its vulnerability to this type of pathology 
and consolidates previous findings of an association between LNs in the CA2 sector of 
the hippocampus with dementia in PD. Tau burden in the CA2 sector was also 
significantly associated with dementia in PD further supporting a primary role of this 
anatomical region for the presence of dementia in PD. The CA2 sector receives input 
from the hippocampal dentate gyrus, septal nuclei, entorhinal cortex, and 
supramammillary region of the hypothalamus and then projects to CAl field which in 
turn projects to the subiculum (Giap et al. 2000). Pathological changes in CA2 will 
disrupt normal hippocampal function by interruption of its connections leading to 
impaired processing and transmission of information. 
Previous studies have shown that high LB densities in the cingulate cortex are 
observed in other conditions such as DLB and Alzheimer's disease (Braak et al. 
1996;Lippa et al. 1999;Harding and Halliday 2001;Rezaie et al. 1996). However, the 
results of this work indicate that aSN burden in the cingulate gyrus could differentiate 
cases with dementia from those without with high sensitivity and specificity. The positive 
predictive value (i.e. the probability of having high scores for dementia on reaching 
moderate to severe aSN burden in the cingulate gyrus) was 85%, further supporting a 
primary role of aSN in the pathological processes of cognitive dysfunction in PD as well 
as pointing to the cingulate gyrus as an important focus of damage in PD. 
Recent surveys have revealed that anywhere from 6% to 60% of PD patients 
experience VH (Cummings 1991;Diederich et al. 2005). Risk factors for VH include 
higher age, duration of disease, cognitive impairment, medication, depression and sleep 
disturbances. In the group of patients characterized by VH but no dementia (PD(H+)) an 
association was observed with longer duration of disease which is in agreement with 
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previous reports (Barnes and David 2001;Fenelon et al 2000). The most frequently 
incriminated drugs for the occurrence of VH in PD patients are dopaminergics 
(Moskovitz et al. 1978;Serby et al. 1978;Feigenson et al. 1976) anticholinergics (Goetz et 
al. 1982;de et al. 1982) and amantadine (Harper and Knothe 1973). Interestingly 
however, all of the cases in this study (with and without VH) received drugs with the 
potential to exacerbate hallucinations (it has to be noted though that the dosages were not 
available). Data from a community based-study in Norway involving 245 PD patients 
demonstrated an association of hallucinations with advanced age, cognitive decline and 
depression but not with antiparkinsonian medication (Aarsland et al. 1999a). In another 
study involving 102 PD patients, VH were associated with lower cognitive scores, lower 
visual acuity, higher Global Deterioration Scale scores and higher Unified Parkinson 
Disease Rating scores (Holroyd et al. 2001). However, there was no association found 
with the use of dopaminergic drugs, other medications, or L-dopa dosage or duration of 
treatment (Holroyd et al. 2001). Therefore the finding in this work supports previous 
reports (Aarsland et al. 1999a;Williams and Lees 2005;Holroyd et al. 2001) of no simple 
direct cause-effect coimection between VH and medication. Thus, it appears that 
medication per se does not clearly account for the presence of VH. This underscores that 
a pathological substrate has a primary role in development of VH with a permissive effect 
of drug administration. 
In this study the majority of cases with VH had concomitant dementia. In fact, 
many studies have found a significant strong association of cognitive impairment and VH 
(Poewe 2003;Klein et al. 1997). Excluding potential confounders such as medication, 
duration of disease and depression, at least three mechanisms have been proposed for this 
association. First, cognitive impairment may be a marker of more diffuse brain disease. 
Second, taking into account that VH occur in many neuropsychiatric diseases, they may 
represent a final common pathway reflecting of a general degradation in information 
processing. Third hallucinations, may relate to a specific impairment of complex visuo-
spatial function in PD, with abnormalities in visual cognition, source monitoring or reality 
testing (Barnes et al. 2003). Interestingly a hypothesis derived from observations from 
AD relates the association between VH and dementia to disturbed cortical muscarinic 
receptor activities (Perry and Perry 1995). 
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It is now well established that the amygdala is a preferential site for LB formation 
in a variety of conditions including PD (Lippa et al. 1999;Lippa et al. 1998;Gelb et al. 
1999;Yamazaki et al. 2000), although our understanding of the importance of this lesion 
in the pathogenesis of PD remains unclear. In this study a significant association was 
found between aSN burden in the amygdaloid complex with VH in demented PD cases. 
Interestingly, VH in non-demented PD subjects (PD(H+)) did not associate with aSN 
burden in the amygdaloid complex. Previous studies by Harding et al., have shown that 
LB burden in the amygdala positively correlate with VH in both demented and non-
demented PD patients (Harding et al. 2002a;Harding et al. 2002b). Recently, 
Papapetropoulos and colleagues have also reported an increased LB burden in the 
amygdala, frontal, temporal and parietal cortices in PD subjects with VH 
(Papapetropoulos et al. 2006). The findings of the present study are in accord with 
clinico-pathological studies pointing to aSN in the amygdala as an important pathological 
substrate of VH in demented PD patients. The absence of association between aSN 
deposition in the amygdala and VH in non-demented PD patients may demonstrate that 
an increased burden of aSN in amygdala is not related to the presence of VH per se but 
rather that an underlying dementia is a significant determinant. However, the number of 
PD cases without dementia but with VH in this study was small which may account for 
the discrepancy between this report and with Harding's et al.,. 
The extent and contributing effect of CAA changes on dementia and VH in PD 
has not been closely studied. The results of the present work indicate that CAA changes is 
a relatively common finding in PD brains with a higher incidence in demented PD cases 
as opposed to non-demented subjects. Furthermore, this report demonstrates that the 
presence of CAA significantly associates with dementia. CAA is a common pathological 
finding in the elderly and AD patients. Estimates of the prevalence of CAA from autopsy 
series are on the order of 10% to 40% in the general elderly population and approximately 
80% in brains with AD (Jellinger 2002;Xu et al. 2003). Whereas autopsy studies may be 
biased by patient selection, a similar high prevalence of CAA has been observed in 21% 
of elderly brains in the population-based Medical Research Council (MRC) clinical-
pathological series (Neuropathological Group.Medical Research Council Cognitive 
Function and Aging Study 2001). The occurrence of CAA changes has been shown to 
relate to dementia. Among subjects in the MRC study, CAA was identified in 34 of 93 
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with dementia versus only 7 of 99 without dementia, yielding an elevated odd ratio for 
dementia of 7.7 (Neuropathological Group.Medical Research Council Cognitive Function 
and Aging Study 2001). The relationship between CAA and dementia could easily be 
confounded by potential covariates such as age or presence of AD pathology. However, 
the effect of CAA remained independent when controlling for potential confounders such 
as age, brain weight, neuritic and diffuse plaques, neocortical and hippocampal NFTs, 
LBs and cerebrovascular disease. In another population-based study, the Honolulu-Asia 
Ageing Study, the presence of CAA in AD brains associated significantly with worse 
cognitive performance during life (Pfeifer et al. 2002). Like the finding in the MRC 
study, the effect of CAA was independent of potential confounders such as NFTs, age, 
plaque counts, infarctions and apolipoprotein E genotype. Further to this, CAA alone has 
been shown to be sufficient to cause dementia in some cases of hereditary cerebral 
hemorrhage with amyloidosis Dutch type (HCHWA-D) independently of AD type 
pathology (van Duinen et al. 1987). In addition, a recent autopsy study comparing 617 
cases of PD with 535 age-matched controls revealed a 44.7% increase in CVLs, including 
CAA, which was slightly lower than AD cases and dementia was more frequent in the PD 
group with CVLs (Jellinger 2003b). In another study the prevalence of vascular (3-
amyloid in PD cases with dementia was higher than in age-matched controls (Mastaglia et 
al. 2003). Thus, the data of this work are in accord to those previous studies pointing to 
an important contribution of CAA to dementia not only in elderly and AD subjects but 
also in PD patients. Interestingly, VH did not associate with CAA although a slightly 
higher incidence was observed among PD cases with VH. More studies with larger 
number of PD cases are needed to unravel the influence CAA on dementia and VH in the 
PD brain. 
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3.5 Conclusions 
This work demonstrates a widespread aSN pathology in the PD brain and 
provides evidence of a clinical relevance of aSN lesions in the limbic system with respect 
to the occurrence of dementia and VH in PD. Of particular interest is the finding that the 
NBM was equally affected in both demented and non-demented PD subjects indicating 
that the incidence of pathological changes in anatomical structures other than the NBM 
are obligatory for the presence of dementia in PD. The selective vulnerability of the CA2 
sector of the hippocampus, with respect to neighbouring sectors and the finding that CA2 
aSN deposition (i.e. LNs) associates with dementia supports a primary role of this 
anatomical region in the pathological processes of cognitive dysfunction in PD. In this 
study, although AD-related pathology associated with dementia in PD, statistical analysis 
demonstrated that aSN in the cingulate gyrus could differentiate cases with dementia 
from those without with high sensitivity and specificity and thus placing aSN pathology 
as a more sensitive indicator of dementia in PD than AD histopathological change which 
is in agreement with prospective studies (Aarsland et al. 2005). The significance of these 
relationships reported in this study will require further elucidation in larger cohorts. 
VH in PD is a complex disturbance and its anatomical and pathological basis 
difficult to unravel, which is perhaps reflected in the few neuropathological studies of PD 
patients with VH. However, the present report indicates that aSN burden in the amygdala 
strongly associates with VH in demented PD subjects. Medication did not seem (at least 
directly) to contribute to the presence of VH in PD further supporting a substrate of brain 
pathology for this disabling symptom. However, further studies are warranted to elucidate 
the cause(s) of VH in demented and non-demented PD patients. 
Finally, this report provides evidence that CAA changes can occur in the PD brain 
alongside PD and AD-related pathological lesions. Interestingly, the current work 
demonstrated that the presence of CAA relates to dementia in PD. However, further 
studies on the effect of CAA in PD clinical symptomatology in larger cohorts are needed. 
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Chapter 4 
Striatal Pathology in Parkinson's Disease: 
Relation to Dementia and Visual Hallucinations 
4.1 Introduction 
Although most studies suggest that aSN-type lesions in neocortical and limbic 
structures are strongly associated with dementia and VH in PD (Mattila et al. 
2000;Mattila et al. 1998;Kovari et al. 2003;Harding et al. 2002a;Harding and Halliday 
2001;Hurtig et al. 2000) the exact morphological and pathophysiological substrate(s) of 
these deficits are still debatable. One reason for this debate is that dementia in the setting 
of PD more likely represents the confluence of additive or synergistic effects of several 
pathologies. Pathologically PD is classically characterised by loss of dopaminergic 
neurons in the SNc (Fearnley and Lees 1991) leading to striatal dopamine depletion. 
Although the motor manifestations of PD are related to this dopaminergic denervation of 
the striatum, the striatal nuclear complex has also been shown to play a major role in 
cognition (Nakano et al. 2000). Nevertheless, there are very few clinico-pathological 
studies that have investigated the clinical relevance of striatal pathology in PD (Liang T et 
al. 2006). The present chapter will therefore try to explore the relationship between 
striatal pathology and cognitive dysfunction in PD with a focus on dementia and VH. 
4.1.1 Functional Anatomy of the Striatum 
Today the striatum more often is divided into three functional territories. The 
sensorimotor territory (the putamen) receives input from motor cortices (primary motor 
cortex, supplementary motor area, premotor cortex) and projects back to them; the 
associative territory (dorsal caudate nucleus) which receives input from the prefrontal 
cortex and projects back to it and the limbic territory (ventral striatum; nucleus 
accumbens) which receives allocortical-mesocortical input and projects to anterior 
cingulate cortex and medial orbitofrontal cortices (Parent 1990;Parent and Hazrati 1995). 
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Thus, these territories process motor, cognitive and emotional or motivational 
information, respectively. 
In the striatum 90-95% of the neurons are medium spiny neurons, which give rise 
to axons which leave the striatum and collaterals that remain within the striatum (Grofova 
1975;Kitai and Kocsis 1979;Kawaguchi et al. 1990). These neurons are GABAergic and 
utilise enkephalin or substance P as co-transmitters (Penny et al. 1986;Gerfen 1984). The 
remaining striatal neurons are aspiny neurons thought to act as interneurons (Graybiel 
1983). Some of these are also known to utilise acetylcholine as a neurotransmitter (Phelps 
et al. 1985). 
Cortical input to the striatum comes mainly from layer 5, 3 and 6 (McGeorge and 
Faull 1989;Gerfen 1989;Gerfen 1989;Yelnik 2002) and primarily terminates on the 
medium spiny projection neurons (Dube et al. 1988;Sesack and Pickel 1990). The cortical 
input to the striatum is excitatory and utilises glutamate as its principal neurotransmitter 
(Fonnum et al 1981). A topographic organization of these cortical inputs has been 
proposed so that the sensorimotor cortex projects to putamen and caudate nucleus and 
mesocortex and allocortex to ventral striatum (nucleus accumbens). 
The striatum also receives input from the midline and intralaminar, ventral lateral 
posterior and posterior nuclei of the thalamus (Veening et al. 1980) which are excitatory 
(i.e. glutamatergic) (Kitai et al. 1976) (but do not appear to terminate on the same spiny 
neuron as a corticostriatal afferent (Dube et al. 1988). A dopaminergic input to the 
striatum originates from the retrorubral area, substantia nigra pars compacta, and ventral 
tegmental area (VTA) (Fallon and Moore 1978). Additionally, serotonergic input to the 
striatum comes from the dorsal raphe nucleus (Veening et al. 1980) and a modest 
projection from the mesopontine reticular formation also innervates the striatum (Jackson 
and Grossman 1983). 
4.1.2 Pathology of the Striatum 
An increased awareness of the complex circuitry of the basal ganglia and the 
advent of more sensitive methods of detecting pathological changes in the brain prompted 
recognition of degeneration of the striatum, to which the major efferents of the substantia 
nigra pars compacta project. There is evidence from imaging studies of volume loss of the 
left caudate nucleus and putamen in AD, DLB as well as other neurodegenerative 
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disorders associated with parkinsonism, such as MSA (Barber et al. 2002;Baron et al 
2001;Konagaya et al. 1994;Wakai et al. 1994;Schulz et al. 1994). PET and SPECT 
studies of the nigrostriatal dopaminergic system have demonstrated significant 
abnormalities in the striatum in several parkinsonian disorders including PD and DLB 
(Brooks 1993;Donnemiller et al. 1997). Bochelmarm et al., and Bugiani et al., 
(Bockelmann et al. 1994;Bugiani et al. 1980) have reported reduced cell number in the 
striatum of PD brains whereas McNeill and colleagues have demonstrated loss of 
dendrites in medium spiny neurons, the major recipient of nigrostriatal input to the 
striatum (McNeill et al. 1988). Further to this, Lach et al., has shown abundance of 
dystrophic neurites in the caudate nucleus (Lach et al. 1992). Although numerous recent 
reports draw attention to the presence of Lewy neurites in patients with PD and DLB in 
the striatum, other studies have suggested that there is no striatal pathology in these 
disorders (Forno and Norville 1979;Forno 1996;Gomez-Tortosa et al. 2000;Irizarry et al. 
1998). These conflicting results have prompted a debate over the definite pathological 
changes in the striatum in PD and DLB. 
It was not until recently however, that Duda and colleagues showed with the use 
of novel synuclein monoclonal antibodies that there is indeed extensive aSN pathology in 
the striatum in LB disorders (Duda et al. 2002). The greatest density was found in 
patients with a combination of AD and DLB followed by cases with DLB alone. PD 
patients showed mild to moderate changes. Although this study described a previously 
underestimated pathology in the striatum in Lewy body diseases no correlation to the 
clinical deficits was performed thus the cUnical relevance of aSN deposition in this region 
remains unclear. 
Following Duba's findings, Liang and colleagues in a small group of patients with 
LB disorders reported a much higher burden of both A(3 and aSN pathologies in the 
striatum (particularly AP) of cases with DLB in comparison to those with the PDD 
phenotype who commonly had a paucity of both (Liang T et al. 2006). Jellinger and 
Attems have confirmed these findings in a larger cohort (n=17), pointing to a 
morphological distinction between DLB and PDD on the basis of differing striatal 
pathology (Jellinger and Attems 2006). More importantly, however, it is not clear 
whether striatal pathology could differentiate PD patients who develop dementia from 
those who remain cognitively intact or have mild or circumscribed cognitive impairments. 
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In addition, examination of striatal pathology in these previous studies was limited to the 
caudate nucleus and putamen omitting the ventral striatum (i.e. nucleus accumbens), a 
region strongly involved in cognition (Nakano et al. 2000). 
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4.1.3 Aims 
Given a lack of information with regards to the clinical correlates and significance 
of striatal pathology in the PD brain, this study aimed to investigate the relationship 
between striatal pathology and dementia and/or VH in PD. To do this the burden of 
striatal aSN and AD type changes (both Ap and tau) was determined in patients at the 
extremes of the spectrum of PD neuropsychiatric involvement in groups of PD patients 
with and without dementia and VH. 
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4.2 Materials and Methods 
4.2.1 Neuropathological Assessment 
Neuropathological assessment and diagnosis were performed as described in 
section 2.2.1. 
4.2.2 Selection of Cases 
The cohort examined in this work is the same as for chapter 3. Therefore, PD 
cases were stratified into four dementia status groups according to clinical characteristics 
as follows: 9 PD cases without dementia and without VH (with the exception of one case 
with mild VH) and with no or mild co-morbid neuropsychiatric features (PD(H-) group), 
12 PD cases with severe dementia and with VH (range 2-3; PDD(H+) group), 4 PD cases 
with moderate to severe dementia alone without VH (range 2-3; PDD(H-) group) and 5 
PD cases with severe VH alone without dementia (range 2-3; PD(H+) group) (Table 4.1). 
For selection of cases refer to section 3.2.2. In addition to neuropsychiatric deficits, the 
clinical severity of motor features was also recorded and rated. The assessment was 
performed on a semi-quantitative global impression scale (0-3+, absent to severe) with 
the assistance of Dr. Ronald K.B. Pearce. The clinical data of the cases are presented in 
Table 4.1. 
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Table 4.1 Clinical data for the PD groups. 
(Following page) Abbreviations: D; Dementia, VH: Visual Hallucinations, A: Anxiety, 
De; Depression, Pr: Paranoia, Dl; Delusions, T; Tremor, G-B; Gait-Balance problems, A-
R, S; Akinesia-Rigidity and Stiffness, H-P: Hemi-Parkinsonism, PD: Parkinson's 
disease, PDD(H-): PD cases with high clinical scores for dementia and no VH, PD(H+): 
PD cases with high clinical scores for VH and no dementia, PDD(H+): PD cases with 
high clinical scores for both dementia and VH, PD(H-): PD cases without dementia and 
without VH, m: male, f: female, semi-quantitative clinical severity scores 0: absent, 1: 
mild, 2: moderate, 3: severe, +: yes, -: no, ±: possibly 
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PD(H4 Group 
Clinical Severity Clinical Severity 
Age at Age at Duration Neuropathological Clinical Severity Scores of Presenting Motor Deficits jScores of Motor deficits 
Case Onset Death of Disease Diagnosis ICONS AD GRADE Braak Scores of Neuro psychiatric Features (within first 2 years) (after 2 years) L-Dopa 
Number Gender (yemrs) (year*) (yesM) (wwwJCDNS.org) (www.ICDNS.org) AD-Stages D VH A De Pr Dl T G-B A-R,S H-P T G-B A - R ^ H-P Responsiveness 
58 f 52 58 6 PD isocortical 0 entorhinal 1 Ml 0 0 1-2 0 0 0 1-2 0 0 0 2 0 1-2 0 t 
74 78 85 9 PD isocotlical II entorhinal 0 Ml 0 0 1 0 0 0 1-2 0 0 1-2 1 1 1 0 + 
95 47 74 27 PD Isocortical 1 - entorhinal 0 Ml 0 0 0 1 0 0 1 0 1 1-2 1 1 2-3 1-2 
23 75 82 7 PD isocortical 1 > entorhinal II Ml 0 0 0 1 0 0 0 1-2 0 0 0 1 2-3 0 
7 68 78 10 PD na Ml 0 0 0 0 0 0 0 1 1 0 1 0 1-2 0 
22 65 75 10 PD isocortical 0 entorhinal 0 0 0 0 0 0 0 0 0 0 2 1-2 1- 0 1 1 
29 70 77 7 PD isocortical 0 entorhinal 1 Ml 0 1 0 0 0 0 1 0 1-2 1 1-2 2 1 1 
32 86 89 3 PD isocortical 0 entorhinal 1 Ml 0 0 0 0 0 0 1 0 1 0 1-2 1-2 1 0 
38 67 77 10 PD Isocortical 0 entorhinal 1 Ml 0 0 0 0 0 0 0 0 0 0 0 1 1 0 
67 77 9.8 
5 57 80 23 PD Isocortical II - entorhinal ill Ml 2 3 0 0 0 0 1 0 0 1 1 0 1-2 1 
16 77 82 5 PD isocortical 1 - entorhinal II 0 2-3 3 1 1 0 0 0 1 1 0 0 1 0 0 
15 56 70 14 PD isocortical IV entorhinal III III 2-3 2 1 0 0 0 1 1-2 0 0 0 1 0 
24 72 31 9 PD isocortical 0 entorhinal 1 Ml 2-3 2 1-2 0 0 0 1-2 1-2 0 0 0 1 ^ 2 0 
30 57 73 16 PD isocortical 1 - entorhinal II Ml 2 2 0 0 0 0 1 0 0 1 2 1 1 1-2 
69 71 82 11 PD isocortical 1 - entorhinal II MI 2 2-3 0 1 0 1-2 1 1 1-2 1 1 1-2 1-2 1-2 
2 75 84 9 PD isocortical 0 entorhinal 1 0 2 2 3 2 0 0 0 0 1 1-2 2 1-2 1-2 1-2 
16 67 85 18 PD isocortical 11 - entorhinal \ 1-11 2-3 2-3 1 1 0 0 1-2 0 1 1 2 0 0 0 
44 74 87 13 PD isocortical 1 - entorhinal II MI 2 3 0 0 0 0 1 0 0 1 1 1 1 
13 54 78 24 PD isocortical 0 entorhinal 1 Ml 2-3 3 2 0 0 0 0 0 1 0 2 1 0 
34 73 84 11 PD isocortical IV entorhinal 111 111 3 2 3 0 0 0 1-2 0 0 1-2 1 1-2 0 1-2 
60 78 84 6 PD isocortical II -entorhinal II MI 2 2 0 0 0 0 0 0 1-2 1-2 0 0 2 0 
Mean 67 80 1 3 j 
11 62 71 9 PD isocortical III entorhinal III Ml 2 0 0 0 0 0 1-2 0 0 1 2 0 1-2 1 
45 61 80 19 PD isocortical 0 - entorhinal 111 111 2-3 0 2 2 0 0 0 1 1 0 0 1-2 0 
50 35 54 19 PD isocortical 0 - entorhinal 1 0 2 1-2 0 0 0 0 1 1-2 1-2 1-2 1 1 1 
14 67 79 12 PD isocortical IV entorhinal III Ml 3 1 0 0 0 0 2-3 0 0 0 0 1 0 + 
56 71 14.7 
63 67 80 13 PD isocortical 0 entorhinal 1 Ml 0 3 0 0 0 0 2 1 0 0 1 0 0 
42 59 79 20 PD isocortical 0 entorhinal 1 Ml 0 2 1-2 1 0 0 0 1 0 0 0 1-2 3 0 + 
72 42 62 20 PD isocortical 0 - entorhinal 0 0 0 2 ^ 0 0 0 0 1 0 0 1 1-2 1 0 1-2 
20 41 75 34 PD Isocortical 1 • entorhinal II Ml 0 2 0 1 0 0 2 0 2 1-2 0 0 1 1 
21 48 76 28 PD Isocortical 0 entorhinal 1 Ml 1 2-3 1 0 0 0 2 0 2 2 0 2 0 0 
Mean 51 74 23 
PDD(H+\ Group 
n=12 
PDDfH-) Group 
n=4 
PDfm-) Group 
n=S 
163 
4.2.3 Immunohistochemistry 
Immunohistochemical reactions were performed as described in section 2.2.4. All 
30 cases were stained for aSN for the identification of aSN inclusions (Becton-Dickinson 
at a dilution of 1:1000), tau for visualization of neurofibrillary changes (Autogen Bioclear 
PHF-Tau (clone ATS) at a dilution of 1:800), 1E8 for visualization of Ap plaques (A(3) (at 
a dilution of 1:1000) and tyrosine hydroxylase (TH) for examination of nigrostriatal fibers 
(Vector at a dilution of 1:30) 
4.2.4 Semi-quantitative Assessment of aSN and AD Lesions 
For each case, three representative sections from the caudate 
nucleus (CN), putamen (Put) and nucleus accumbens (NAcc) were assessed for the 
occurrence of aSN, A|3 and tau immunoreactivity respectively. The nucleus accumbens 
was defined as the roughly triangular portion of the striatum at the ventral edge of the 
internal capsule (Brilliant et al. 1997). The pathology was examined semi-quantitatively 
based on a scale ranging from 0-3 (absent to frequent; Figure 4.1). Sections were screened 
in their entirety at lOx primary magnification for overall deposit burden. Examination of 
aSN and AD pathology was also conducted in the temporal and entorhinal cortices, CA2 
sector of the hippocampus and superior frontal gyrus and assessed semi-quantitatively 
from 0-3 (absent to frequent; for semi-quantitative ratings of pathology also refer to 
section 3.2.4). Sections were graded by two investigators (Mr. Michail E. Kalaitzakis and 
Dr. Stephen M Gentleman). Cohen's kappa statistics revealed an inter-rater reliability of 
0.75 for aSN, 0.8 for tau and 0.84 for Ap lesions (as mentioned in previous chapters, 
kappa statistic has a range of 0-1, with larger values indicating better reliability; generally 
a kappa of >0.70 is considered satisfactory). Intra-rater reliability was also examined (see 
section 2.2.6). The raw data for aSN, tau and Ap pathology are given in Appendix IV. 
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Figure 4.1 Semi-quantitative assessment of aSN and Ap deposition in the striatum 
from representative PD cases. 
(Following page) Semi-quantitative ratings of pathology. Assessment of Ap pathology in 
the striatum was carried out using a CERAD-based (Mirra et al. 1991) visual impression 
of the numerical density of plaques ranging from 1-3 (b, c, d) corresponding to spai'se, 
moderate and frequent. A value of 0.5 was assigned to those fields where only a single 
lesion was present (a). In a few cases, where the density did not clearly fit into one of the 
main categories, intermediate values were assigned. Similar ratings were carried out on 
the Ap pathology in the neocortex (e) and on the extent of aSN pathology in the striatum 
(f, g, h). Primary magnification xlO 
Abbreviations: aSN: a-synuclein, AP: amyloid p deposits 
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4.2.5 Statistical Analysis 
Statistical analysis was performed using the SPSS programme version 15.0 for 
Windows XP and GraphPad Prism 4. The differences in aSN, tau and Ap burden as well 
as age at death, onset and duration of disease among the cognitively impaired and PD(H-) 
groups were analyzed by the non-parametric Mann-Whitney [/-test. The Kruskal-Wallis 
test was applied followed by Dunn's post hoc multiple group comparisons to detect 
differences in severity of tremor, gait-balance, akinetic-rigid and hemi-parkinsonism 
signs among all groups as well as for analysis of pathological data between groups. 
Cohen's kappa statistic was used to test inter-rater reliability for the aSN, tau and Ap 
semi-quantitative assessment between the two investigators. Intra-rater reliability was 
also examined by measuring the striatum of five randomly selected subjects on five 
occasions at least a week apart. On each occasion, all operator-dependent processes (i.e. 
region of interest semi-quantitative assessment) were performed blinded to previous 
values. High intra-rater reliability was observed. Correlations were calculated with 
Spearman's two-tailed correlation analysis (non-parametric). P values <0.05 were 
considered significant. 
The diagnostic performance of AP deposition in the striatum in predicting 
dementia (regardless of the presence of VH) was calculated with measures of sensitivity, 
positive predictive value (PPV), specificity and negative predictive value (NPV). The 
methodology of Harding et al.,(Harding and Halliday 2001) was adopted. Briefly, 
sensitivity refers to the probability of having moderate to severe Ap deposition with high 
clinical scores for dementia. Specificity refers to the probability of not reaching moderate 
to severe Ap burden in cases not having high clinical scores for dementia. PPV refers to 
the probability of having high scores for dementia with moderate to severe Ap deposition. 
NPV refers to the probability of not having high scores for dementia in the absence of 
moderate to severe Ap burden. 
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4.3 Results 
4.3.1 Assessment of Clinical Data 
A total of 30 cases were included in this study. Statistical analysis (Kruskal-
Wallis) detected no differences in clinical severity of tremor, gait-balance, akinetic-rigid 
and hemi-parkinsonian signs among the different PD groups. 
4.3.2 TH Striatal Pathology 
TH immunohistochemistry was performed in all cases included in this study in 
order to examine the extent of dopamine denervation in the different regions of the 
striatum (i.e. putamen, caudate nucleus and nucleus accumbens). The overall pattern of 
cellular staining was noted in the CN, Put and NAcc. All cases showed severe 
dopaminergic terminal denervation of the striatum compared to a control. 
4.3.3 aSN Striatal Pathology 
In the PD(H-) group, 5/9 cases (55.5%) showed mild aSN pathology (LBs and 
LNs) in CN, Put and NAcc while in the remaining cases (44.5%) no aSN pathology was 
observed. No aSN staining was seen in the CN and Put in 40-50% of cognitively 
impaired cases while NAcc was negative in 14%. aSN pathology for the rest of the 
cognitively impaired cases was mild (with the exception of one case showing moderate 
aSN pathology) and when compared with the PD(H-) group no significant differences 
were detected (Figure 4.2). Total burden of aSN (expressed as the average load across all 
regions under examination) between the PD(H-) and all cognitively impaired groups did 
not differ significantly (Figure 4.3). When present, aSN lesions in the CN were mostly 
found laterally towards the internal capsule with the caudato-lenticular gray bridges also 
involved. 
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Figure 4.2 Severity of aSN, tau and Ap pathology in the striatum of PD(H-), PDD(H-
), PD(H+) and PDD(H+) patients. The columns represent mean values ± SEM. 
(Following page) Abbreviations: PD; Parkinson's disease, PDD(H+); cases with high 
clinical scores for both dementia and VH, PDD(H-): PD cases with high clinical scores 
for dementia and no VH, PD(H+): PD cases with high clinical scores for VH and no 
dementia, PD(H-): PD cases without dementia and without VH, CN: Caudate Nucleus, 
Put: Putamen, NAcc: Nucleus Accumbens, aSN; a-synuclein, A(3; amyloid (3 deposits. * 
denotes significant difference (Marm-Whitney [/-test, p<0.05). 
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Figure 4.3 Total burden of aSN, tau and Ap pathology between PD(H-) and 
cognitively impaired (PD(H+), PDD(H-) and PDD(H+)) PD patients across all 
striatal regions examined. The columns represent mean values ± SEM. 
(Following page) Abbreviations: PD: Parkinson's disease, PD(H-): PD cases without 
dementia and without VH, Cognitively Impaired (PDD(H+): cases with high clinical 
scores for both dementia and VH, PDD(H-): PD cases with high clinical scores for 
dementia and no VH, PD(H+): PD cases with high clinical scores for VH and no 
dementia), aSN: a-synuclein, A(3; amyloid p deposits. * denotes significant difference 
(Marm-Whitney U-test, p<0.05). 
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4.3.4 Tau Striatal Pathology 
Tau pathology (neurofibrillary tangles and neuropil threads) in the PD(H-) group 
was mild in CN (3/9 cases; 33.3%), in Put (5/9 cases; 55.5%) and NAcc (7/9 cases; 
77.7%), while the rest of the cases were negative. Tau pathology was also mild or absent 
in all cognitively impaired groups (PDD(H+), PD(H+), PDD(H-)) with the exception of 
one case demonstrating moderate tau pathological changes in NAcc. No statistical 
differences were detected between the PD(H-) and cognitively impaired groups with 
respect to tau burden in CN, Put and NAcc or the total tau striatal burden (Figure 4.2 and 
4.3). 
4.3.5 Ap Striatal Pathology 
The morphology of Ap deposits were of four types in all striatal regions as 
follows; 1) large plaques that resemble diffuse cortical plaques, 2) smaller, more intensely 
stained deposits of a diffuse type that outnumbered the larger plaques by a factor of 
approximately 3:1, 3) small, presumably extracellular, deposits (size of a glial cell 
nucleus) and 4) dot-like aggregates (Figure 4.4). On the whole, Ap lesions were more 
frequent and more severe than aSN and tau pathology in the demented [PDD(H-) and in 
PDD(H+)] groups. Ap was absent in 7/9 of PD(H-) cases (77.7%) and only minimal in 
the remaining 2 cases (22.3%) in CN, Put and NAcc. Similarly, PD(H+) cases showed 
sparse Ap deposition in all striatal regions, with the exception of one case showing 
moderate Ap burden in NAcc. In contrast, PDD(H-) and especially PDD(H+) cases 
demonstrated moderate to severe Ap pathology (Figure 4.2). When compared with the 
PD(H-) group, Ap burden in the PDD(H-) cases was significantly greater in the NAcc 
(p=0.04) (Figure 4.2) whereas PDD(H+) cases showed a significantly higher burden of 
Ap pathology in all striatal regions [CN (p=0.002). Put (p=0.003) and NAcc (p=0.03)] 
when compared with the PD(H-) group (Figure 4.2 and 4.4). Statistical analysis for group 
comparisons revealed a significant greater AP burden in the putamen of PDD(H+) cases 
in comparison to non-demented PD cases with VH (PD(H+)) (Kruskal-Wallis; p=0.02). 
These differences can not be attributed to age, as correlational analysis revealed that Ap 
burden did not correlate with age at death. Comparison between non-demented and 
demented PD cases, irrespective of the presence of VH, revealed a significantly greater 
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Ap burden in the latter group (p=0.001) (Figure 4.5). Furthermore, the severity of Ap load 
in the striatum did not associate with the severity of Ap deposits in cortical regions. 
Looking at the AD grading of isocortical and entorhinal pathology in demented PD cases 
(with and without VH) (Figure 4.6C), 60% of cases had abundant Ap deposition in the 
striatum independently of cortical AD pathology. This was more apparent when looking 
at isocortical and entorhinal AD pathology independently (Figure 4.6B and C). 
Interestingly, demented cases (with and without VH) showed a significantly greater 
overall AP deposition in the striatum than in the cortex (Figure 4.7). 
Figure 4.4 Immunostaining for p-amyloid deposits in the caudate nucleus. 
(Following page) A) A large number of Ap deposits in the caudate nucleus of a case with 
high clinical scores for both dementia and VH. B) Caudate nucleus without Ap deposits 
from a PD case with no dementia and no VH. Magnification 20x. 
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Figure 4.5 Scatter plot showing the extent of Ap deposition in the striatum of 
demented PD subjects [(PDD(H+) and PDD(H-) (n=16)] and non-demented PD 
subjects [(PD(H-) and PD(H+) n=14)]. Each data point represents the averaged Ap 
severity score for all striatal regions assessed (CN, Put and NAcc). 
(Following page) Abbreviations: PDD(H+): cases with high clinical scores for both 
dementia and VH, PDD(H-); PD cases with high clinical scores for dementia and no VH, 
PD(H+): PD cases with high clinical scores for VH and no dementia, PD(H-): PD cases 
without dementia and without VH, PD: Parkinson's disease, CN: Caudate Nucleus, Put: 
Putamen, NAcc: Nucleus Accumbens, A^: amyloid (3 deposits, * denotes significant 
difference (Mann-Whitney tZ-test, p<0.05). 
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Figure 4.6 Scatter plots (A-C) showing the association between AD pathology in iso-
and entorhinal cortices with the overall extent of Ap deposition in the striatum of 
demented PD subjects (PDD(H+) and PDD(H-)) (n=16). 
(Following page) A) Relation of iso- and entorhinal AD pathology with Ap deposition 
severity in the striatum of demented PD subjects. B) Association between AD pathology 
in the entorhinal cortex with severity of striatal Ap deposits. C) Relationship between AD 
pathology in isocortex and severity of striatal Ap deposition. Striatal Ap pathology in the 
striatum tends to dissociate from appreciable tandem AD co-morbidity in isocortex and 
entorhinal cortex. 
Each data point for the Ap pathology in the striatum represents the averaged Ap severity 
score across all striatal regions assessed (CN, Put and NAcc). 
Abbreviations: PD: Parkinson's disease, AD: Alzheimer's disease, (PDD(H+): cases with 
high clinical scores for both dementia and VH, PDD(H-); PD cases with high clinical 
scores for dementia and no VH, AP: amyloid p deposits, CN: Caudate Nucleus, Put: 
Putamen, NAcc: Nucleus Accumbens 
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Figure 4,7 Scatter plot showing the overall extent of Ap deposition in the striatum 
and cortex of demented PD subjects (PDD(H+) and PDD(H-)) (n=16). A significantly 
greater deposition of Ap burden is observed in the striatum than in the cortex 
(p=0.03). 
(Following page) Each data point for the striatum represents the averaged Ap severity 
score for all striatal regions assessed (CN, Put and NAcc) while each data point for the 
cortex corresponds to the semi-quantitative averaged Ap severity score across the 
following cortical regions; temporal and entorhinal cortices, CA2 sector of the 
hippocampus and superior frontal gyrus. 
Abbreviations: PDD(H+): cases with high clinical scores for both dementia and VH, 
PDD(H-): PD cases with high clinical scores for dementia and no VH, PD: Parkinson's 
disease, CN: Caudate Nucleus, Put: Putamen, NAcc: Nucleus Accumbens, AP: amyloid P 
deposits, * denotes significant difference (Mann-Whitney [/-test, p<0.05). 
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In order to test the diagnostic performance of AP deposition in the striatum in 
predicting dementia (regardless of the presence of VH) the sensitivity, PPV, specificity 
and NPV in all striatal regions was calculated (Table 4.2). The sensitivity (i.e. the 
probability of having moderate to severe Ap deposition with high clinical scores for 
dementia) was 56% whereas the PPV (the probability of having high clinical scores for 
dementia on reaching moderate to severe Ap deposition) was 90%. Furthermore, the 
specificity and NPV for cases without dementia (i.e. PD(H-) and PD(H+) groups) was 
high in the range of 65-93% (Table 4.2). Further to this, total Ap burden was significantly 
greater in the cognitively impaired cases than cognitively intact (p=0.0001) (Fig 3). 
Table 4.2 Two by two contingency table for calculation of sensitivity, PPV, 
specificity and NPV for Ap burden in the caudate nucleus, putamen and nucleus 
accumbens in clinically demented PD cases regardless of the presence of VH (i.e. 
PDD(H+) and PDD(H-) groups). 
(Following page) Sensitivity of demented PD cases (9/16X100)= 56%, PPV for demented 
PD cases (9/10X100)= 90%. Specificity for cases without dementia (13/14X100)= 92.8%, 
NPV for cases without dementia (13/20X100)= 65% 
Abbreviations: AP: amyloid P plaques, PPV: positive predictive value, NPV: negative 
predictive value 
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Two by two contingency table for calculation of sensitivity, PPV, 
specificity and NPV for Ap burden in the CN, Put and NAcc in demented PD cases 
regardless of visual hallucinations [(PDD(H+) and PDD(H-) group] 
Caudate Nucleus, Putamen and 
Nucleus Accumbens A|3 burden Clinically Total 
Demented number of cases 
yes no 
2-3 9 1 10 
0-1 7 13 20 
Total Cases 16 14 30 
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4.4 Discussion 
Recent pathological studies point to LB-type pathology in limbic and neocortical 
regions as a main cause of cognitive impairment/dementia and VH in PD (Mattila et al. 
2000;Mattila et al. 1998;Hurtig et al. 2000;Harding and Halliday 2001;Apaydin et al. 
2002;Aarsland et al. 2005;Kovari et al. 2003;Hurtig et al. 2000), while others have not 
found a clear relationship (Parkkinen et al. 2005a). The present literature is further 
confounded by the AD type changes that often co-exist with aSN pathology. Despite 
extensive anatomical surveys in the literature, striatal pathology has not been examined in 
detail. In this study striatal aSN deposition was mild in all striatal regions under 
investigation, with no statistical differences detected between different PD clinical 
phenotypes with or without dementia. Furthermore, all groups showed minimal or absent 
striatal tau pathology. These findings demonstrate that there is no evident association 
between aSN and tau pathology in the striatum with dementia or VH. This result by 
implication provides further evidence that LBs in neocortical and limbic structures are 
more likely responsible for the development of dementia and VH in PD. 
While aSN and tau pathology did not differ between PD demented and non-
demented and between hallucinating and non-hallucinating groups, Ap deposition in the 
striatum distinguished PD patients with dementia from those without. More specifically, 
an increased Ap in the NAcc of cases with dementia but without VH (PDD(H-)) was 
observed and when we looked at dementia with VH as an added complication 
(PDD(H+)), all striatal regions exhibited increased Ap burden and this increase was 
independent of the extent of co-morbid cortical AD pathology. The observation that Ap 
deposition was minimal in the PD(H+) group implies that increased striatal Ap deposition 
does not relate to the presence of VH but rather to cognitive impairment. The results of 
the present work also indicate that Ap burden in all striatal regions could differentiate 
cases with dementia from those without with high sensitivity and specificity, further 
supporting a primary role of striatal Ap deposition in the pathological processes of 
cognitive dysfunction in PD as well as pointing to the striatum as an important focus of 
damage in PD. It is worth noting that the clinical severity of motor deficits was similar 
among all PD groups demonstrating that the pathology observed was not related to motor 
features. Altogether, the results demonstrate a greater Ap striatal pathology in PD cases 
with cognitive impairment/dementia in the absence of prominent cortical Ap deposition. 
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Early reports found no clear abnormality of the striatum in PD (Fomo and Norville 1979). 
However, two recent studies have revealed an abundant Ap burden in the striatum of 
DLB cases that was more pronounced than in PDD, pointing to a morphological 
distinction between those two diseases (Jellinger and Attems 2006;Liang T et al. 2006). 
Herein, the existence of cases with extensive striatal Ap pathology is confirmed and also 
this work shows for the first time a clinical relevance of AP deposition in the striatum in 
PD patients. 
The emerging view since the mid-1970s has been that dementia can be separated 
into cortical and subcortical types, a distinction that has been supported from both the 
clinical (Pillon et al. 1993) and aetiological perspectives (Darvesh and Freedman 1996). 
In cortical dementias with AD as the prototype of the most common dementing illness 
(dementia of the AD-type), neuropathological changes occur predominantly in cortical 
regions (e.g. temporal, frontal and parietal cortices). Senile plaques and NFTs populate 
the cortex and there is generalised cortical atrophy, especially in frontal and temporal 
lobes, with neuronal degeneration affecting particularly the outer three layers. The typical 
clinical findings include dyscalculia, aphasia, apraxia and agnosia that are said to be 
indicative of cortical dysfunction. On the other hand, in subcortical dementias the lesions 
occur predominantly in the basal ganglia, the brainstem and the cerebellum (Darvesh and 
Freedman 1996) and the clinical picture is correspondingly different with a profound 
slowness of thought and information processing (bradyphrenia), memory disturbances, 
frontal executive dysfunction and changes in personality and affect in the absence of 
aphasias, apraxias and agnosias (Cummings 1986). Although, subcortical dementia may 
result from numerous diseases, PD is one of the most common. The result of this work 
demonstrates the presence of prominent AP deposition within the striatum of demented 
patients with PD that dissociated from appreciable tandem AD co-morbidity and this 
offers a firm pathological substrate for features ascribed to subcortical dementia in these 
individuals giving rise to a distinctive clinical presentation. 
Although AD and PD are largely understood as distinct disease entities, the 
frequent overlap of clinical and pathological features raises the possibility that these 
neurodegenerative diseases may involve common pathogenetic pathways (Kotzbauer et 
al. 2001). Many AD patients develop extrapyramidal symptoms whereas a high 
proportion of PD patients become demented (Galvin et al. 2001). Pathological studies 
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have shown that LBs are frequently found in AD with some reports estimating aSN 
positive inclusions in 50-60% of patients with AD or Down syndrome (Lippa et al. 
1998;Hamilton 2000). The findings of the present work lead to further acknowledgement 
of a molecular link between PD and AD with respect to AP deposition, with the 
topography of involvement in subcortical regions (i.e. striatum) to be distinctive in those 
cases with concomitant dementia (i.e. FDD) independently of a formal second diagnosis 
of AD in these brains. 
There is considerable diversity of opinion regarding the significance of plaque 
formation in the neocortex to the etiopathogenesis of both AD and PD (Arnold et al. 
1991;Arriagada et al 1992a;Terry 1996;Mattila et al. 2000;Kovari et al. 2003). For 
example there have been inconsistent reports on the correlation between A(3 burden and 
various measures of clinical deficit in both diseases (Vickers et al. 2000). Furthermore, in 
elderly subjects without overt dementia, plaques are found in the neocortex and viewed as 
part of normal ageing (Arriagada et al. 1992b). In contrast, Ap deposition in the striatum 
is universally found in AD brains but is rarely observed in non-demented elderly 
individuals (Gearing et al. 1993;Suenaga et al. 1990). Further to this, according to the 
phases of P-amyloid deposition in the human brain proposed by Thai et al., Ap deposition 
in the striatum occurs in phase 3 with associated clinical dementia and thus it appears to 
reflect a disease specific pathological change in clinical proven AD subjects (Thai et al. 
2002). This evidence makes the striatum as an important anatomical region that is closely 
related to dementia in AD. This study confirms these previous reports and shows for the 
first time that striatal pathology in the PD brain strongly associates with clinical dementia. 
In PD the striatum, a primary affected brain area, shows an heterogeneous pattern 
of dopamine denervation as reflected by tyrosine hydroxylase immunoreactivity 
(Graybiel et al. 1987). The dorsolateral caudate-putamen exhibits more severe dopamine 
denervation than the ventral striatum (nucleus accumbens) (Perez-Otano et al. 1994). It is 
thus possible that the pattern of dopamine terminal loss may influence the distribution of 
Ap deposits. However, according to the present findings the distribution of plaques in 
different regions within the striatum did not appear to be affected by the diminution of 
tyrosine hydroxylase which was universal in the striatum irrespective of dementia status. 
These results suggest that progression to clinical dementia in PD is associated with an 
increased Ap burden in the striatum that does not reflect tyrosine hydroxylase positive 
186 
terminal nigrostriatal denervation. Further studies are needed however, to unravel any 
possible links between the chemoarchitecture of the striatum and striatal Ap distribution. 
Previous studies have shown that the morphology of striatal AP plaques in Lewy 
body disorders is of the diffuse cortical type (Jellinger and Attems 2006) however, this 
study shows that striatal Ap deposits portray a diversity of morphologies that by and large 
could be grouped into four categories. This finding demonstrates that the Ap deposits in 
the striatum may not represent morphologically a mere extension of the cortical plaques, 
but may relate to the mosaic distribution of striatal projection systems. The striatum 
exhibits a mosaic pattern with markers for a variety of neurotransmitters and other 
substances (Gerfen 1984). While patches or striosomes are enriched in enkephalin and 
substance P immunolabel, the matrix is acetylcholinesterase-positive (Gerfen 1984). 
These two compartments of the striatum also exhibit different patterns of connectivity 
with other brain regions (Gerfen 1984;Kincaid and Wilson 1996). Although in this study 
Ap deposition was not examined in relation to the striatal mosaic pattern, it is possible 
that the different morphologies of Ap deposits observed in this study reflect striatum's 
complex yet well-established heterogeneous microenvironment. Further evidence that 
striatal plaques may not represent a mere extension of cortical plaques comes from 
morphological studies in AD brains which report that striatal diffuse plaques are smaller 
than their cortical counterparts and in the range of lOjim to 30)im in diameter while 
diffuse plaques in the neocortex reaching up to 1000|im in diameter (McKenzie et al. 
1996). Although, both cortical and striatal diffuse plaques are comprised of p-amyloid 
terminating at residue 42 and contain little or no AP40, striatal plaques do not label with 
antibodies to apolipoprotein E (Gearing et al. 1995;Kida et al. 1994). In contrast, cortical 
diffuse plaques are apolipoprotein E-positive (Kida et al. 1994;Gearing et al 1995). 
These differences, in addition to the fact that the predominant plaque type in the striatum 
of AD brains, regardless of age and disease duration, is the diffuse plaque (Gearing et al. 
1993;Braak and Braak 1990;Suenaga et al. 1990) supports a distinct Ap pathological 
change in the striatum. This is also reflected by the diverse morphologies of Ap deposits 
reported in this PD study and needs further elucidation. 
A dopaminergic deficit is regarded as the main neurochemical impairment in PD. 
In this cohort, we found a universal dopaminergic denervation of the striatum. This 
finding demonstrates that loss of striatal monoaminergic terminals is severe in all PD 
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cases with or without cognitive impairment. The present resuhs are in agreement with 
imaging studies showing that the rate of striatal dopaminergic loss does not seem to 
increase as dementia develops (Colloby et al. 2005). Furthermore, the daily clinical 
experience that dementia does not improve with levodopa treatment suggests that the 
dopaminergic deficit is not the main neurochemical impairment responsible for dementia 
inPD. 
While part of the motor loop, the striatum also plays a major role in cognition and 
behavior (Nakano et al. 2000). The CN contributes to memory (Wise 1996), learning 
(Nakano 2000;Knowlton et al. 1996) and behavioral functions and lesions lead to apathy 
and decreased recent memory (Schultz et al. 1997). The NAcc receives input from 
prefrontal and limbic regions (Nakano et al. 2000), its efferents primarily pass to 
extrapyramidal centers but also to a number of limbic-related structures including the 
septum and the bed nucleus of the stria terminalis (Newman and Winans 1980). 
Abnormal deposition of A(3 plaques would disrupt striatal function by interruption of 
limbic connections and thus directly or indirectly contribute to dementia in PD. 
Nevertheless, the cellular mechanisms of this increased Ap pathology in the striatum of 
PD brains are unclear. However, recent studies suggest an interaction between AP 
pathology and aSN lesions (Pletnikova et al. 2005). In DLB brains the presence of AP 
deposits in the neocortex was associated with increased aSN lesions and higher levels of 
insoluble Ap (Pletnikova et al. 2005). These data suggest a synergistic reaction between 
Ap and aSN as has been suggested also for tau and aSN (Galpern and Lang 2006;Iseki et 
al. 2003) although the specific molecular mechanisms of this synergistic interface 
between abnormally aggregated proteins awaits further clarification. 
Predominant motor symptoms (bradykinesia, rigidity and tremor) have been 
differentially linked to severity of intellectual decline in PD. Research has demonstrated 
that bradykinesia and rigidity correlate with cognitive impairment, whereas tremor does 
not (Iwasaki et al. 1989;Huber et al. 1992;Huber SJ 1991;Portin RJ 1989). Portin and 
colleagues (Portin RJ 1989) found that patients with predominant bradykinesia and 
rigidity were more likely than patients with tremor to show mental status decline. Huber 
and colleagues (Huber SJ 1991) compared patients with predominant tremor to those with 
predominant bradykinesia and rigidity and found only the latter group of patients 
exhibited deficits in memory, visuospatial and executive skills. Iwasaki and colleagues 
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(Iwasaki et al. 1989) reported a negative correlation between bradykinesia and 
visuospatial tasks and rigidity and memory tasks in patients with PD. These findings, 
apart from suggesting that the pathophysiological mechanisms responsible for producing 
bradykinesia and rigidity may also underlie PD-related cognitive deficits also point to an 
interaction between motor symptoms and cognitive decline. Although the present study 
did not aim to examine the influence of motor disability on cognitive dysfunction, the 
finding that motor deficits were similar among the PD groups irrespective of dementia 
status argues against a straightforward association between cognition and motor deficits 
rather the relationship seems to be more complex as supported by previous reports 
(Katzen et al. 2006) that implicate laterality of motor disability as an important 
determinant for the development and severity of mental deficits. Further studies are 
needed to explain the relationship between predominant motor deficits in PD on cognition 
and behaviour. 
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4.5 Conclusions 
The present work demonstrates an increased Ap striatal burden in PD cases with 
dementia as opposed to non-demented PD subjects. This finding provides direct evidence 
of a clinical relevance of striatal pathology in PD. Of particular interest was the finding 
that the increased striatal Ap pathology was observed in the absence of prominent cortical 
Ap deposition which offers a firm pathological substrate for features ascribed 
to subcortical dementia in these individuals giving rise to a distinctive clinical 
presentation. Nevertheless, the neuropathology of demented PD individuals emphasise 
the interaction of both cortical and subcortical lesions (see also chapter 3). Also, the 
findings of this study provide further acknowledgement of a molecular link between PD 
and AD with respect to Ap deposition, as well as highlighting a primary role of the 
striatum in the pathological processes of cognitive dysfunction in PD. 
The present work also shows that striatal Ap deposits portray a diversity of 
morphologies that may not represent a mere extension of cortical plaques, but may relate 
to the intrinsic mosaic distribution of striatal projection systems. Further studies are 
needed to unravel the possible links between the chemoarchitecture of the striatum and 
the distribution of striatal Ap plaques in the brain of both PD and AD subjects. 
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Chapter 5 
Anxiety in Parkinson's Disease: Possible Anatomical and 
Pathological Correlates of this Disabling Symptom 
5.1 Introduction 
Dementia and VH have been recognised as two major non-motor complications 
typically associated with PD. However, PD is accompanied by a spectrum of psychiatric 
symptoms with more than 60% of PD patients having one or more neuropsychiatric 
symptoms (Aarsland and Karlsen 1999;Aarsland et al. 1999c) including depression, 
apathy, agitation, delusions, euphoria, paranoia, irritability and anxiety. The most studied 
of these features is depression (Tandberg et al. 1996), while much less attention has been 
given to anxiety despite an up to 40% incidence among PD sufferers (Lauterbach and 
Duvoisin 1991;Starkstein SE et al. 1993) and an increased risk for anxiety in PD patients 
compared to non-PD age-matched controls (Richard et al. 1996;Menza and Mark 1994) 
(see also section 1.2.3.1). Nevertheless, there is no study to date investigating whether PD 
individuals with anxiety can be differentiated from those without at a neuropathological 
level. The present chapter will therefore try to investigate possible pathological correlates 
of anxiety in PD. 
5.1.1 Anxiety in PD 
Anxiety is a state characterized by a vague and unpleasant sense of apprehension, 
often accompanied by autonomic symptoms such as palpitations and dry mouth. Anxiety 
can be beneficial when warning of impending danger, but it may also be pathologic if 
symptoms are prolonged or excessive or if they occur inappropriately. An anxiety 
disorder connotes the presence of a significant disturbance interfering with normal well 
being due to anxiety. There are several different types of anxiety disorders which are 
distinguished from one another by their clinical context symptom constellation, response 
to medication, and in some cases presumed etiologic mechanism. While in many studies 
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the type of anxiety disorder is not specified by the authors others have reported a wide 
range of anxiety disorders in patients with PD. In a study by Stein and colleagues of the 
nine PD patients with significant anxiety disorder, one had generalised anxiety disorder, 
two had panic disorder, one had long standing panic disorder with depression, one had 
panic disorder with social phobia, three had social phobia alone, and one had anxiety 
disorder not otherwise specified (Stein et al. 1990). Vazquez et al., described only panic 
disorder, whereas Schiffer et al., reported the presence of panic disorder and generalised 
anxiety disorder (Vazquez et al 1993;Schiffer et al. 1988). In familial parkinsonism the 
following rates have been reported: simple phobia; 34.27%, agoraphobia; 15.8%, 
obsessive-compulsive disorder; 13.2%, panic disorder; 7.9%, generalised anxiety 
disorder; 5.3% and social phobia; 5.3% (Lauterbach and Duvoisin 1991). Thus the 
diagnoses of anxiety disorders in patients with PD appear to be clustered in the panic 
disorder, phobic disorder and generalised anxiety disorder (Menza et al. 1993;Lauterbach 
and Duvoisin 1991;Stein et al. 1990;Schiffer et al. 1988). Nevertheless, further studies 
are needed in larger patient populations and standard psychiatric interviews to clarify the 
relative frequencies of the various anxiety disorder types in PD. 
5.1.2 Pathophysiology of Anxiety in PD 
Despite a high incidence of anxiety in PD it is still unclear why PD patients are 
especially prone to anxiety. Anxiety may relate to the psychological and social difficulties 
of the disease. Patients with PD experience higher stress than people without the disease 
(Ellgring et al. 1990). Patients with PD may suffer from social anxiety; patients are afraid 
of being negatively evaluated in public and thus anxiety and social withdrawal may then 
result. However, Schiffer et al., found a higher frequency of anxiety in depressed 
parkinsonian patients than in depressed multiple sclerosis patients (Schiffer et al. 1988). 
Therefore anxiety in PD may not simply be the result of psychological and social 
difficulties of the disease but may reflect specific neurobiological mechanisms. 
Anxiety in PD may relate to the neurochemical changes of the disease itself. There 
is evidence to suggest that dopamine may be involved in the development of anxiety 
directly (Stein et al. 1990) or via its interaction with the variable deficits of noradrenalin 
and serotonin that are also known to occur in PD (Lauterbach and Duvoisin 1991;Iruela et 
al 1992). The ventral tegmental area and the locus coeruleus which give rise to 
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mesolimbic and noradrenergic pathways, demonstrate significant neuronal loss in PD 
(Forno 1996). Dopamine inhibits the rate of firing of the locus coeruleus and a loss of 
dopamine inhibition could explain the high prevalence of anxiety in PD. More 
specifically, there is strong evidence to suggest that noradrenergic dysfunction, 
particularly of ai-adrenergic receptors, and perhaps in the locus coeruleus itself, in the 
development of primary anxiety disorders especially panic disorder (Nutt and Lawson 
1992;Heninger and Charney 1988). Interestingly, several abnormalities in the 
noradrenergic system have been also discovered in PD (Agid et al. 1989). Bernal and co-
workers suggest that untreated PD is associated with a significant reduction in aj-
adrenergic sensitivity (Berlan et al. 1989). It is thus possible that PD patients are more 
vulnerable to panic attacks because they have an alteration of the ai-adrenergic receptor. 
Anxiety may be caused by abnormalities of serotonin. A functional polymorphism 
in the promoter region of the transporter gene has been recently Hnked to anxiety. Menza 
and colleagues have reported that PD patients who carry the short allele of the serotonin 
transporter score significantly higher than non-carriers on anxiety scales (Menza et al. 
1999). These findings suggest that a genetic defect may play role in susceptibility to 
anxiety in PD. 
The potential role of GABA in the genesis of anxiety is suggested by the efficacy 
of benzodiazepines for the treatment of panic disorder and generalised anxiety disorder; 
these anxiolytic drugs produce their effects by activating GABA receptors in the brain 
(Chamey et al. 1990). In most of the PD brain examined so far, an increased 
concentration of GABA in putamen and pallidum and a decreased concentration in 
cortical areas have been observed (Agid et al. 1989). 
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5.1.3 Aims 
Aside fi-om the neurotransmitter systems and their possible link to anxiety in PD 
there is no up-to-date neuropathological study to examine pathologic burden in relation to 
anxiety in the PD brain. Therefore, this study aimed to investigate the relationship 
between aSN and AD-type pathology (both tau and AP) in cortical, limbic and brainstem 
nuclei in PD patients with and without anxiety as a means of identifying possible 
pathological correlates of anxiety in PD and thus provide a better understanding of the 
pathophysiological mechanisms responsible for this disabling symptom. 
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5.2 Materials and Methods 
5.2.1 Neuropathological Assessment 
Neuropathological assessment and diagnosis were performed as described in 
section 2,2.1. 
5.2.2 Selection of Cases 
A total of 81 cases were included in this study. The cases were screened and the 
clinical severity of dementia, VH, anxiety, depression, delusions and paranoia were 
graded on a semi-quantitative global impression scale (0-3+, absent to severe) by two 
investigators as described in section 2.2.2.1. Out of the 81 cases initially screened 57 
received a clinical and neuropathological diagnosis of PD. Of these cases 44% 
experienced anxiety alone or in combination with other neuropsychiatric signs. Anxiety 
co-existed with dementia and VH in 29% of cases while anxiety in combination with 
depression occurred in 22%. Interestingly, 21% of cases had anxiety without depression. 
Among non-demented PD subjects 14% had anxiety. The degree of co-morbidity between 
anxiety, delusions and paranoia was less pronounced (12.2% and 7% respectively). For 
the purpose of the present work, PD cases were categorised according to anxiety status as 
follows; PD cases without anxiety and with no co-morbid neuropsychiatric features (n=9) 
(PD (A-) group), and PD cases with moderate to severe clinical scores for anxiety (n=6) 
(range 2-3; PD (A+)) (Table 5.1). 
In addition to neuropsychiatric deficits the clinical severity of motor features was 
also recorded and rated in this study. The assessment was performed on a semi-
quantitative global impression scale (0-3+, absent to severe) by two investigators. The 
clinical data of the cases are presented in Table 5.1. 
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Table 5.1 Clinical data for the PD groups. 
(Following page) Abbreviations: PD(A+): PD cases with high clinical scores for anxiety, 
PD(A-): cognitively intact PD cases, D: Dementia, VH: Visual Hallucinations, A: 
Anxiety, De: Depression, Pr: Paranoia, Dl: Delusions T: Tremor, G-B: Gait-Balance 
problems, A-R, S: Akinesia-Rigidity and Stiffness, H-P: Hemi-Parkinsonism, PD: 
Parkinson's disease, m: male, f: female, semi-quantitative clinical severity scores 0: 
absent, 1: mild, 2: moderate, 3: severe, +: yes, -: no, ±: possibly 
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Table 1 Clinical data for the PD groups 
PD(A-1 
A g e a t A g e a t Dura t ion N e u r o p a t h o l o g i c a l 
C a s e O n s e t Death of D i s e a s e D i a g n o s i s (CDNS AD GRADE Braal< 
N u m b e r G e n d e r (years) (years) (years) (www.ICDNS.org) (www.ICDNS.org) A D - S t a g e s 
Clinical Seve r i ty 
S c o r e s of N e u r o p s y c h i a t r i c F e a t u r e s 
VH A De Pr Dl 
Clinical Sever i ty 
S c o r e s of P r e s e n t i n g Motor Defic 
(within f i r s t 2 y e a r s ) 
T G-B A-R,S H-P 
Clinical Sever i ty 
S c o r e s of Motor de f ic i t s 
(af ter 2 y e a r s ) L-Dopa 
G-B A-R,S H-P R e s p o n s i v e n e s s 
PDfA-H) 
58 52 58 6 PD isocortical 0 - entorhinal 1 l- 1 0 0 1-2 0 0 0 1-2 0 0 0 2 0 1-2 0 ± 
74 76 8 5 9 PD isocortical 11 - entorhinal 0 1-1 0 0 0 0 0 1-2 0 0 1-2 0 + 
95 47 7 4 27 PD Isocortica! 1 - entorhinal 0 1-1 0 0 0 1 0 0 1 0 1-2 2-3 1-2 + 
2 3 75 8 2 7 PD isocortical 1 - entorhinal II 1-1 0 0 0 1 0 0 0 1-2 0 0 0 2-3 0 + 
7 6 8 7 8 1 0 PD na 1- 1 0 0 0 0 0 0 0 1 0 0 1-2 0 + 
2 2 6 5 7 5 10 PD isocortical 0 - entorhinal 0 0 0 0 0 0 0 0 0 2 1-2 0 1 + 
29 70 7 7 7 PD isocortical 0 - entorhinal 1 1- 1 0 0 0 0 0 1 0 1-2 1-2 2 1 + 
32 86 8 9 3 PD isocortical 0 - entorhinal 1 1- I 0 0 0 0 0 0 1 0 0 1-2 1 -2 0 + 
36 67 77 10 PD isocortical 0 - entorhinal 1 1- I 0 0 0 0 0 0 0 0 0 0 0 0 + 
Mean 67 77 9.8 
19 54 72 18 PD isocortical 1 - entorhinal 0 I-I 0-1 0 2 1 0 1 3 0 0 3 3 0 2 0 + 
37 85 87 2 PD isocortical 0 - entorhinal 1 1- 1 0 0 2 0 0 0 1-2 1-2 2 0 1-2 0 + 
3 9 6 9 8 2 1 3 PD isocortical 1 - entorhinal 1 1-X 0 3 3 0 0 1-2 0 0 1-2 1-2 0 + 
41 67 77 10 PD Isocortical I - entorhinal 11 1- 1 1 0 3 3 0 0 1-2 0 0 1-2 1 -2 0 0 1-2 + 
5 4 6 4 7 5 11 PD isocortical III -entothinal III 1- 1 0-1 0 2 0 0 0 1 0 0 1-2 1 -2 0 1 + 
94 61 7 5 14 PD Isocortical 0 - entorhinal II 1- 1 0 2 2 0 0 0 1-2 0 1-2 0 1-2 + 
Mean 66.6 78 11.3 
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5.2.3 Immunohistochemistry 
Immunohistochemical reactions were performed as described in section 2.2.4. All 
15 cases were stained for aSN for the identification of aSN inclusions (Becton-Dickinson 
at a dilution of 1:1000), tau for visualization of neurofibrillary changes (Autogen Bioclear 
PHF-Tau (clone ATS) at a dilution of 1:800) and 1E8 for visualization of Ap plaques 
(AP) (at a dilution of 1:1000). 
5.2.4 Semi-quantitative Assessment of aSN and AD Lesions 
For each study case, three representative sections from the temporal, cingulate and 
entorhinal cortices as well as the hippocampal CA2 sector, subiculum, amygdala, nucleus 
basalis of Meynert (NBM), locus coeruleus and raphe nuclei were assessed for the 
occurrence of aSN, Ap and tau immunoreactivity. The semi-quantitative rating scheme 
was used based on a scale ranging from 0-3 (absent to severe) as described in previous 
chapters 3 and 4. Sections were graded by two investigators (Mr. Michail E. Kalaitzakis 
and Dr. Stephen M Gentleman). Cohen's kappa statistics revealed an inter-rater reliability 
of 0.75 for aSN, 0.8 for tau and 0.8 for Ap. For visual representation of the severity rating 
system please refer to image Figure 3.1. The raw data for aSN, tau and AP pathology are 
given in Appendix V. 
5.2.5 Statistical Analysis 
Statistical analysis was performed using the SPSS programme version 15.0 for 
Windows XP and GraphPad Prism 4. The differences in aSN, tau and AP burden as well 
as age at death, onset and duration of disease among PD cases with anxiety and those 
without (the PD(A-) group) were analyzed by the non-parametric Mann-Whitney [/-test. 
The Kruskal-Wallis test was applied followed by Dunn's post hoc multiple group 
comparisons to detect differences in severity of tremor, gait-balance, akinetic-rigid and 
hemi-parkinsonism signs among the groups. Cohen's kappa statistic was used to test 
inter-rater reliability for the aSN, tau and Ap semi-quantitative assessment between the 
two investigators. P values <0.05 were considered significant. 
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5.3 Results 
5.3.1 Assessment of Clinical Data 
Gender, age at PD onset, age at death, duration of disease, as well as the clinical 
severity of the individual neuropsychiatric and motor symptoms assessed are presented in 
Table 5.1. All apart from possibly one case were L-Dopa responsive (Table 5.1). Age at 
death, age at disease onset and duration of disease did not differ between the PD(A+) and 
PD(A-) groups. PD(A+) cases had a significantly greater degree of tremor severity 
(p=0.01) within the first 2 years of the disease course. No differences were observed with 
respect to the other motor signs assessed. 
5.3.2 Pathological Data 
The PD(A-) group comprised 9 PD cases without anxiety and with no or only mild 
concomitant neuropsychiatric signs. Among this group LBs were sparse in the 
neocortical, limbic and brainstem regions. Of note, however, is the extent of aSN 
pathology in the NBM among the PD(A-) group which was clearly more pronounced than 
the other regions assessed. Most of the PD(A-) cases displayed a mild degree of AD type 
pathological change. 
In the PD(A+) group there was a trend towards increased aSN burden in all 
regions under investigation (Figure 5.1). However, when compared with the PD(A-) 
group this was only significantly greater for the amygdaloid complex (p=0.004), CA2 
sector of the hippocampus (p=0.008) and locus coeruleus (p=0.04) (Figure 5.1 and Figure 
5.2). Among the PD(A+) group however, there were three cases with concomitant 
depression. Exclusion of these cases from the analysis resulted in a loss of statistical 
significance for the locus coeruleus although an increased aSN burden in the amygdala 
and CA2 sector of the hippocampus was still apparent (p-0.01 and 0.04, respectively). 
Neither tau nor Ap burden in any region showed any relationship to anxiety. 
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Figure 5.1 aSN burden in the PD(A+) and PD(A-) groups 
(Following page) Semi-quantitative assessment of aSN burden in cases with anxiety 
reveals a significant difference when compared with the PD(A-) group in the CA2 sector 
of the hippocampus, amygdaloid complex and locus coeruleus. The columns represent 
mean values ± SEM. 
Abbreviations: PD(A+): PD cases with high clinical scores for anxiety, PD(A-): 
cognitively intact PD cases, C: Cingulate gyrus, T; Temporal Cortex, EC: Entorhinal 
Cortex, AC; Amygdaloid Complex, NBM: Nucleus Basalis of Meynert, CA2: CA2 sector 
of the Hippocampus, SUB: Subiculum, LC: Locus Coeruleus, RN; Raphe Nuclei * 
denotes significant difference (Mann-Whitney [/-test, p<0.05). 
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Figure 5.2 Photomicrographs of the amygdala of a PD case with anxiety and a PD 
case without 
(Following page) aSN immunostaining of a PD case without anxiety (A) and a PD case 
with anxiety (B). Primary magnification 20x 
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5.4 Discussion 
Anxiety is a common complication of PD (Cvimmings 1992). In this study the 
overall frequency of anxiety of 44% is consistent with previous reports (Richard et al. 
1996;Walsh and Bennett 2001). Anxiety and other neuropsychiatric disturbances, 
particularly depression, commonly co-exist in PD. Patients with the disease have 
significantly higher levels of depression and anxiety than normal controls (Hillen and 
Sage 1996) and in fact anxiety in combination with depression may represent a specific 
depressive subtype in PD. Henderson and colleagues have found a prevalence of 38% of 
PD patients with depression and anxiety compared with 8% of healthy spouse controls: 
depression and anxiety were highly correlated in PD patients (Henderson et al. 1992). In 
this cohort the prevalence of 22% of what is slightly less than previous studies, more 
likely reflects the smaller sample size studied (n=57). Although, studies have reported a 
close link between anxiety and depression, anxiety can clearly occur in the absence of 
depression. A study by Liu et al., revealed that, although the severities of anxiety and 
depression via standardised rating scales were generally correlated, 14 of 58 PD patients 
(24%) determined to be free of depressive symptoms fulfilled DSM-III-R criteria for 
generalised anxiety disorder (Liu et al. 1997). In this cohort, 21% of the cases had anxiety 
without depression confirms previous reports that anxiety can occur without associated 
depressive symptomatology. 
Although there is some evidence for an increased rate of anxiety in primary 
dementia disorders (Wands et al. 1990) the relationship between anxiety and dementia in 
PD is uncertain. Most of the studies that examined anxiety in PD either failed to comment 
on the cognitive status of the patients (Schiffer et al. 1988;Henderson et al. 1992) or 
deliberately excluded patients with dementia (Stein et al. 1990;Menza et al. 1993;Siemers 
et al. 1993). Nevertheless, Iruela et al., (Iruela et al. 1992) has found that the prevalence 
of anxiety is lower in demented than non-demented patients. On the contrary, in this study 
29% of demented patients had co-existent anxiety while among the non-demented 
patients 14% had anxiety. Thus, our results are in agreement with Lauterbach (Lauterbach 
1993) pointing to an increased incidence of anxiety in demented PD patients, although 
studies in a larger population are needed to confirm the present findings. 
The relationship between anxiety and motor symptoms is controversial. A number 
of studies have found that the severity of motor state in PD is not related to anxiety (Stein 
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et al. 1990;Menza et al. 1993). However, some authors have reported higher degrees of 
anxiety in patients who experience 'on-off motor fluctuations (Menza et al. 
1993;Henderson et al. 1992). One could conjecture that the unpredictable nature of the 
on-off states might result in anxiety behaviour similar to that which occurs in laboratory 
animals after they are exposed to unpredictable aversive stimuli (Seligman 1968). Most 
authors have noted that in patients who do experience the on-off phenomenon, anxiety 
tends to occur most often during the 'off phase (Stein et al 1990;Siemers et al 
1993;Henderson et al. 1992). Further to this, one study revealed that in most patients 
mood or anxiety improved significantly from 'off to 'on', but then worsened again in the 
'on' state when dyskinesias appeared (Menza et al. 1990). In this PD(A+) group we noted 
a significantly greater degree of tremor severity, presenting within the first two years of 
the disease course, although no differences were detected with respect to severity of other 
motor signs assessed between the PD(A+) and PD(A-) groups. Thus the results of the 
present report support previous studies of a connection between the motor state and 
anxiety in PD and accentuate tremor as an important clinical feature relating to anxiety. 
However, it has to be noted that in the present study it was not possible examine the 
severity of anxiety during on-off fluctuations. 
The findings of this report point to aSN pathology in the amygdala and 
hippocampus as possible candidate regions underlying the pathogenesis of anxiety in PD. 
Although these regions have been previously related to dementia and VH (Harding et al. 
2002a;Samuel 1998) in PD the results of the present study show that they may also 
underlie anxiety as the PD(A+) cohort was relatively free of dementia and VH. In fact it 
is not difficult to rationalise an involvement of amygdala and hippocampus in the 
pathogenesis of anxiety in PD as these regions have also been implicated as dysfunctional 
in pure mood disorders (Drevets 1998). For example, in panic disorder 
amygdalohippocampal structures have a central role in the elaboration of panic attacks 
and related symptoms of arousal and fearful avoidance (Grove et al. 1997). The amygdala 
is a key structure for emotional processing in humans and mediates fear processing and 
anxiety (LeDoux 2000) while it is also highly interconnected with other regions of the 
limbic system (Swanson and Petrovich 1998). Electrical stimulation of the amygdala in 
humans evokes strong visceral and emotional fears responses while ablation studies in 
primates suggest loss of the fear response to previously threatening stimuli, as part of the 
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the Kluver-Bucy syndrome (Davis 1997;Deakin JFW and Graeff FG 1991). It is also of 
interest to note that the amygdala provides a widespread efferent network with projections 
to centres regulating endocrine and autonomic functions (Swanson and Petrovich 1998). 
It is not then surprising that PD patients with anxiety experience more complaints related 
to autonomic function (e.g. postural dizziness, urinary frequency, dry mouth) than 
controls, possibly as a result of amygdala pathology (Berrios et al. 1995). 
Anxiety in PD has been mainly investigated in neuroimaging studies, both directly 
and indirectly. In a study by Remy et al , (Remy et al. 2005) anxiety severity negatively 
correlated with bilateral amygdala ['^C]RTI-32 binding in PD subjects. Furthermore, 
Benkelfat and colleagues(Benkelfat et al. 1995) found rCBF increases in amygdala 
associated with cholecystokiniru-induced anxiety. Although no study so far has 
implicated hippocampal abnormalities in PD patients with anxiety, the hippocampus may 
facilitate the presence of anxiety by retrieval of fear-signifying memories and thus work 
in close proximity with the amygdala, with which it is reciprocally intercormected. The 
neuropathological correlates of anxiety in PD have not been previously studied. The 
findings reported herein are largely in agreement with previous functional imaging 
studies implicating the amygdala as a possible candidate for anxiety in PD but also point 
for the first time to hippocampal pathology as an important region for the development of 
anxiety in PD although the exact pathophysiological mechanisms remain to be elucidated. 
The pathological basis of depression in PD is not yet fully understood. Although 
this study did not aim to describe an association between focal pathology and depression, 
we did find that aSN pathology in the locus coeruleus was increased in PD subjects with 
both depression and anxiety. The fact that aSN in the locus coeruleus did not differ 
significantly between the PD(A-) and PD(A+) group (when depressed cases were 
excluded) may suggest that aSN in the locus coeruleus plays an important role in the 
development of depression. Although depression in PD has been associated with 
noradrenaline deficiency in PD patients (Scatton et al. 1983), damage to the locus 
coeruleus occurs both with and without clinical manifestations of depression (Sandyk 
1989) thus leaving the definitive contribution of noradrenaline to depression in PD 
unclear. To our knowledge this is the first study to observe an association between 
depression and aSN burden in locus coeruleus but does require further study. 
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5.5 Conclusions 
The present work provides the first prehminary chnico-pathological investigation 
of anxiety in PD. The findings demonstrate an increased aSN burden in the amygdala and 
hippocampus CA2 sector in PD cases with anxiety. Nevertheless, it is important to note 
that the PD(A+) group had other neuropsychiatric deficits while the PD(A-) group was 
cognitively intact thus the pathological changes observed may be a surrogate marker of 
extranigral involvement of more severe disease. The present findings can be confirmed if 
two additional PD groups had been studied that would include PD cases without anxiety 
but with additional neuropsychiatric deficits and PD cases with anxiety without any 
concomitant neuropsychiatric symptoms. Even with these reservations this study provides 
evidence that anxiety in PD is not simply the result of psychological and social 
difficulties of the disease but rather possibly relates to specific neurobiological 
mechanisms. These findings (although preliminary) possibly also shed some light on 
common neurobiological mechanisms of anxiety in PD and mood disorders. Further 
studies with well matched PD groups for anxiety are needed to confirm the involvement 
of amygdala and CA2 sector of the hippocampus in the pathogenesis of anxiety in PD. 
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Chapter 6 
The dorsal motor nucleus of the vagus is not an obligatory 
trigger site of Parkinson's disease: A critical analysis of a-
synuclein staging 
6.1 Introduction 
The term "synucleinopathy" has been used broadly to designate a spectrum of 
progressive degenerative disorders of the human nervous system that share, among other 
properties, the presence of abnormal aSN immunoreactive inclusion bodies in neurons 
and/or macroglial cells (Takeda et al. 1998;Galvin et al. 2001). The term currently 
encompasses neurobiologically and neuropathologically diverse, but also, in part, 
clinically overlapping entities, such as multiple system atrophy (MSA), PD, dementia 
with Lewy bodies (DLB), the Lewy body variant of Alzheimer's disease (LBVAD), and 
neurodegeneration with brain iron accumulation type 1 (NBIA I) (Gorell et al. 1994;Papp 
and Lantos 1994;Arawaka et al. 1998;Gai et al 1998;Bayer et al. 1999b;Dickson et al. 
1999). 
PD is the most frequently occurring synucleinopathy. Involvement of the 
substantia nigra and obliteration of dopaminergic neurons in the pars compacta are 
universally acknowledged hallmarks of PD (Mann and Yates 1983;Graybiel et al. 
1990;Agid et al. 1993). However, as described in earlier chapters, PD is a multisystemic 
illness with pathology occurring in a variety of cortical and subcortical regions including 
the olfactory bulb and related areas, the dorsal motor nucleus of the vagal nerve and 
adjoining intermediate reticular zone, the tegmental pedunculopontine nucleus, 
nonthalamic nuclear nuclei with diffuse projections to cortical and subcortical regions, 
intralaminar and midline thalamic nuclei, the amygdala, NBM, trans- and entorhinal 
cortices, hippocampal formation, temporal and frontal cortices (Richard et al. 2002;Braak 
et al. 2003;Pahapill and Lozano 2000;Rub et al. 2002;Braak and Braak 2000;Braak et al. 
1994;Braak et al. 1998;Rub et al. 2002;Jellinger 1991). The question had arisen as to 
whether these aSN lesions in the PD brain evolve simultaneously or whether regions 
show different susceptibility to develop this PD-related pathology. Recently, a few 
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studies have suggested that involvement of aSN pathological lesions in the PD brain is 
not random but in fact follows a predictable stereotypic pattern. 
6.1.1 Staging of PD-related pathology 
A prerequisite for the post-mortem diagnosis of PD is the assessment of the 
pathognomonic lesions (Gibb et al. 1991). As a result of a conformational change in the 
predominantly presynaptic protein aSN and the subsequent failure of intracellular 
proteasomal recycling systems to eliminate the misfolded proteins (see also section 
1.3.2.3), affected neurons develop LNs in their cellular processes and LBs in their somata. 
In addition, abnormal neurofilaments, synphilin, and the stress protein ubiquitin also 
contribute to the formation of these nearly insoluble aggregates (Trojanowski and Lee 
2000;Takeda et al. 1998;Gai et al. 1995;Spillantini et al. 1998;Baba et al. 
1998;Trojanowski and Lee 1998;Golbe 1999). 
On the basis of the occurrence of these PD-related histopathological hallmarks in 
the PD brain (LBs and LNs), Professor Braak and colleagues have proposed that PD 
progresses in six neuropathological stages (Braak et al. 2003). The proposed staging 
system rests in the following two assumptions. The first assumption is that incidental 
Lewy body pathology is the first step along a disease continuum. If one regards PD as a 
dynamic biological process then the so-called incidental lesions (presence of LBs and 
LNs at neuropathological examination in neurologically unimpaired individuals) 
represent presymptomatic correlates of a pathological condition ultimately capable of 
leading to the manifestation of clinical PD. The second prerequisite for staging PD is that 
the pathological process associated with PD (i.e. LBs and LNs) increases in extent and 
severity with disease progression. Based on these assumptions the design for the staging 
system included both clinically PD cases as well as cases with incidental LBs and LNs 
therefore presumably reflecting the entire spectrum of the PD pathological process. 
Stage 1 
In stage 1 aSN lesion in the brain are seen in the dorsal motor nucleus of the 
vagus nerve (DMV) and olfactory bulb and related portions of the anterior olfactory 
nucleus (Braak et al. 2003). LBs and LNs are limited to these 2 regions and cases in stage 
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1 do not demonstrate aSN pathology in any other brain region. Since the pathology does 
not advance further from olfactory structures into the neocortex, the DMV is viewed as 
the main start point. 
Stage 2 
aSN pathology in the DMV is more severe than in stage 1. In stage 2 lesions occur 
in the caudal raphe nuclei, gigantocellular reticular nucleus and locus coeruleus. In the 
first 2 stages of the disease the pathology is confined to the lower and upper brainstem. 
This means that the pathological process that ultimately leads to clinical PD does not 
begin in the substantia nigra (SN). 
Stage 3 
In stage 3 the pathology in caudal regions (regions in stages 1 and 2) increases 
progressively in severity. The brain structures affected in this stage are the amygdala, 
Nucleus Basalis of Meynert (NBM), pedunculopontine nucleus and most notably the 
substantia nigra pars compacta. At this stage the cerebral cortex is uninvolved. 
Stage 4 
In stage 4 cortical LBs and LNs appear in the temporal mesocortex 
(transentorhinal regions and the CA2 sector of the hippocampus). The neocortex is not 
affected. It is in this stage and in some cases in stage 3 that the presymtomatic phase gives 
rise to the clinically recognisable phase of the disease. 
Stage 5 
In stage 5 the density of lesions in the temporal mesocortex is more striking and 
the disease is present in the insular and cingulate mesocortex. The temporal neocortex 
becomes involved. 
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Stage 6 
In stage 6 the key feature is the involvement of nearly the entire neocortex. The 
premotor areas, the primary motor field, the first order sensory association and primary 
sensory areas are affected but show mild changes. 
6.1.2 Important considerations of the proposed PD-staging system 
The criteria by which Professor Braak initially classified cases creates an inherent 
bias in experimental design. Cases with no clinical symptoms of PD are screened and 
categorised based on the presence of aSN deposition in the DMV prior to an examination 
of additional anatomical areas. In another study by the same research group (DelTredici 
et al. 2002), cases with aSN in the DMV were described as also showing inclusions in 
additional lower brainstem nuclei, particularly the locus coeruleus and in the olfactory 
bulbs. These are considered secondary induction sites on the basis that they are never the 
sole area in which inclusions are observed. However this is an experimental impossibility 
given that all cases were initially pre-selected on the basis of pathological inclusions in 
the DMV. 
In the Braak et al. paper (2003) the clinical profiles of the 'incidental' pathology 
subjects are not described in a clear or concise fashion. There are cases with "mild 
alterations" and cases with "a few cases with severe pathology were misdiagnosed or did 
not receive a clinical diagnosis". This lack of clinical information is a serious failing in a 
paper that surports to define a definitive pathological staging system ranging from normal 
controls to full blown PD, for ultimately the integrity of the proposed system must rely on 
strict clinico-pathological correlation. 
It is also very interesting that involvement of the SN was found in none of the 
'incidental' Lewy body disease cases. Classical 'Incidental Lewy body Disease' (ILBD) 
is based on the finding of Lewy bodies in the susbtantia nigra in individuals without a 
history of any clinical sign of PD. It is reckoned that this pre-clinical phase of PD 
pathology is present in 10% of those in their seventies, 15% of those in their eighties, 
20% of those in their nineties and in a third or more of those living over the age of 100. 
These results were obtained using older techniques less sensitive than current aSN 
immunohistochemical staining. Thus, there should have been about 3 cases with nigral 
involvement from the 'incidental' group described by the Braak et al., or even more than 
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this number, considering that all of these subjects were pre-selected on the basis of aSN 
pathology already present in the lower brainstem and were studied with highly sensitive 
aSN immunohistochemistry. We know that one must loose 80% of striatal dopamine and 
about 60% of substantia nigra neurons at least before the disease becomes clinically 
manifest (Bemheimer et al. 1973). The preclinical phase of the illness may last anywhere 
from 5-20 years. Thus, it is highly surprising and appears implausible that none of the 
'incidental' cases described had any pathological involvement in the substantia nigra. 
Indeed, this implies that none of these individuals would have developed clinically 
apparent PD over the ensuing decade at least. 
In addition, to the abovementioned important concerns about the Braak PD 
staging scheme although the system indicates an ascending path of aSN pathology, lower 
parts of the nervous system (i.e. spinal cord) were not examined and therefore the 
comparative incidence of aSN pathology in the spinal cord and DMV has not been 
studied. aSN lesions in the spinal cord are often found in both PD and neurologically 
unimpaired subjects (Bloch et al. 2006;Wakabayashi and Takahashi 1997b;Wakabayashi 
and Takahashi 1997a). 
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6.1.3 Aims 
Given these important issues with regards to the experimental design used by the 
Braak research group, the aim of this work was based upon the following view: It would 
be necessary initially to screen clinically and neuropathologically well substantiated PD 
cases for pathology in multiple vulnerable regions (e.g. the locus coeruleus, substantia 
nigra, hippocampus and meso- and neocortex) and confirm that they all show additional 
inclusions in the DMV before it can be considered a probable candidate for the site in 
which aSN inclusions are first observed in clinically unaffected cases. This study 
therefore aimed to determine the incidence and topographic distribution of aSN lesions in 
a large unselected PD cohort collected by the UKPDSTB at Imperial College, London. 
The pathology was examined in eight brain regions along the rostro-caudal axis in 
addition to the spinal cord. 
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6.2 Materials and Methods 
6.2.1 Neuropathological Assessment 
Neuropathological assessment and diagnosis were performed as described in 
section 2.2.1. All cases with a clinico-pathological diagnosis other than PD were excluded 
from this study. 
6.2.2 Clinical Assessment and Selection of Cases 
The clinical assessment of cases followed established criteria (see section 2.2.2). 
A total of 101 cases were examined. These cases represent the first 101 cases accrued by 
the UKPDSTB. From this sample 30 cases were diagnosed clinically or 
neuropathologically with a condition other than PD (e.g. 6 MSA, 8 PSP, 3 ET, 7 DLB, 5 
with age-related changes and 1 with possible fragile-X ataxia) and thus excluded from 
further analysis. Therefore a total of 71 cases well substantiated with a clinical and 
neuropathological diagnosis of PD were included in this study (50 males, 21 females, age 
range between 50 and 89, mean age at death 78 years; Table 6.1). 
6.2.3 Immunohistochemistry 
Immunohistochemical reactions were performed as described in section 2.2.4. All 
cases were stained for aSN for the identification of aSN inclusions. In this study for 
antigen unmasking, 5 minutes formic acid (100%) pre-treatment was performed with a 
dilution of 1:300 of the primary antibody (Becton-Dickinson). 
6.2.4 Semi-quantitative assessment of aSN lesions 
Representative sections from the dorsal motor nucleus of vagus (DMV), locus 
coeruleus (LC), substantia nigra (SN), Nucleus Basalis of Meynert (NBM), amygdaloid 
complex (AC), CA2 sector of the hippocampus (CA2), entorhinal cortex (EC; 
mesocortex) and superior frontal gyrus (SFG; neocortex) were obtained and the burden of 
aSN was assessed semi-quantitatively as follows: -= absent, += mild or moderate and 
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++= severe (Figure 6.1). The spinal cord (SC) of 24 PD cases was also examined. aSN 
positive lesions in the SC were examined at the cervical, thoracic and lumbar levels and 
the most severely affected structure was taken for rating using the same semi-quantitative 
rating scale used previously (-= absent, += mild or moderate and ++= severe). The 
absence of aSN positivity in the DMV and SC was verified in each case through 
examination of three additional consecutive sections. DMV sections were carefully 
inspected for integrity of preservation of vagal neurons in addition to assessment of aSN 
burden. 
Figure 6.1 Semi-quantitative assessment of aSN positive lesions 
(Following page). The pathology was either absent (0) or present in scant to moderate 
severity (+) or severely and significant present (++). Representative section from the CA2 
sector of the hippocampus. 
215 
V •' 
0 
f '••• >• 
f.' 
> •• 
f » 
M'' / -' ' 
/ (- - : . • 
* ' • ' V , 
V -V-/ ' r ' ( -
- ' ~ - . . . . 4* / ? •y 
: / y i 
? . .. 
- ' -.-"1« 
; V Vv 
L—.. / • :--• • - "i-i- f.V 
o / . 
9^-1 - . . : . 
^ . 
r ^ 
J + i 
>"•. V 
I - -VjC V* f *-* % ' c' ^ ' • 
"»K # 
I- \ 
* ' / a \ t^  ... ; " :%' ; 
'-i»" 
. a - . - •ty A 
• \ ' . 
»••., -—'T. -»• 
* 
216 
* * # ..« 
• • * ' " " • 
/ " : 
'V^ * 
•*. 
.. f t 
6.2.5 Statistical Analysis 
Statistical analysis was performed using GraphPad Prism 4. Differences between 
groups were determined using the non-parametric Mann-Whitney [/-test. P values <0.05 
were considered significant. 
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6.3 Results 
A total of 71 PD cases (30 PDD and 41 PD) were included in this study, none of 
which had received a diagnosis of AD or DLB. In no case was aSN pathology confined 
solely to the SN. aSN immunoreactive deposits displayed a variety of morphologies. A 
photographic representation of the heterogeneity of LB and LN-type lesions are given in 
Figure 2.6. LB and LN-type lesions in the spinal cord are shown in Figure 6.2. 
Figure 6.2 LBs and LNs in the spinal cord 
(Following page) Lewy bodies and Lewy neurites in the intermediate lateral column of 
the thoracic spinal cord (case 17). Magnification 20x 
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6.3.1 Incidence of aSN pathology in brainstem and telencephalic regions 
In our cohort, the SN was affected in 100% of cases. The NBM was affected in 
98.5% of the cases, making it the second most vulnerable nucleus. The melanised neurons 
of the LC were aSN immunopositive in 97% and the DMV in 92.9% of cases (Figure 
6.3). The AC (90.1%) and EC (90.1%) were equally affected. The CA2 sector of the 
hippocampus was affected in 85.9% of the cases and the least affected region was the 
SFG (80.2%) (Table 6.1). 
Figure 6.3 Microphotograph of a coronal section of the medulla from a PD case 
(Following page) aSN positive inclusions (LBs and LNs) are seen in the DMV (dotted 
box) of PD case 65. aSN positive LNs could be traced from the DMV area to the 
peripheral portion of the vagus nerve (arrows). Primary magnification 4x 
220 
> 5 
Q 
Rl 
! / 
Table 6.1 Clinical characteristics and topographic distribution of aSN lesions in the 
PD brain. 
(Following page) The occurrence of aSN is indicated as absent, +: mild and moderate, 
and ++: severe. 
Abbreviations: PD: Parkinson's disease, PDD: Parkinson's disease with dementia, DMV: 
dorsal motor nucleus of vagus, LC: locus coeruleus, SN: substantia nigra, NBM: Nucleus 
Basalis of Meynert, AC: amygdaloid complex, CA2: CA2 sector of the hippocampus, EC: 
entorhinal cortex and SFG: superior frontal gyrus. 
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6.3.2 Topography of aSN lesions 
The topographical distribution of aSN lesions is shown in table 6.1. In 38 cases 
(1-38) aSN inclusions were seen in nearly all regions under investigation with little or no 
aSN interregional variability. Among these cases the most frequently severely affected 
region was the NBM (11/38). Seventeen cases (39-55) showed a severe load of aSN in 
the SN with mild to moderate involvement of the DMV. These cases did not demonstrate 
neuronal loss in the DMV sufficient to explain the insignificant deposition of aSN. Cases 
with high densities of aSN in the SN also exhibited severe lesions in the LC and NBM. In 
5 cases (56-60) the DMV was severely affected in the absence of prominent involvement 
of more rostral meso- and neocortical regions. Among these cases, 4 (56, 57, 59 and 60) 
showed no aSN pathology in the frontal cortex despite severe pathology in the DMV. In 
cases 61-66 the meso-cortex was severely affected together with pathology in the basal 
forebrain nuclei NBM and AC with lesser affection of lower brainstem structures 
including the DMV despite preservation of neurons in this nucleus. In 5 cases (67-71) no 
aSN lesions were seen in the DMV in spite of the presence of aSN inclusions in more 
rostrally situated regions (Figure 6.4). It is of interest to note that case 70 showed severe 
involvement of the SN in the absence of aSN pathology in the DMV. All of the PD cases 
devoid of aSN in the DMV demonstrated well preserved neurons in this nucleus. 
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Figure 6.4 Absence of aSN pathology in the DMV of a PD case 
(Following 2 pages) A) Low magnification of a medullary section from PD case 71 
showing absence of aSN positivity. B) Higher magnification of DMV from PD case 71 
showing preservation of neurons but absence of aSN immunopositivity. Primary 
magnification for A) 4x and for B) 20x. 
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6.3.3 aSN pathology in the Spinal Cord and its relation to DMV lesions 
In a subset of cases (n=24) aSN pathology at all levels of the SC (cervical, 
thoracic and lumbar) was also examined. We assessed all cases (n=5) that were negative 
for aSN in DMV, as well as 19 others that were randomly selected from the initial 71 
cases of PD/PDD (Table 6.2). In cases with DMV affection, involvement of the SC was 
observed in 89.4% (17/19) of cases while only 2 cases (54 and 34) had no aSN pathology 
in the SC. One case (16) showed higher density of aSN lesions in the SC than in the 
DMV. In cases with no aSN lesions in the DMV (67-71), 60% (3/5) showed aSN 
inclusions in the SC. 
Table 6.2 Clinical characteristics and topographic distribution of aSN lesions in the 
spinal cord and supraspinal regions in the PD brain. 
(Following page) The occurrence of aSN is indicated as absent, +: mild and moderate, 
and ++: severe. 
Abbreviations: PD: Parkinson's disease, PDD: Parkinson's disease with dementia, SC: 
spinal cord, DMV: dorsal motor nucleus of vagus, LC: locus coeruleus, SN; substantia 
nigra, NBM: Nucleus Basalis of Meynert, AC: amygdaloid complex, CA2: CA2 sector of 
the hippocampus, EC: entorhinal cortex and SFG: superior frontal gyrus. 
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6.3.4 Clinical assessment of PD cases without DMV affection 
The mode of presentation as well as neuropsychiatric and autonomic disturbances 
experienced by cases without DMV affection are presented in Table 6.3. Age at disease 
onset, age at death and duration of disease did not differ between cases with and without 
DMV involvement. PD cases with no aSN lesions in the DMV demonstrated a diverse 
clinical picture and were all L-Dopa responsive with the exception of possibly one (Table 
6.3). None of these cases was classified as atypical. 
aSN pathology in relation to dementia 
Dementia was present in 42% of the entire cohort examined. In comparison to 
non-demented PD cases, individuals with dementia demonstrated more severe aSN 
deposition in the CA2 sector of the hippocampus (p=0.006). The NBM was severely 
involved in 47% of cases with dementia and 32% of cases without, while the SN was 
severely affected in 30% and 36%, respectively. 
Table 6.3 Clinical characteristics of PD cases without DMV involvement. 
(Following page) 
Abbreviations: +: yes, no, ±: possibly, R: right, 
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Actual L-Dopa 
Number PD Case Mode of Presentation Neuropsychiatric Complications Autonomic Complications Responsiveness 
PD06 67 Asymmetric (R) Akinetic-Rigid Syndrome Dementia, Confusion Bladder Symptoms ± 
PD09 68 Tremor, Poor Balance Depression, Apathy Constipation. Bladder Frequency + 
PD14 69 Tremor Confusion, Hallucinations, Memory Loss Sialorrhoea, Constipation + 
PD58 70 Tremor Confusion, Anxiety Sialorrhoea + 
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6.4 Discussion 
Intense research has been directed at elucidating the molecular pathophysiology of 
aSN in PD (Baba et al. 1998;Lotharius and Brundin 2002) with effort also focused on 
exploring the distribution of aSN in the PD brain to obtain a better understanding of the 
disease process (DelTredici et al. 2002;Braak et al. 2004;Braak et al. 2003). Some studies 
using aSN immunohistochemistry have found aSN pathology in the DMV but not in SN 
(DelTredici et al. 2002;Braak et al. 2003) and have interpreted this as indicate of an early 
pathological stage of aSN deposition. Based on observations of post-mortem tissue from 
diagnosed cases with PD as well as cases without PD, a staging system has been proposed 
(Braak et al. 2004;Braak et al. 2003). According to this system, early stages show 
pathological inclusions in the lower brainstem and no clear clinical manifestations. In 
later stages the disease advances to the upper brainstem including the substantia nigra 
(SN) and then moves from mesocortex to neocortex, with the pathology in caudal regions 
increasing progressively in severity (Braak et al. 2003). In the present study, 53% of 
cases showed a distribution pattern of aSN which is compatible with this view of a caudo-
rostral spread of aSN through the PD brain. We have not seen cases that would suggest 
weak alpha-synuclein labelling of the DMV as a result of neuronal cell loss. If we accept 
the assumption that the extent and severity of aSN lesions increase as the disease 
progresses (i.e. this is a prerequisite according to the proposed staging scheme), a 
significant number of cases did not follow this predicted pattern of spread, with 24% 
showing severe involvement of the SN in the absence of prominent DMV pathology. In 
9%, the mesocortex was severely affected together with basal forebrain nuclei, NBM and 
AC, with less pronounced pathology in lower brainstem structures including the DMV. 
Interestingly, in 7% of cases with typical clinical features of PD, the DMV was not 
affected, but aSN inclusions were found in the SN, NBM, AC, CA2 sector of the 
hippocampus, EC and SFG. Jellinger and Parkkinen et al have also reported multiple aSN 
inclusions with preservation of vagal medullary nuclei (Jellinger 2003a;Parkkinen et al. 
2005a). Our results highlight the involvement of multiple neuronal populations in the PD 
brain and contest the theory that the DMV is an obligatory trigger site for aSN pathology. 
Although the design of our study does not allow us to pinpoint trigger site(s) or how aSN 
evolves in the PD brain in early disease our data clearly demonstrate that the DMV is not 
always affected in a significant number of otherwise typical and clinico-pathologically 
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confirmed PD cases. Our results also underscore the pathological regional heterogeneity 
of disease affliction in the PD brain which is in line with molecular findings (Moran et al. 
2006). 
An important consideration for the acceptance of the proposed PD staging system 
is that of the criteria used in case selection by Braak and colleagues. Cases with no 
clinical symptoms of PD were selected based on the presence of aSN deposition in the 
DMV prior to an examination of additional anatomical areas. Thus, the pre-selection of 
brains showing involvement of the DMV represents a serious bias and confounding factor 
in the interpretation of their data. Interestingly, in a recent study by this research group a 
number of cases (19/301) diverged from their staging scheme (Braak et al. 2006b). In 
these cases olfactory structures and amygdala were predominantly involved in the 
absence of brainstem pathology (Braak et al. 2006b). This is in line with our own results. 
The search for an induction site of PD-related pathology has relied solely on the 
presence or absence of aSN immunostaining. However, one needs to ask whether the 
presence of aSN inclusions per se is indicative of PD at all. Aside from the obvious 
problem that there is no way pathologically to differentiate 'sub-clinical' PD from any 
other synucleinopathy in its 'sub-clinical' phase, a fundamentally more important concern 
is that perhaps not enough is known about aSN inclusions for them to be regarded with 
such assurance as pathological indicators and thus incorporated as the sole pathology in a 
disease staging scheme. Parkkinen et al., (Parkkinen et al. 2005b) have recently reported 
widespread and abundant aSN pathology in a neurologically unimpaired subject. While 
aSN inclusions may be indicative of an underlying pathological process they are not 
necessarily pathogenic in that process. By restricting our observations to aSN inclusions 
alone, we may be excluding brain regions that are affected differently. For example, the 
pre-supplementary motor area shows a significant loss of neurons in PD, but no aSN 
deposition is observed there (Macdonald and Halliday 2002). It could be that different 
pathological processes occur in different brain regions in PD. Thus, looking at other 
indicators of disease, such as nerve cell number and glial activation (Croisier and Graeber 
2006), is mandatory. These other indicators must also be addressed in the brain of ageing 
individuals without signs of Parkinsonism as well as in PD cases, if we wish to better and 
more fully document disease progression in PD. 
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One must loose 80% of striatal dopamine and about 60% of SN neurons before 
PD becomes clinically manifest and the preclinical/premotor phase of the illness may last 
anywhere from 5-20 years (Hawkes C.H and Deeb J 2006). It is generally known that 
olfaction, autonomic function and sleep are perhaps the best substantiated symptoms in 
this preclinical period. It may be argued that the predictive power of these clinical signs 
would identify subjects at risk for the future development of PD and provide a window of 
opportunity for early intervention. However, a variety of premorbid indicators of PD 
exist that challenge the clinical significance of such prodromal features. For instance, the 
Honolulu-Asia Aging study suggested the mid-life obesity and slow reaction time as the 
most significant premorbid indicators of PD (Ross et al. 2006;Abbott et al. 2002). In 
addition, depression, anxiety, phobia and impaired color discrimination have all been 
shown as important premotor features (Lauterbach et al. 2004;Nilsson et al. 
2001;Postuma et al. 2006). These features implicate widespread brain involvement and 
do not support a medullary primary focus of pathology. Furthermore, the clinical 
relevance of the proposed staging scheme has been recently challenged by Parkkinen and 
colleagues (Parkkinen et al. 2005a). 
Until now few studies have investigated the presence of aSN immunoreactive 
lesions in the spinal cord of aged neurologically unimpaired as well as PD cases (Bloch et 
al. 2006;Wakabayashi and Takahashi 1997b;Wakabayashi and Takahashi 1997a). In PD, 
LBs have been documented in the intermediolateral nucleus of the thoracic spinal cord 
(Wakabayashi and Takahashi 1997a;Wakabayashi and Takahashi 1997b;Oppenheimer 
1980) and in various grey areas of the spinal cord including the posterior, lateral and 
anterior horns (Hishikawa et al. 2003). More importantly, however, the comparative 
incidence of aSN pathology in the spinal cord and DMV has not been closely studied. In 
this cohort 89.4% of cases with DMV pathology showed aSN inclusions in the spinal 
cord highlighting a near universal occurrence of aSN positive lesions in the spinal cord of 
PD patients. In a recent study by Bloch et al., (Bloch et al. 2006) a high incidence of aSN 
lesions in the spinal cord was also reported in neurologically unimpaired individuals 
underscoring pathological involvement of the spinal cord at an early stage probably far 
below disease threshold for motor symptoms of PD. Nonetheless, Bloch et al., found no 
cases with isolated spinal or medullary pathology and thus have proposed that aSN spread 
could follow both an ascending course to more rostrally situated regions as well as 
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descending towards the spinal cord. However, in this cohort 60% of cases with no aSN in 
the DMV showed aSN lesions in the spinal cord. This result questions both an ascending 
as well as a descending course of aSN pathology spread in the PD brain and further 
challenges the existence of a medullary induction site of aSN pathology in the PD brain. 
Although it becomes increasingly evident that aSN pathology in the SC is a 
common histopatho logical feature of PD (Wakabayashi and Takahashi 
1997b;Wakabayashi and Takahashi 1997a;Braak et al. 2007) the clinical relevance of 
such pathology remains unclear. Pathological changes in the intermediate lateral column 
of the thoracic spinal cord including neuronal loss and LB inclusions have been 
implicated in autonomic dysfunction in PD (e.g. orthostatic hypotension)(Wakabayashi 
and Takahashi 1997a). In addition, the parasympathetic autonomic nuclei of the sacral 
cord give rise to sacral nerves that supply the descending and distal colon. Pathological 
changes in this region may contribute to colonic dysmotility leading to 
constipation(Oyanagi et al. 1990). Indeed, bowel problems in PD are common and it has 
been recently shown that constipation is a risk factor for PD decades before typical 
Parkinsonian motor symptoms appear (Abbott et al. 2001;Abbott et al. 2007). The 
findings of the present study of a high incidence of aSN pathology in the SC support 
previous reports that the central and peripheral autonomic nervous system is heavily 
involved. Systematic studies are warranted to examine the clinical correlates of aSN 
pathology in the SC. 
In this study aSN was found in the NBM in 99% of the cases thus demonstrating 
that this nucleus is particularly vulnerable to aSN pathology in PD. In addition it was the 
most severely affected region in both demented and non-demented PD cases. The NBM 
was one of the first nuclei in which LBs were first observed in PD by Lewy in 1913. 
Degeneration of the NBM is characterized by neuronal loss and shrinkage more 
noticeably in the Ch4 region which projects to the neocortex (Nieuwenhuys R et al. 
1988;Steriade M and Biesold D 1990). Studies have shown that in PD, the NBM cell 
depletion ranges from 0-77% and more severe involvement of the intermediate and 
posterior parts of Ch4, with comparative preservation of the Ch2 and Ch3 portions, where 
significant neuronal loss occurs in AD (Etienne et al. 1986b;Etienne et al. 1986a). The 
extent of NBM cell loss shows no correlation to age or duration of illness (Tagliavini et 
al. 1984). Irrespective of cortical pathology, NBM neuronal loss has been reported to be 
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much higher in demented PD subjects (50-77%), in whom it approaches the values in AD, 
than in non-demented PD patients (0-40%), who show values slightly higher than those 
aged-matched controls. In other studies, however, considerable NBM cell loss (about 
50%) has also been reported in non-demented PD subjects (Gaspar and Gray 1984) with 
no relationship between cell counts and mental status (Tagliavini et al. 1984;Paulus and 
Jellinger 1991). The finding of the present work of a predominant involvement of aSN 
deposition in the NBM in PD subjects confirms previous reports of a primary 
degenerative process of the cholinergic forebrain system in PD as well as corroborates the 
results presented in chapter 3 where the extent of aSN inclusions in the NBM was high in 
both demented and non-demented PD patients highlighting a universal cholinergic deficit 
in PD, with or without clinical cognitive decline. Given the heterogeneity of cell loss in 
the different subdivisions of the NBM as well as its primary degeneration in PD both in 
terms of neuronal depletion and aSN deposition, further studies are needed to unravel the 
basic mechanisms by which this nucleus is affected in the PD brain. 
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6.5 Conclusions 
The results of the present study demonstrate a predominant involvement of the 
NBM pointing to a universal cholinergic deficit in the PD brain which is in agreement 
with previous findings. In addition, the distribution of aSN pathology in this PD cohort 
followed the recent Braak staging scheme in 53% of the cases analysed, however, a 
significant number of cases did not seem to fit this predicted caudo-rostral spread. At 
variance to the proposed staging scheme, a number of subjects demonstrated severe 
involvement of the SN with less affection of the DMV, while others showed severe DMV 
aSN deposition with no affection of the meso- or neocortex. Other PD subjects exhibited 
severe aSN pathology in the NBM and AC with less affection of the DMV and a number 
of cases demonstrated no aSN pathology in the DMV despite aSN lesions in more 
rostrally situated regions. Of particulate interest is the finding that aSN lesions in the SC 
was a common pathological finding in PD subjects with or without DMV involvement 
which further challenges the theory that the DMV is the trigger site for aSN pathology in 
the PD brain. 
Additional studies are needed to confirm Braak's findings as well as further 
analysis of aSN distribution in the ageing brain is required to redress Braak's 
confounding systematic bias in deciding to exclude cases without DMV inclusions. 
While, the chnical and pathological significance of aSN deposition at the molecular level 
has yet to be determined, studies looking at other indications of disease, such as decreased 
cell number and glial activation, suggest that degeneration is not confined solely to 
inclusion-rich areas. These other indicators must also be addressed in the ageing brain of 
individuals without signs of Parkinsonism as well as in PD cases with proper 
experimental design, if we wish to fully document disease progression in PD. 
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Chapter 7 
General Discussion 
The aim of this thesis was to examine possible associations between the most 
common neuropsychiatric complications associated with PD (dementia, VH and anxiety) 
and pathology in specific anatomical areas as a means of providing a better insight into 
their aetiopathogenesis and thus provide a bridge between clinical phenomenology and 
regional pathological involvement in the PD brain. The results presented herein 
demonstrate that PD as well as AD-related pathology in limbic and striatal regions play a 
principal role in the development of cognitive and behavioural dysfunction in PD. In 
addition, the present thesis demonstrated that the dorsal motor nucleus of the vagus is not 
an obligatory trigger site of Parkinson's disease. 
7.1 Methodological Considerations 
The number of cases studied in chapters 3 and 5 may be viewed as relatively small 
but they were carefully drawn from a larger cohort with stringent selection criteria 
apphed. While for some variables correlations and associations may be more evident in 
larger samples, the careful case selection employed in these chapters greatly strengthens 
the positive clinico-pathological associations for the neuropsychiatric features assessed. 
The sample size presented in chapter 3 is similar to Churchyard and Lees (1997) and 
other previous clinico-pathological studies such as Mattila et al., 2000, Harding et al., 
2002a,b, Hurtig et al., 2000, Bertrand et al., 2004 ((Mattila et al. 2000;Harding et al. 
2002a;Harding et al. 2002b;Hurtig et al. 2000;Bertrand et al. 2004) that have investigated 
the pathological correlates of dementia and VH in PD. Furthermore, the studies presented 
in chapters 3 and 4 have the advantage that PD subjects presented with the two clinical 
signs under study (dementia and VH) in different combinations and with minimal to 
absent concomitant neuropsychiatric disturbances (e.g. anxiety, depression) thus enabling 
a greater understanding of the anatomical and pathological basis of dementia and VH. 
This is very important as previous reports failed to take into account concomitant 
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neuropsychiatric deficits in the subjects analysed. The sample size for Chapter 4 is the 
largest studied so far while for chapter 6 it is similar to previous studies (Braak et al 
2003;Parkkinen et al. 2005a). 
For all cases the clinical diagnosis was based on established criteria (section 
2.2.2). However, our report has limitations germane to all retrospective clinico-
pathological studies. Although clinical details were available for all cases studied, 
incomplete and inaccurate observations may have introduced an ascertainment bias for 
some of our clinical severity scores. For example, it may be that some patients in the 
PD(H-) group had cognitive impairment, dementia or VH that was not recorded in the 
patient notes and therefore may have been underestimated by our assessment. A selection 
bias that typically operates in brain-bank samples (e.g. patients with more severe or 
rapidly progressive disease) cannot be excluded, although every attempt was made to 
limit any potential bias. Further to this, PD patients often present with several types of 
behavioural change. Thus, overlapping behaviours complicate the analysis and make it 
difficult to examine changes related to a single behaviour in isolation. However, in all 
studies presented in this thesis every effort was made to isolate dementia, VH and anxiety 
and assess their anatomical and pathological correlates. 
Data obtained from postmortem tissues may be influenced by variations in tissue 
processing. All immunohistochemical reactions were performed with the same reagents 
and by the same investigator (Mr Michail E. Kalaitzakis) to reduce variability. In 
addition, the specificity of immunodetection was ensured by employing well-
characterized and/or widely used antibodies (e.g., ATS and aSN (clone 42) see section 
2.1.2) and negative and positive controls for every immunohistochemical run. 
Neuropathological studies do not allow the elucidation of the molecular 
mechanisms underlying disease state. However, while descriptive in character, when 
combined with clinical information this permits the optimum characterisation of the brain 
in a diseased state and consequently the data provided can be instrumental for the testing 
of new hypotheses and for the delineation of novel concepts. 
239 
7.2 General Conclusions 
In Chapter 3, the relationship between pathological protein deposition (both PD-
and AD-related) and the presence of dementia and VH alone or in combination was 
investigated by assessing eight regions of the brain that have been shown to play a role in 
cognitive function. The results of this work demonstrate that aSN in limbic regions 
strongly relates to the occurrence of dementia in PD while AD-type pathological change 
may have a permissive and or synergistic effect in precipitating dementia in PD. An 
important finding of this work was also that aSN pathology in the NBM was high in both 
demented and cognitively intact cases highlighting a universal cholinergic deficit in PD, 
with or without clinical cognitive decline. This finding demonstrates that degeneration of 
the NBM alone is not sufficient to cause dementia in PD thus the contribution of 
additional anatomical regions (i.e. limbic structures, striatum) are necessary for the 
development of dementia. Furthermore, the findings of this study also show that aSN in 
the amygdala closely relates to the presence of VH but only in those cases with 
concomitant dementia. Overall, the data presented in chapter 3 apart from providing 
further evidence of a clinical relevance of aSN deposition in the PD brain also point to 
pathological changes in the limbic system as an important determinant for progression to 
clinical dementia and VH in PD. 
In Chapter 4 the relationship between striatal pathology and dementia and VH in 
PD was investigated as a means of examining further the link between neuropathology 
and cognitive dysfunction. The reason striatum was chosen as a possible candidate for 
exploration was the central role of these nuclei in PD pathophysiology and their putative 
role in cognitive function. The results of this work demonstrate an increased AP striatal 
burden in PD cases with cognitive impairment/dementia in the absence of prominent 
cortical Ap deposition. In fact this is the first report to demonstrate a clinical relevance of 
striatal pathology with respect to cognitive dysfunction in PD. Further to this, the findings 
of this work also underscore a molecular link between PD and AD with respect to Ap 
deposition. This is of particular importance as it is still unclear whether PD and AD 
represent separate and distinct disease entities or extremes of a common 
neurodegeneration. The results of chapter 4 clearly demonstrate a link between PD and 
AD and thus challenge the notion that NFT, Ap plaques and aSN inclusions are specific 
markers for AD and PD, respectively. Indeed the view that these abnormal protein 
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deposits represent morphologic features that are inherent to these diseases and that they 
provide a valid means by which each disease can be morphologically identified and 
defined is no longer tenable. However, further research is needed to explore at the 
molecular level the interrelationship between PD and AD. Also, in this study a link 
between the chemoarchitecture of the striatum and the distribution of striatal A(3 plaques 
was considered, as the morphology of striatal A|3 plaques did not seem to represent a 
mere extension of their cortical counterparts. Taken as a whole, chapters 3 and 4 
demonstrate that dementia in the setting of PD more likely represents the confluence of 
additive and/or synergistic effects of pathologic involvement of limbic and striatal regions 
while VH seem to associate with pathological changes in limbic structures (i.e. 
amygdala). However, it has to be noted that the selection of brain regions examined may 
have introduced a bias and thus the findings do not exclude the contribution of additional 
anatomical areas for the development of dementia or VH in PD. 
In Chapter 5 a common but understudied neuropsychiatric complication 
associated with PD symptomatology was investigated. The aim of this chapter was to 
examine the possible anatomico-pathological correlates of anxiety in PD and thus further 
our understanding of the possible substrate(s) of this rather neglected psychiatric 
abnormality. The findings point to amygdala and the CA2 sector of the hippocampus as 
key regions for the development of this disabling symptom. In fact this is the first study to 
explore the neuropathological basis of anxiety in the PD brain and although preliminary 
possibly sheds some light on common neurobiological mechanisms of anxiety in PD and 
mood disorders. A link between anxiety and tremor was also found pointing to an 
influence of motor disability on behaviour in PD. Overall the results presented in this 
research may provide the backbone for future studies into anxiety in PD. 
An improved understanding of the anatomical and pathological basis of cognitive 
and psychiatric symptoms in PD may ultimately contribute towards the evolution of better 
treatment strategies for these aspects of the illness and by studying the relationship 
between centres in the brain that control behaviour in PD disease state one will by 
inference add to a greater understanding of brain function in normal individuals. 
Having looked at aSN pathology in a relatively large number of regions in the PD 
brain the need arose as to whether this PD-related pathological change indeed follows the 
proposed predicted caudo-rostral spread suggested by Professor Braak and colleagues. 
241 
Thus, quite apart from the pathological basis of neuropsychiatric features of PD studied in 
the previous chapters, chapter 6 dealt with the examination of the topographic distribution 
of aSN in the PD brain. The findings of this study showed that a significant number of 
cases did not fit the proposed predicted caudo-rostral spread of aSN pathology with some 
cases (n=5) showing no aSN pathology in the DMV despite aSN lesions in more rostrally 
situated regions including the SN and cortex. In addition, this investigation demonstrated 
that aSN in the SC is a common pathological finding in PD subjects with or without 
DMV affection. Taking together these results, this chapter contests the theory that the 
DMV is an obligatory trigger site for aSN pathology. These data can be instrumental for 
future studies by highlighting the need to study additional PD-related pathological 
changes (i.e. decreased cell number, glial activation) if we wish to fully document disease 
progression in PD. 
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Appendix I 
Representative Neuropathological Report of a PD case (PD69) 
Cllnlco-pathological Autopsy Report 
CLINICAL SUMMARY 
Name: Date of Birth; Age at death: 82 
Sex:I\/Iale GP: 
Clinical cause of death: Ischaemic & degenerative heart disease, carcinoma of 
? liver. 
Quality of notes; Good 
Age at Onset: 71 (1993, Dx 1995) 
Disease Duration: 11 years 
Presentation: Akinetic-rigid syndrome (shuffling, festinating gait, poor fine 
motor skills, flexed posture, drooling, micrographia, cogwheeling L wrist, 
then later R arm signs). 
Disease Details: Two years of symptoms prior to formal diagnosis. 
Akinetic-rigid syndrome with L wrist rigidity. 
Drugs: Selegiline, Sinemet 110, Sinemet Plus & CR, Ropinirole, Entacapone 
Quetiapine, Risperidone, Fludrocortisone, Amitriptyline, Clonazepam, 
Rivastigmine, Cipramil, Sertraline. 
Complications: Falls. Restless legs. Nocturnal jerking of legs (?REM sleep 
disorder). Wearing-off episodes/ Freezing/ On-off fluctuations. 
Dyskinesia when on. 
Autonomic: Drooling. Swallowing problems. Soft monotonous voice/ gruff 
Somnolence/ Disturbed sleep. Postural hypotension; Bradycardia. Sexual 
dysfunct ion/ Impotence. Nocturia. Seborrhoeic rash. 
(Reduced smell & taste on Selegiline) 
Psychiatric: Depression. Memory loss. Dementia (visuospatial problems/ 
dressing apraxia). Hallucinations (upsetting, worse with medication). 
Delusions. Agitation. 
Premorbid & Risks: Non-smoker. Golfer. 
(Detailed Clinical History available) 
MACROSCOPIC NEUROPATHOLOGICAL FINDINGS: 
(Photographic documentation available) 
Brain weight: 1,204 grams 
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The meninges overlying the convexity are translucent. The gyration appears to 
be normal with the exception of the right occipital pole where there is a small 
arachnoid cyst which measures about 1 x 0.8 cm in diameter. The uncus 
hippocampi is indented on both sides, more so on the left. The blood vessels at 
the base of the brain are not preserved but the middle cerebral artery bilaterally 
does not show any atherosclerotic deposits. The nigra is pale especially in its 
lateral parts. Inspection of the coronal sections does not reveal significant 
abnormalities with the exception of a small accumulation of what appears to be 
blood in the base of the anterior horn of the left lateral ventricle. This may just be 
a preparation artefact but histology is taken. The ventricular system is somewhat 
compressed. There are no other abnormalities. 
Brain regions sampled: 1) Superior frontal gyrus, 2) cingulate gyrus, 3) nucleus 
accumbens, 4) putamen and caudate, 5a) nucleus basalis of Meynert, 5b) globus 
pallidus, 6) hypothalamus with mamillary body, 7) amygdala, 8) thalamus, 9) 
hippocampus, 10) temporal cortex, 11) precentral gyrus, 12) visual cortex, 13) 
parietal lobe, 14) cerebellum and dentate nucleus, 15) substantia nigra, 16) pons 
at the height of the locus coeruleus, 17) medulla with inferior olive, 18) spinal 
cord at three levels. 
Immunohistochemical labellings performed: anti-alpha synuclein 
(monoclonal, BD), anti-A-beta peptide (residues 8-17) (monoclonal, NCL), anti-
tau (monoclonal AT8, NBS Biological) and anti-ubiquitin (monoclonal, Dako). 
MICROSCOPIC FINDINGS 
The haematoxylin-eosin stained sections of the superior frontal gyrus, cingulate, 
precentral gyrus, parietal lobule, temporal neocortex, primary visual cortex, 
nucleus accumbens, nucleus pallidus, hypothalamus, thalamus, amygdala, 
medulla and spinal cord look unremarkable. Putamen shows artefacts due to 
poor fixation and embedding. The section containing nucleus basalis of Meynert 
is characterised by reactive astrocytes is and deposition of haemosiderin. A few 
nerve cells show large, eosinophilic cytoplasm. The section from hippocampus 
demonstrates loss of pyramidal nerve cells in the CA1 sector of the hippocampus 
and the subiculum. The cerebellum shows a mild reaction of Bergmann's glia and 
reactive astrocytosis of the dentate. There is severe loss of pigmented nerve cells 
from the substantia nigra associated with reactive gliosis, an increase in the 
number of microglial cells and free-lying neuromelanin pigment. Some pigmented 
nerve cells contain Lewy bodies. Severe loss of pigmented neurones is also 
found in the locus coeruleus. The section from the block labelled „lesion" shows 
periventricular white matter with no significant pathological changes. 
Alpha synclein: Immunostains for alpha-synuclein demonstrate diffuse, finely 
granular immunolabelling in the grey matter of the superior frontal gyrus, and a 
few neurons containing Lewy bodies. Accumulation of alpha-synuclein is seen in 
the nucleus basalis and the amygdala, more prominent in the cortical nucleus, 
hippocampus, substantia nigra and pons. The hippocampus shows alpha-
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synuclein positive Lewy body-like structures in a few nerve cells, and prominent 
alpha-synuclein accumulation is seen in dendrites and axons of the CA2 sector. 
Lewy body-like alpha-synuclein immunoreactive inclusions are also seen in the 
subicular and entorhlnal cortex. The substantia nigra shows widespread 
accumulation of alpha-synuclein in nerve cells, the neuropil and oligodendroglia. 
Alpha-synuclein positive inclusions are also present in the locus coeruleus, 
neurons of the raphe nucleus, the pontine reticular formation and the hypoglossal 
nucleus 
Tau and A-beta peptide: There are A-beta positive, tau-negative diffuse and 
focal deposits in the superior frontal gyrus and the entorhinal cortex. 
Immunostaining for phosphorylated tau demonstrates neurofibrillary tangles in 
some nerve cells and axons of the hippocampus and entorhinal cortex. These 
features are consistent with isocortical grade 1 and entorhinal grade 2 Alzheimer-
type pathology (www.ICDNS.org). There is no tau accumulation in the substantia 
nigra. 
CLINICAL DIAGNOSIS: Akinetic-rigid syndrome with typical progression 
(cognitive & autonomic involvement) complicated by dyskinesia. 
NEUROPATHOLOGICAL DIAGNOSIS: Alpha-synucleinopathy, brain stem-
predominant, consistent with clinical Parkinson's disease (www.ICDNS.org) 
Yours sincerely, 
Federico Roncaroli MD 
Clinical Senior Lecturer in Neuropathology 
Honorary Consultant, 
Hammersmith Hospitals Trust 
University Department of Neuropathology 
Imperial College London and Hammersmith 
Hospitals Trust 
Stephen M. Gentleman PhD 
Reader in Experimental Neuropathology 
University Department of Neuropathology 
Imperial College London and Hammersmith 
Hospitals Trust 
Ronald KB Pearce MD PhD FRCPC FRCP 
Consultant Neurologist 
Honorary Senior Lecturer in Neuropathology 
University Department of Neuropathology 
Imperial College London and Hammersmith 
Hospitals Trust 
Manuel B. Graeber MD PhD FRCPath 
Professor of Neuropathology 
Honorary Consultant, Hammersmith 
Hospitals Trust 
Chair, University Department of 
Neuropathology 
Imperial College London and Hammersmith 
Hospitals Trust 
09/09/2005 Department of Neuropathology 
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Representative Clinical Summary of a PD case (PD69) 
PD69 31/05/1922 M 
Quality of Notes: Good 
Presentation: 
Akinetic-rigid syndrome 
(shuffling, festinating gait, poor fine motor skills, flexed posture, drooling, 
micrographia, cogwheeling L wrist, then later R arm signs) 
Age of onset: 71 (1993, Dx 1995) 
Disease Duration: 11 years 
Two years of symptoms prior to formal diagnosis. Akinetic-rigid syndrome 
with L wrist rigidity. 
Drugs: 
Selegiline, Sinemet 110, Sinemet Plus & CR, Ropinirole, Entacapone 
Quetiapine, Risperidone, Fludrocortisone, Amitriptyline, Clonazepam, 
Rivastigmine, Cipramil, Sertraline 
Complications: 
Falls 
Restless legs 
Nocturnal jerking of legs (?REM sleep disorder) 
Wearing-off episodes/ Freezing/ On-off fluctuations 
Dyskinesia when on 
Autonomic: 
Drooling 
Swallowing problems 
Soft monotonous voice/ gruff 
Somnolence/ Disturbed sleep 
Postural hypotension; Bradycardia 
Sexual dysfunct ion/ Impotence 
Nocturia 
Seborrhoeic rash 
(Reduced smell & taste on Selegiline) 
Psychiatric: 
Depression 
Memory loss 
Dementia (visuospatial problems/ dressing apraxia) 
Hallucinations (upsetting, worse with medication) 
Delusions 
Agitation 
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Premorbid & Risks: 
Non-smoker. Golfer. 
Neuropathological Diagnoses: 
Primary: 
Secondary: 
Remarks: 
PD69 31/05/1922 
Medical Practitioner 
(Medical Advisor to Foreign Office) 
Cause of death (09/ 09/2004): "Ischaemic & degenerative heart disease, CA of 
liver" (?correct?) 
GP: Dr 
CLINICAL HISTORY: 
1995 
Two year history of "Deteriorating golf sv^ i^ng & unusual fatigue on exercise. 
Restless aching legs when resting". Golf handicap falling off. Festinating gait, 
tendency to drool, poor fine motor skills & micrographia. Rigidity at L wrist. 
Slower, stiffer, flexed with a shuffling gait, poverty of arm swing & impassive face. 
Speech soft & monotonous. Marked improvement on Sinemet 110 & significant 
improvement adding Selegiline to Sinemet 110 QD. Mild extrapyramidal features. 
1996 
Mild bradykinesia, little tremor. BP 130/80 lying & 105/70 standing. Poor smell. 
Mobility reduced off Selegiline. Stable on Sinemet Plus QD. Sexual dysfunction. 
1997 
More of a stiuggle to keep mobile, especially playing golf. Falls asleep in day. 
Insomnia/ restless legs & L leg tiemor at night. More akinetic-rigid than tremulous. 
BP drops from 140/70 to 120/70. To increase Sinemet. 
1998 
Depression, poor memory (vs. pseudo-dementia). More flexed & slow in thought 
and movement. 
1999 
Improved mobility, alertness & sleep on low dose Ropinirole. 
2000 
Dyskinetic fidgets. 
2001 
Muscle spasms & twitching evenings/ nights. To increase Ropinirole. Off episodes 
reduced on increased Ropinirole. CT scan: some generalised atrophy. Some help 
with dressing & meals. Difficulty in bed turning over. Minimal bradykinesia in R 
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hand & reduced arm swing on R. Difficulty with spatial awareness & short-term 
memory (great trouble on escalators), 
2002 
On/ off & freezing. Dressing apraxia & perseveration. Good stride but reduced arm 
swing on R. R arm bradykinesia & arm dyskinesia. Tone normal. Word-finding 
problems, speech worsening, losing track, worried about dementia or Alzheimer's. 
Walked with upright posture, good arm swing, minimal rigidity & no tremor. 
2003 
Neuropsychological assessment: impaired (esp. visual function) not to drive. 
Entacapone effective in reducing wearing-off episodes but increased hallucinations & 
disturbed thoughts. On Ropinirole 16 mg/ day. Confused & muddled. Speech 
gruff, word-finding difficulties, swallowing problems. 
2004 
Confused ("rapidly dementing"), hallucinosis (upsetting), visuospatial problems & 
dressing apraxia. Falls. Risperidone for agitation. Jerking ("myoclonic") spasms of 
legs. Better on Rivastigmine & decreased hallucinations. To decrease Ropinii'ole, 
Generally bradykinetic. 
OTHER MEDICAL: 
2004 
Seborrhoeic excema. CA liver. 
2003 
Senile dementia. 
2002 
Bradycardia & Hypotension (170/70 dropping to 120/60). Cardiology opinion. 
2000-2001 
Sensorineural hearing loss consistent with age. Basal Cell Carcinoma 
1999 
Age-related macular degeneration 
1998 
L inguinal hernia repair, "Neurotic depression reactive type". 
1993 
Fungal infection hand & groin. Persistent excema. 
1988 
Seborrhoeic keratosis 
1954 
FAMILY HISTORY: 
None 
MEDICATION: 
Selegiline, Sinemet 110, Sinemet Plus, Sinemet CR, Ropinirole, Sertraline, Quetiapine, 
Risperidone, Entacapone, Fludrocortisone, Quinine, Amitriptyline, Clonazepam, 
Rivastigmine, Cipramil. 
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Appendix II 
Standard Operating Procedure 
De-waxing, dehydrating and clearing of paraffin embedded human 
sections 
De-waxing sections 
Slides are placed in the appropriate racks, and then moved through the following 
solutions; 
1. Xylene 
2. Xylene 
3. 100% alcohol 
4. 100% alcohol 
5. 90% alcohol 
6. 70% alcohol 
7. Distilled water 
5 mins 
5 mins 
5 mins 
5 mins 
5 mins 
5 mins 
5 mins 
Dehydrate and clearing sections 
1. Distilled water 
2. 70% alcohol 
3. 90% alcohol 
4. 100% alcohol 
5. 100% alcohol 
5 mins 
5 mins 
5 mins 
5 mins 
5 mins 
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6. Xylene 5 mins 
7. Xylene 5 mins 
Application: Indirect immunoperoxidase technique using monoclonal/polyclonal 
antibodies. On Human Tissue (Immunocytochemistry) 
1. Sections to Water (refer to Appendix II on de-waxing) 
2. Block in Hydrogen peroxide/methanol 30 mins 
3. Rinse in PBS 3 X 5 mins 
4. Carry out any pre-treatments (see next page) 
5. Rinse in water 5 mins 
6. Rinse in PBS 3 x 5 mins 
7. Individually remove sections from the PBS, wipe around sections and the back of the 
slide apply pap pen around the sections and place in moist incubation chamber. 
8. Add 1^ ' layer antibody at appropriate concentration and incubate overnight at 4°C 
The antibody was diluted at correct concentration and that the sections DO NOT dry 
out. 
9. Rinse in PBS 3 x 5 mins 
10. Secondary antibody added at a concentration of 1:100 room temp Ihour 
For Rabbit polyclonal 1 °antibody a goat anti-rabbit 2° layer is used 
Four Mouse monoclonal 1 ° antibody a horse anti-mouse 2° layer is used 
11. Rinse in PBS 3 X 5 mins 
12. Third layer complex incubate sections in 3"" layer 1 hour 
Vectastain elite regents A & B should be combined to a final concentration of 1:200 
with respect to both components (e.g. 5p.l A + Spil B : 990^1 Diluent) This layer was 
made up at least 30 minutes in advance. 
13. Rinse in PBS 3 x 5 mins 
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14. Visualize: 5mins 
Incubate the slides with 1 aliquot of DAB into 400nils of PBS 16 drops of Hydrogen 
peroxide. 
15. Remove the slides and rinse in running water 
Waste DAB to be put in appropriate container for disposal 
16. Lightly counter stain in Haematoxylin 
17. DCM (refer to Appendix II on de-hydration of sections) 
Formic acid pre-treatment of paraffin wax sections sections. 
• After de-waxing and blocking of endogenous peroxidases in sections, sections were 
placed into a coplin jar of 80% or 100% Formic acid for 8 or 60 minutes. 
• Slides were then removed and place into running water. 
Microwave pre-treatment of tissue sections. 
• Sections placed in plastic rack 
• The rack was placed in a suitable microwave container, filled with an adequate 
amount of EDTA. 
• Sections were microwaved on medium (40%) for lOmins and then a further lOmins 
on medium high (40%) 
• The dish was then removed from the microwave and placed in a sink of cold water for 
at least 20 minutes in order to cool the solution and slides down. 
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Buffers and Solutions 
lOx Phosphate Buffered Saline (PBS) 
21 g Sodium dihydrogen orthophosphate dehydrate 
193g di-sodium hydrogen orthophosphate 12 hydrate 
20g Potassium chloride 
800g Sodium chloride 
Made up to 101 with dHiO, pH 7.4 
Ix PBS 
l l o f l O x PBS 
91 dHzO 
pH 7.4 
3,3'-diaininobenzidine (DAB) 
5g DAB powder 
200ml dHzO 
(4ml aliquots of this solution was stored in a freezer and used) 
Primary diluents 
490ml PBS 
1.5ml triton X-100 
1.5g sodium azide 
10ml of normal horse serum 
Second and third diluents 
500ml PBS 
1.5ml triton X-100 
EDTA Microwave solution 
• Weigh out 0.3722g of EDTA 
• Add the EDTA to 1 liter of distilled water 
• MIX well 
• Adjust the pH to 8 using either HCL or sodium hydroxide. 
• Solution stored until ready to use. 
295 
Publications arising from this work 
1. M.E. Kalaitzakis, M.B. Graeber, S.M. Gentleman, R.K.B. Pearce (2007). The dorsal 
motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: A 
critical analysis of a-synuclein staging Neuropath. Appl. Neuro. (in press) 
2. M.E. Kalaitzakis, M.B. Graeber, S.M. Gentleman, R.K.B. Pearce (2008). Striatal P-
Amyloid Deposition in Parkinson's Disease with Dementia. J. Neuropath. Exp Neurol (in 
press) 
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aSN 
PD(H-) Group 
Appendix III 
Cingulate Gyrus Superior Frontal Gyrus Temporal Cortex Entorhinal Cortex Amygdaloid Complex 
PDD(H+) Group 
PDD(H-) Group 
PD(H+) Group 
0.5 0.5 0 0 0 
1.5 1 0.5 1 1.5 
1 1 1 1 1 
1 0 1 1 0.5 
0.5 0.5 0 0.5 0 
0.5 0 0 1 1.5 
0 0.5 0.5 0.5 1 
0 0.5 0 0 0 
1 0.5 0.5 0.5 0 
1 1 1 3 3 
2 0.5 0.5 1 1 
1.5 1 1.5 2.5 3 
2 0.5 1 1 1.5 
1.5 1 0.5 1 0.5 
1.5 1 1 2 2 
0.5 0.5 1.5 1 1.5 
1 1.5 1 1 1 
2.5 0 0.5 3 0 
1.5 1 1.5 2 2 
2.5 1.5 1.5 1.5 1.5 
2 1 1 2 2.5 
2 1.5 2.5 3 2 
2.5 2 1.5 2 3 
2 1 1 1.5 2.5 
0.5 0.5 0 2 2 
1 0.5 0.5 0 . 1 
1 0.5 1 1 2 
1 1 1 0.5 1.5 
1.5 1 1 2.5 ' 2.5 
1.5 1 1 1 0.5 
NBM 
2 
2 
2 
0.5 
1.5 
1 
1 
3 
1 
2 
2 
2.5 
3 
2.5 
2 
1 
2 
1 
2 
2.5 
2 
2.5 
2.5 
2 
2 
3 
2 
2 
2 
2 
CA2 
0 
0.5 
1.5 
0.5 
0.5 
0.5 
0 
0 
0 
2 
1 
1.5 
3 
0.5 
2.5 
0.5 
3 
2 
2.5 
0.5 
3 
2 
1.5 
1 
2 
0 
0.5 
0.5 
3 
1.5 
Subiculum 
0 
0.5 
0.5 
0 
0 
0 
0 
0 
0 
0 
0.5 
0.5 
0 
0 
0 
2 
2 
1 
0.5 
1.5 
1 
0 
1 
1 
0 
0 
0 
0 
0.5 
1 
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M 
PD(H-) Group 
PDD(H+) Group 
PDD(H-) Group 
PD(H+) Group 
Cingulate Gyrus Superior Frontal Gyrus Temporal Cortex Entorhinal Cortex Amygdaloid Complex NBM CA2 Subiculum 
0 0 0.5 0 0 0 0 0 
0.5 0.5 0.5 0.5 0.5 0.5 0 0.5 
0.5 0.5 0.5 0.5 0.5 0 0 0.5 
0 0.5 0.5 0.5 0.5 0 0 0 
0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 
0.5 0.5 0.5 0.5 0.5 0 0 0 
0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 
1.5 2 2 1.5 0.5 0.5 0.5 0.5 
0.5 0.5 0.5 0.5 0.5 0 0 0 
1.5 1 2 1.5 0.5 1 0.5 1 
0.5 0 0.5 0 0.5 0 0 0 
1.5 1 1 1 0.5 2 0 0.5 
0.5 0 0.5 0.5 0.5 0.5 0 0.5 
0.5 0.5 0.5 1 0.5 0 0 0.5 
1.5 0.5 0.5 0.5 1 0 0.5 0.5 
0 0 0.5 0.5 0 0 0 0 
2 2 1.5 2 1 2 1 0 
2 2 2 1.5 1 1.5 0.5 0.5 
1 0.5 0.5 0.5 0.5 0 0 0.5 
1.5 2 2 1.5 1 1 0 0 
2 0.5 1.5 1 1 2 0.5 1 
0 0 0 0 0 0 0 0 
0.5 0.5 0.5 1 0.5 1 0 0 
0.5 0 0 0 0 0 0 0 
0 0 0 0 0 0 0.5 0 
0 0 0 o" 0 0 0 0 
1.5 1.5 2 0.5 0.5 0.5 0 0 
0.5 0.5 1.5 0.5" 0.5 0.5 0 0 
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Tau 
PD(H-) Group 
PDD(H+) Group 
PDD(H-) Group 
PD(H+) Group 
Cingulate Gyrus 
0.5 
0.5 
0 
0 
0.5 
0.5 
0 
0 
0 
1 
0.5 
1 
0 
0 
0.5 
0 
0 
0 
0.5 
0.5 
0 
0.5 
0.5 
0 
0 
0 
0 
0 
0.5 
0.5 
Frontal Gyrus Temporal Cortex Entorhinal Cortex Amygdaloid Complex NBM CA2 Subiculum 0 0 1 0.5 0.5 0 0 0 0 1 0 0.5 0.5 0 0 1 1 1.5 0 1 0 0 0 0.5 0.5 0 0 0.5 0 0.5 1 0.5 0.5 0 0.5 0.5 0.5 1 1 1 0.5 0.5 0 0.5 1.5 0.5 1 0.5 0.5 0.5 0.5 0.5 0.5 1 0.5 0 0.5 0.5 1 0.5 0.5 0 0.5 
0 1 1 1.5 0 1 1 1 0 0 0 0 0.5 0.5 1 2 1 2 1 1 2 0 0 0 0.5 0 1.5 0 0 0 1 0 2 0 0 0 0 1 0.5 0.5 0.5 0.5 0 0 1.5 1 1 0.5 0 0 
1 
0 1 1 0 1.5 2 
0 1 0 0.5 0.5 0 0.5 0 1 0.5 1.5 0.5 0.5 1 1 1 1.5 2 1 1 0 0 1 1 0.5 1.5 0.5 
1 1 1.5 1.5 0 0 0 0 0.5 1 1.5 2 1.5 1 0 0 0 0 1 1 0 0 0 1 0.5 0.5 1 0 
0 0 0 0.5 0.5 0.5 0 0 0 0.5 0.5 0 0 0.5 0 0 0.5 0 0.5 0.5 0.5 0.5 0.5 1.5 0.5 0.5 1 0 0 0.5 1.5 0.5 1 0.5 1 
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Recorded MMSE 
PDD(H+) 
PDD(H-) 
19/30 
20/30 
4/10 
16/30 
11/28 
20/30 
20/30 
20/30 
3nn 
Appendix IV 
aSN 
Caudate Nucleus Putamen Nucleus Accumbens 
PD(H-) Group 0.5 0.5 0 
0.5 0.5 1 
1 1 1 
0.5 1 1 
0 0 1 
0 0 0 
0.5 0.5 0.5 
0 0 0 
0 0 0 
PDD{H+) Group 0 0 0.5 
0 0 0.5 
0.5 0.5 1 
0.5 0.5 2 
1 1.5 0.5 
0.5 0.5 1 
1 2 0.5 
0 0 0 
0 0 0 
0.5 0 0.5 
0 0 1.5 
1 1.5 0.5 
PDD(H-) Group 0 0 2 
2 2 0.5 
0.5 1.5 0 
0 0 0.5 
PD(H+) Group 0.5 1 0.5 
0.5 1 15 
0.5 1 0.5 
0.5 0 0.5 
0 0 0.5 
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Ag 
Caudate Nucleus Putamen Nucleus Accumbens 
PD(H-) Group 0 0 0 
0,5 0.5 0 
0.5 1 2 
0 0 0.5 
0 0 0 
0 0 0 
0 0 0 
0 0 0 
0 0 0 
PDD(H+) Group 3 3 3 
1 1 0.5 
3 3 2.5 
0 0 0 
2 2 2 
1 1 1 
2 2 3 
3 3 3 
0 0 0 
2.5 3 3 
1 1.5 2 
2.5 2.5 3 
PDD(H-) Group 2 2 2 
2 2 2 
0 0 0 
0.5 0.5 0.5 
PD(H+) Group 0 0 0 
0 0 0 
0 0 0 
1.5 0.5 2 
0 0 0 
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Tau 
Caudate Nucleus Putamen Nucleus Accumbens 
PD(H-) Group 0 0.5 0.5 
0 0.5 0.5 
0 0 0.5 
0 0 0.5 
0.5 0 0 
0.5 0,5 0.5 
0 0.5 0 
0.5 0.5 0.5 
0 0 0.5 
PDD(H+) Group 0 0 0.5 
0 0.5 1 
1 1 0 
0 0 0.5 
0.5 0.5 0 
0 0 0.5 
0 0.5 0.5 
0 0 0 
0 0 0.5 
0 0.5 2 
0.5 0.5 0.5 
0 0 0 
PDD(H-) Group 0 0 1 
0.5 0.5 0 
0 0 0.5 
0 0 0 
PD(H+) Group 0.5 0 0.5 
0 0.5 0.5 
0 0.5 0 
0.5 0 0.5 
0 0 0 
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Appendix V 
aSN 
PD(A-) Group 
PD(A+) Group 
Cingulate Gyrus Temporal Cortex Entorhinal Cortex Amygdaloid Complex NBM CA2 Subiculum Locus Coeruleus Raphe Nuclei 
0.5 0 0 0 2 0 0 0.5 0.5 
1.5 0.5 1 1.5 2 0.5 0.5 0.5 1.5 
1 1 1 1 2 1.5 0.5 1.5 1 
1 1 1 0.5 0.5 0.5 0 1.5 1 
0.5 0 0.5 0 1.5 0.5 0 0.5 0.5 
0.5 0 1 1.5 1 0.5 0 0 0 
0 0.5 0.5 1 1 0 0 0.5 1 
0 0 0 0 3 0 0 1 0.5 
1 0.5 0.5 0 1 0 0 0.5 0 
1 0.5 1.5 1.5 1.5 1.5 0.5 2.5 2 
2.5 1 3 3 1.5 3 2 2 2 
0 0.5 1 3 2 3 0.5 2 1 
1.5 0.5 0.5 2 2 1.5 0 2 3 
2.5 0.5 1 2 2 0.5 0.5 0.5 0 
1 0.5 1 1.5 1.5 1.5 0.5 1.5 0.5 
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M 
PD(A-) Group 
PD(A+) Group 
Cingulate Gyrus Temporal Cortex Entorhinal Cortex Amygdaloid Complex NBM CA2 Subiculum Locus Coeruleus Raphe Nuclei 
0 0.5 0 0 0 0 0 0 0 
0.5 0.5 0.5 0.5 0.5 0 0.5 0 0 
0.5 0.5 0.5 0.5 0 0 0.5 0 0 
0 0.5 0.5 0.5 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0.5 0.5 0.5 0.5 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
0 0 0 0 0 0 0 0 0 
1 1.5 1 2.5 0 0 1 0 0 
0.5 1 0 0.5 na 0 0 0 0 
2 1.5 2 2 0 0.5 1 0 0 
0.5 0.5 0.5 1 0 0 0 0 0 
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Tau 
PD(A-) Group 
PD(A+) Group 
Cingulate Gyrus Temporal Cortex Entorhinal Cortex Amygdaloid Complex NBM CA2 Subiculum Locus Coeruleus Raphe Nuclei 
0.5 0 1 0.5 0.5 0 0 0.5 0 
0.5 0 1 0 0.5 0.5 0 0.5 0.5 
0 1 1 1.5 0 1 0 0.5 0.5 
0 0 0.5 0.5 0 0 0.5 0.5 0.5 
0.5 0.5 1 0.5 0.5 0 0.5 0.5 0.5 
0.5 0.5 1 1 1 0.5 0.5 0.5 0.5 
0 0.5 1.5 0.5 1 0.5 0.5 na na 
0 0.5 0.5 0.5 1 0.5 0 0.5 0 
0 0.5 1 0.5 0.5 0 0.5 0.5 0 
0 0 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
0.5 0.5 1 2.5 0.5 1 1 0.5 0.5 
0 0.5 1 2 0.5 0.5 0.5 0.5 1 
0 0.5 1 na 0.5 0.5 1.5 na na 
0 0.5 0.5 1 0.5 1 0.5 0.5 0 
0 0 1 0 0.5 0.5 0.5 0 0 
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